[["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP (TAR DNA-binding protein) gene encodes TDP-43, a multifunctional RNA-binding protein involved in RNA processing and protein homeostasis. Mutations in TARDBP are strongly associated with frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). TDP-43 pathology, characterized by the mislocalization and aggregation of TDP-43 protein, is a hallmark of several neurodegenerative diseases. Specifically, TARDBP mutations contribute to FTLD with TDP-43 proteinopathy and ALS, where TDP-43 aggregates in motor neurons. These mutations impair RNA metabolism and lead to neuronal loss. The involvement of TARDBP in these pathways highlights its critical role in maintaining cellular homeostasis and its contribution to neurodegeneration. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP (TAR DNA-binding protein) gene encodes TDP-43, a key RNA-binding protein involved in RNA processing and stress granule formation. Mutations in TARDBP are strongly associated with **frontotemporal lobar degeneration (FTLD)**, particularly **FTLD with motor neuron disease (FTLD-MND)**, which overlaps clinically with **amyotrophic lateral sclerosis (ALS)**. TDP-43 pathology is also a hallmark of **ALS** and **limbic encephalopathy with succinate dehydrogenase deficiency**. The dysfunction of TDP-43 leads to its mislocalization and aggregation in neuronal cytoplasm, disrupting RNA metabolism and causing neurodegeneration. This pathway also includes components of **complex I** of the mitochondrial electron transport chain, suggesting a link between mitochondrial dysfunction and neurodegeneration. Mutations in these genes can contribute to oxidative stress and impaired energy production, further exacerbating neuronal damage. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes TDP-43, a RNA-binding protein involved in RNA processing and stress granule formation. Mutations in TARDBP are associated with the mislocalization and aggregation of TDP-43, a hallmark of several neurodegenerative diseases. Specifically, TARDBP mutations contribute to amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the accumulation of insoluble TDP-43 protein inclusions in motor neurons, disrupting essential cellular functions and ultimately leading to neuron death. TARDBP is also implicated in frontotemporal lobar degeneration (FTLD), particularly FTLD with ubiquitin-positive inclusions (FTLD-U). Mutations in TARDBP are among the most common genetic causes of familial ALS and are associated with both sporadic and inherited forms of the disease. \\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, is critical for ubiquitin ligase activity targeting HIF1A. Under normoxia, VHL promotes the degradation of HIF1A, preventing its stabilization and subsequent transcriptional activation of genes like SLC2A1, VEGFA, TGFB, PDGFB, and TGFA. Loss-of-function mutations in VHL disrupt this process, leading to HIF1A stabilization and hypoxia-inducible gene expression under normoxic conditions. This dysregulation drives angiogenesis, cell survival, and epithelial-to-mesenchymal transition, contributing to tumor progression. The VHL pathway is central to the pathogenesis of clear cell renal cell carcinoma (ccRCC), a malignancy of the kidney. Mutations in VHL are a hallmark of ccRCC, leading to the hallmark \"papillary\" histology and vascular abnormalities. The VHL allele's role in this pathway directly contributes to the development and progression of clear cell renal cell carcinoma.\n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene encodes the von Hippel-Lindau tumor suppressor protein, which is part of an E3 ubiquitin ligase complex involving RBX1, ELOC, ELOB, and CUL2. This complex targets hypoxia-inducible factor 1 alpha (HIF1A) for degradation under normoxic conditions. When VHL is mutated, HIF1A stabilizes, leading to the activation of downstream genes like ARNT, which promotes the expression of genes such as VEGFA, SLC2A1, PDGFB, and TGFs. This pathway is critical in hypoxia response and angiogenesis. Mutations in VHL disrupt this regulation, leading to uncontrolled angiogenesis and tumor formation. This contributes to the development of **von Hippel-Lindau disease**, a hereditary cancer syndrome characterized by the growth of cysts and tumors in multiple organs, including the kidneys, brain, and adrenal glands. The hallmark is the formation of hemangiomas and clear cell renal cell carcinomas. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele plays a critical role in cellular homeostasis by regulating the von Hippel-Lindau tumor suppressor protein. This protein is part of an E3 ubiquitin ligase complex that targets hypoxia-inducible factor 1 alpha (HIF1A) for degradation under normoxic conditions. When VHL is inactivated, HIF1A accumulates, leading to the activation of downstream genes such as VEGFA, PDGFB, and TGFB, which drive angiogenesis, cell proliferation, and fibrosis. This dysregulation contributes to the formation of hypervascular tumors. The VHL pathway is essential in preventing angiogenic switch and maintaining vascular homeostasis. Mutations in VHL are strongly associated with **Von Hippel-Lindau disease**, a hereditary disorder characterized by the development of multiple benign and malignant tumors, particularly in the central nervous system, adrenal glands, and kidneys. The disruption of this pathway leads to uncontrolled tumor growth and vascular abnormalities.\n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits CDK4/6, preventing the phosphorylation of RB1 and thereby blocking the activation of E2F transcription factors, which drive cell cycle progression. In the given pathway, CDKN2A negatively regulates MDM2, which normally ubiquitinates and degrades TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its ability to suppress tumor growth. Loss or mutation of CDKN2A disrupts this regulatory mechanism, leading to unchecked cell proliferation and genomic instability. This contributes to the development of various cancers, most notably **melanoma** and **pancreatic cancer**, where CDKN2A inactivation is a common early event. The loss of CDKN2A also synergizes with TP53 mutations, further promoting tumorigenesis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in the regulation of the p53 tumor suppressor pathway. CDKN2A encodes for p14ARF, which inhibits MDM2, a negative regulator of TP53. By blocking MDM2, CDKN2A stabilizes TP53, enabling it to induce cell cycle arrest and apoptosis in response to DNA damage. This pathway also leads to the inhibition of CDK4/6 and cyclins (CCND1-3), preventing the phosphorylation of RB1 and thus blocking E2F-dependent transcription of S-phase genes. Loss or mutation of CDKN2A disrupts this checkpoint, leading to uncontrolled cell proliferation. This dysfunction is a key driver in multiple cancers, particularly melanoma and pancreatic adenocarcinoma. The CDKN2A allele is strongly associated with the development of melanoma, especially in individuals with constitutional mutations in this gene. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits cyclin-dependent kinases, including CDK4 and CDK6, and also negatively regulates MDM2, an E3 ubiquitin ligase that targets TP53 for degradation. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor-suppressive functions. Mutations or inactivation of CDKN2A disrupt this regulatory pathway, leading to reduced TP53 stability and impaired cell cycle control. This promotes uncontrolled cell proliferation and genomic instability, contributing to carcinogenesis. CDKN2A mutations are strongly associated with various cancers, most notably melanoma and pancreatic adenocarcinoma. The loss of CDKN2A function is particularly critical in cancers where TP53 is also inactivated, as it removes a key barrier to oncogenic transformation. Thus, CDKN2A mutations are a hallmark of several aggressive malignancies.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with the **APP** gene, which encodes the amyloid beta precursor protein. Mutations in **APP** can lead to the abnormal production and accumulation of **Abeta**, a peptide associated with **neurodegeneration**. The pathway proceeds through **mAChR** (cholinergic receptors), **GNAQ**, **PLCB**, and **IP3**, ultimately leading to the release of **Ca\u00b2+** into the cytosol and mitochondria via **MCU**. Excess mitochondrial calcium triggers the **MPTP** (mitochondrial permeability transition pore), causing mitochondrial dysfunction and the release of **cytochrome c**, which initiates **apoptosis**. This cascade is strongly linked to **Alzheimer's disease**. Mutations in **APP** and downstream components of this pathway contribute to the pathological hallmarks of Alzheimer's, including **plaques** and **neurofibrillary tangles**, leading to **cognitive decline** and **neuronal death**. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes a signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the release of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChR), and subsequent activation of GNAQ and phospholipase C (PLCB). This results in the production of IP3, which triggers the release of calcium from the endoplasmic reticulum, and subsequent mitochondrial calcium uptake via MCU. Increased mitochondrial calcium can lead to the opening of the mitochondrial permeability transition pore (MPTP), causing the release of cytochrome c (CYCS), a key initiator of apoptosis. This pathway is central to neurodegenerative processes, particularly in Alzheimer's disease, where aberrant APP processing and amyloid-beta accumulation are hallmarks. The involvement of mitochondrial calcium dysregulation and cytochrome c release contributes to neuronal apoptosis and cognitive decline. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta (Abeta), which activates muscarinic acetylcholine receptors (mAChR), subsequently engaging GNAQ and phospholipase C beta (PLCB) to generate IP3. IP3 then triggers the release of calcium ions (Ca2+) from the endoplasmic reticulum, which enters mitochondria via the mitochondrial calcium uniporter (MCU). Excessive mitochondrial calcium can induce mitochondrial permeability transition pore (MPTP) opening, releasing cytochrome c (CYCS), a key initiator of apoptosis. This pathway is central to neurodegenerative processes, particularly in Alzheimer's disease, where APP processing leads to amyloid-beta accumulation, mitochondrial dysfunction, and neuronal apoptosis. The involvement of multiple genes in this pathway supports its role in the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in regulating neuronal excitability by modulating membrane potential. Mutations in KCNC3 can disrupt normal ion flow, leading to hyperexcitability of neurons. This is particularly relevant in the central nervous system, where altered potassium channel function can cause seizures. Mutations in KCNC3 have been associated with **epilepsy**, specifically **genetic generalized epilepsy** and **early myoclonic encephalopathy**. These mutations may lead to impaired neuronal repolarization, increasing the likelihood of spontaneous seizure activity. The K+ pathway involvement highlights the gene's role in maintaining proper electrical signaling in neurons. Therefore, the biological effect of the KCNC3 allele is a contribution to **epilepsy**.\n\n\\boxed{Epilepsy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a potassium voltage-gated channel subunit, which plays a critical role in repolarizing neuronal membranes. Mutations in KCNC3 can lead to abnormal neuronal excitability. Specifically, loss-of-function mutations in KCNC3 are associated with **epilepsy**, particularly **benign familial neonatal seizures (BFNS)**. These mutations result in reduced potassium currents, leading to hyperexcitability of neurons and increased seizure susceptibility. KCNC3 is part of the K+ channel pathway, and its dysfunction disrupts normal electrical signaling in the brain, contributing to seizure onset. This genetic alteration is typically inherited in an autosomal dominant manner. The impaired function of KCNC3 thus directly contributes to the pathophysiology of **epilepsy**. \n\n\\boxed{Epilepsy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit (Kv3.4), which plays a crucial role in regulating action potential repolarization in cardiac and neuronal cells. Mutations in KCNC3 can disrupt normal ion flow, leading to arrhythmias. Specifically, gain-of-function mutations in KCNC3 are associated with **congenital long QT syndrome type 6 (LQTS6)**, a condition characterized by prolonged QT interval on ECG, which increases the risk of torsades de pointes and sudden cardiac death. This disorder is typically inherited in an autosomal dominant manner. The altered potassium channel function leads to delayed repolarization of cardiac myocytes, creating a favorable environment for triggered activity and arrhythmias. Therefore, the biological effect of a pathogenic KCNC3 allele is the disruption of cardiac electrical stability, contributing to **congenital long QT syndrome type 6**.\n\n\\boxed{Congenital long QT syndrome type 6}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChR), and subsequent signaling through GNAQ and PLCB, resulting in the release of Ca\u00b2\u207a from the endoplasmic reticulum and mitochondria. The accumulation of mitochondrial calcium and subsequent opening of the mitochondrial permeability transition pore (MPTP) leads to the release of cytochrome c (CYCS), triggering apoptosis. This pathway is central to neurodegenerative processes. Mutations in APP, particularly those leading to increased amyloid-beta production, are strongly associated with **Alzheimer's disease**. The accumulation of toxic amyloid-beta plaques and subsequent mitochondrial dysfunction and apoptosis contribute to neuronal loss in Alzheimer's. Thus, this pathway is a key contributor to **Alzheimer's disease**.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with the **APP (amyloid beta precursor protein)** gene, which is central to **Alzheimer's disease (AD)**. The cascade involves the production of **amyloid-beta (Abeta)** peptides, which aggregate to form plaques in the brain\u2014a hallmark of AD. These plaques disrupt cellular function and trigger neurodegeneration. The pathway continues through **mAChR (muscarinic acetylcholine receptors)**, **GNAQ**, **PLCB**, **IP3**, and **ITPR**, leading to **mitochondrial calcium influx via MCU**. This calcium overload activates the **mitochondrial permeability transition pore (MPTP)**, releasing **cytochrome c (CYCS)**, which initiates **apoptosis**. This mechanism is critical in AD pathogenesis, linking APP dysfunction to neuronal death and cognitive decline. The involvement of multiple genes in this pathway underscores its role in **Alzheimer's disease**.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway, starting with **APP** (amyloid beta precursor protein), leads to the production of **Abeta**, which interacts with **mAChR** (muscarinic acetylcholine receptors) and activates **GNAQ**, triggering a cascade involving **PLCB** and **IP3**. This results in the release of **Ca2+** from the endoplasmic reticulum, which is taken up by mitochondria via **MCU** (mitochondrial calcium uniporter). Excessive mitochondrial calcium can lead to **MPTP** opening, releasing **cytochrome c** (**CYCS**), initiating apoptosis. This pathway is central to **neurodegeneration**. Mutations in **APP** are strongly associated with **Alzheimer's disease**, as they contribute to **Abeta** accumulation, mitochondrial dysfunction, and neuronal apoptosis. The pathway highlights a key mechanism linking **APP dysfunction** to **Alzheimer's disease**.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein quality control and RNA metabolism. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of misfolded proteins, cellular stress, and neurodegeneration. This contributes to Spinocerebellar Ataxia Type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination, motor impairments, and ataxia. The pathway involving ATXN3 is part of a calcium signaling cascade that regulates mitochondrial function and apoptosis. Dysregulation of this pathway due to ATXN3 mutations disrupts calcium homeostasis, mitochondrial integrity, and neuronal survival, exacerbating the neurodegenerative process. These molecular alterations are central to the pathogenesis of SCA2. \n\n\\boxed{Spinocerebellar Ataxia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is involved in the genomic pathway starting from glutamate signaling through GRM1, GNAQ, and PLCB, leading to IP3 release and subsequent Ca\u00b2+ influx via ITPR1. This Ca\u00b2+ is transported into mitochondria via MCU and VDACs, contributing to mitochondrial Ca\u00b2+ overload. This process activates the MPTP (mitochondrial permeability transition pore), leading to mitochondrial dysfunction and the release of cytochrome c (CYCS), which is critical for apoptosis. Mutations in ATXN3 are associated with spinocerebellar ataxia type 2 (SCA2), an inherited neurodegenerative disorder characterized by progressive loss of coordination. The ATXN3 allele contributes to the pathogenesis of SCA2 by disrupting calcium homeostasis and mitochondrial function, ultimately leading to neuronal degeneration. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein quality control. Mutations in ATXN3 lead to the expansion of its polyglutamine tract, causing dysfunctional protein folding and aggregation. This results in neurodegeneration. The inclusion of ATXN3 in the genomic pathway involving calcium signaling and mitochondrial dysfunction underscores its role in cellular stress responses. The pathway highlights how disruptions in calcium homeostasis and mitochondrial function contribute to neuronal damage. The specific genetic mutation in ATXN3 is a hallmark of spinocerebellar ataxia type 2 (SCA2), a hereditary neurological disorder characterized by progressive loss of coordination and motor control. The interaction of ATXN3 with ITPR1 and MCU further supports its role in modulating calcium dynamics, which are critical for neuronal function. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving stress response and protein folding. SOD1, a copper/zinc superoxide dismutase, catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described includes HSPA5 (binding immunoglobulin protein), EIF2AK3 (PERK), and downstream effectors like EIF2S1, ATF4, and DDIT3, all of which are involved in the unfolded protein response (UPR) and cellular stress. Mutant SOD1 contributes to neurotoxicity by inducing ER stress, impairing protein folding, and triggering neuronal apoptosis. These mechanisms are key to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. This pathway is associated with cellular stress responses, particularly in the endoplasmic reticulum (ER). Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The SOD1 gene encodes an enzyme that normally detoxifies superoxide radicals, but pathogenic mutations lead to protein misfolding and aggregation, triggering ER stress and activating the unfolded protein response. The downstream genes in this pathway, such as ATF4 and DDIT3, are involved in stress-induced transcriptional responses. These molecular mechanisms contribute to neuronal death, which is a hallmark of ALS. Therefore, the biological effect of this SOD1 allele is the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a signaling pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by progressive loss of motor neurons. The pathway involving SOD1, BIP, EIF2AK3, EIF2S1, ATF4, and DDIT3 is implicated in the unfolded protein response (UPR) and stress-induced translational regulation. Mutant SOD1 proteins can misfold and aggregate, leading to cellular stress, mitochondrial dysfunction, and neuronal death. This pathway's dysregulation contributes to the pathogenesis of ALS. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is central to the production and degradation of amyloid-beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The pathway illustrates the cleavage of the amyloid beta precursor protein (APP) leading to the generation of Abeta peptides. These peptides are then regulated by the 26S proteasome, which includes ATPases (like PSMC1-6) and non-ATPase subunits (like PSMD1-14), essential for protein degradation. Impaired proteasomal function or dysregulation of APP processing leads to the accumulation of Abeta, forming plaques in the brain, a hallmark of Alzheimer's disease. Therefore, this pathway is directly implicated in the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is central to the production and degradation of amyloid-beta (Abeta), a protein fragment implicated in neurodegeneration. The pathway involves the cleavage of the amyloid beta precursor protein (APP) to generate Abeta, which can accumulate as plaques in the brain. The 26S proteasome, composed of subunits like PSMC and PSMD proteins, is responsible for degrading misfolded or damaged proteins, including Abeta. Impaired proteasome function leads to Abeta accumulation, contributing to neuronal toxicity. This process is a hallmark of Alzheimer's disease, where the accumulation of Abeta plaques and neurofibrillary tangles drive cognitive decline. Mutations or dysregulation in APP or proteasome subunits are associated with increased risk and severity of Alzheimer's. Thus, this pathway is directly linked to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele, as indicated by the pathway involving APP \u2192 Abeta \u2192 26S, is the production of amyloid-beta peptides, which are central to the pathogenesis of Alzheimer's disease. The proteasome subunits listed, particularly those of the 26S proteasome, are involved in the degradation of misfolded or damaged proteins. Impaired proteasome function, including that of the 26S subunits, leads to the accumulation of toxic amyloid-beta plaques in the brain, a hallmark of Alzheimer's. Mutations or dysregulation in APP and proteasome subunits contribute to impaired clearance of amyloid-beta, promoting neurodegeneration. This pathway is thus directly implicated in the development of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical for cell growth and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in aberrant cell proliferation and survival. Specifically, activating mutations in FGFR3 are most commonly associated with **Bladder Urothelial Carcinoma** (also known as urothelial bladder cancer). These mutations drive uncontrolled cell growth in the urothelial lining of the bladder, leading to tumor formation. FGFR3 mutations are particularly prevalent in low-grade, non-invasive bladder cancers and are often found in conjunction with other genetic alterations. The activation of the ERK and MYC pathways contributes to oncogenesis by promoting cell cycle progression and anti-apoptotic signals. \\boxed{Bladder Urothelial Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation. Mutations in FGFR3, particularly activating mutations or fusions, lead to constitutive activation of the downstream signaling cascade, including RAS and RAF, resulting in aberrant MAPK/ERK activation. This dysregulation promotes uncontrolled cell growth and proliferation. In particular, gain-of-function mutations in FGFR3 are strongly associated with **bladder cancer**, specifically **bladder urothelial carcinomas**. These mutations drive tumor progression by enhancing cell survival, proliferation, and resistance to apoptosis. FGFR3 mutations are most commonly found in **low-grade papillary urothelial carcinomas** but can also occur in high-grade tumors. The resulting hyperactivation of the MAPK pathway contributes to oncogenesis by promoting transcriptional changes that support tumor growth and metastasis. \\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in regulating cell growth and differentiation, particularly in bone development. Mutations in FGFR3, especially gain-of-function mutations, lead to constitutive activation of the pathway, driving uncontrolled cell proliferation. This is most notably associated with **blastic meningioma**, a type of brain tumor. FGFR3 mutations are also implicated in **multiple myeloma** and **schwannomatosis**, but the strongest association is with **blastic meningioma**, where activating mutations in FGFR3 drive tumor formation by hyperactivating the downstream RAS-RAF-MEK-ERK signaling cascade, promoting proliferation and survival of meningioma cells. The specific disease linked to FGFR3 mutations in this context is \\boxed{Blastic Meningioma}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction leads to Huntington's disease. In this pathway, HTT interacts with STX1A, a key component of the SNARE complex involved in neurotransmitter release, and modulates VGCC (N-type) channels, which regulate calcium entry into neurons. Mutations in HTT, such as CAG trinucleotide expansions, result in the production of an abnormal huntingtin protein that disrupts synaptic vesicle fusion and calcium homeostasis. This leads to neuronal dysfunction and degeneration, particularly in the striatum and cortex. The resulting disease is characterized by progressive motor, cognitive, and psychiatric symptoms. The pathway highlights the role of HTT in maintaining neuronal integrity and calcium signaling. The biological effect of the HTT allele is thus central to the pathogenesis of \\boxed{Huntington's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant form causes Huntington's disease. In the given pathway, HTT interacts with STX1A and VGCC (N-type), leading to increased intracellular Ca\u00b2\u207a levels. Mutations in HTT, particularly expanded CAG repeats, result in toxic huntingtin protein aggregation, disrupting synaptic function and neuronal homeostasis. This leads to progressive neurodegeneration, particularly in the striatum and cortex, causing motor, cognitive, and psychiatric symptoms. The pathway's disruption contributes to calcium dyshomeostasis, a key mechanism in Huntington's disease pathology. Thus, the biological effect of the HTT allele is the development of Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in intracellular transport and vesicle docking. In the given pathway, HTT interacts with STX1A (syntaxin 1A), a key component of the SNARE complex required for synaptic vesicle fusion. STX1A also interacts with VGCC (N-type), which allows calcium influx. Mutations in HTT, particularly expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long huntingtin protein, disrupting cellular processes like protein degradation and mitochondrial function. This primarily affects neurons, leading to neurodegeneration. The most well-known disease associated with HTT mutations is Huntington's disease, a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric impairments. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for mitochondrial quality control and protein degradation. Mutations in PRKN lead to impaired ubiquitination, disrupting proteostasis and mitochondrial function. This contributes to the accumulation of damaged mitochondria and protein aggregates, triggering neurodegeneration. PRKN mutations are a primary cause of autosomal recessive Parkinson's disease. The pathway involving UBCH7/8 (E2 enzymes) and CDCREL1 supports ubiquitination processes essential for parkin-mediated degradation. Dysfunction in this pathway compromises neuronal survival, particularly in the substantia nigra. Thus, PRKN mutations directly contribute to Parkinson's disease by disrupting ubiquitin-dependent clearance mechanisms. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Its role in protein quality control and mitochondrial function makes it critical for neuronal health. Mutations in PRKN lead to impaired ubiquitination and accumulation of damaged proteins, disrupting cellular homeostasis. This contributes to neurodegeneration. PRKN mutations are a well-established cause of autosomal recessive Parkinson's disease (PD), specifically PARK2. The pathway involving UBCH7/8 and CDCREL1 is linked to ubiquitination processes, supporting PRKN's role in protein degradation. Dysfunction in this pathway exacerbates neurodegeneration, reinforcing PRKN's contribution to PD. The biological effect of PRKN allele dysfunction is thus a key driver of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase that plays a critical role in ubiquitin-mediated protein degradation. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and CDCREL1, is linked to the ubiquitin-proteasome system, which is essential for maintaining protein homeostasis. Dysfunction in this pathway leads to the accumulation of misfolded proteins and neuronal toxicity. PRKN mutations impair the degradation of damaged mitochondria and other substrates, contributing to neurodegeneration. This results in the progressive loss of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease. Therefore, the biological effect of PRKN allele dysfunction is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 gene is a key regulator in the Wnt/\u03b2-catenin signaling pathway. In the given pathway, AXIN1 functions as a negative regulator, inhibiting the stabilization of CTNNB1 (\u03b2-catenin). When AXIN1 is mutated or dysfunctional, \u03b2-catenin accumulates, leading to aberrant activation of TCF/LEF transcription factors, which drive the expression of oncogenes like MYC and CCND1. This dysregulation promotes uncontrolled cell proliferation and inhibition of apoptosis, contributing to tumor development. Mutations in AXIN1 have been implicated in various cancers, most notably **colorectal cancer**, where loss of AXIN1 function disrupts the Wnt pathway, leading to \u03b2-catenin stabilization and oncogenic transformation. Therefore, the biological effect of a pathogenic AXIN1 allele is the promotion of tumorigenesis, particularly in **colorectal cancer**.\n\n\\boxed{Colorectal cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 allele plays a critical role in the WNT signaling pathway. AXIN1 functions as a scaffolding protein that facilitates the degradation of \u03b2-catenin (CTNNB1) by forming a destruction complex with APC and GSK3B. This prevents the accumulation of \u03b2-catenin in the cytoplasm, thereby inhibiting its nuclear translocation and subsequent activation of TCF/LEF target genes such as MYC and CCND1. Mutations or loss of function in AXIN1 disrupt this regulatory mechanism, leading to \u03b2-catenin stabilization and aberrant activation of downstream oncogenes. This dysregulation contributes to uncontrolled cell proliferation and is a key driver in several cancers. Specifically, AXIN1 mutations are strongly associated with **colorectal cancer**, where they impair the WNT pathway's tumor-suppressive function. \\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 gene is a critical negative regulator of the WNT/\u03b2-catenin signaling pathway. In the given pathway, AXIN1 functions in parallel with GSK3B and APC to promote the degradation of CTNNB1 (\u03b2-catenin). When AXIN1 is mutated or dysfunctional, this degradation is impaired, leading to the accumulation of \u03b2-catenin. This results in aberrant activation of TCF/LEF transcription factors, which in turn upregulate oncogenes such as MYC and CCND1. This pathway dysregulation is a hallmark of several cancers. Specifically, mutations in AXIN1 contribute to the development of colorectal cancer, where the WNT pathway is frequently activated. Such mutations are also associated with other malignancies, including certain types of leukemia and lymphoma. The biological effect of a pathogenic AXIN1 allele is therefore the promotion of uncontrolled cell proliferation and tumor formation. \\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) allele plays a critical role in prostate cancer progression. In the given pathway, AR activates KLK3 (kallikrein-related peptidase 3), a serine protease that contributes to prostate tumor growth and aggressiveness. Mutations or variations in AR can enhance its activity, leading to increased KLK3 expression, which promotes epithelial-to-mesenchymal transition, invasion, and metastasis. This pathway is central to androgen-dependent prostate cancer development. Altered AR function, such as gain-of-function mutations or increased expression, is associated with disease recurrence and resistance to androgen deprivation therapy. These genetic changes drive the progression of prostate cancer, making AR a key contributor to the disease. \n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) allele plays a crucial role in prostate development and function. In the context of the provided pathway, AR activation by ligands such as testosterone (T), dihydrotestosterone (DHT), and others leads to the expression of KLK3 (kallikrein-related peptidase 3). Elevated KLK3 levels are associated with prostate cancer progression. Mutations or aberrant activation of AR can drive uncontrolled cell growth and contribute to the development and aggressiveness of prostate cancer. The pathway highlights AR's role in prostate biology, and altered AR function is a key factor in the pathogenesis of prostate cancer. Therefore, the biological effect of this AR allele is the contribution to prostate cancer.\n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) allele plays a critical role in prostate development and function. Its activation by androgens such as testosterone (T), dihydrotestosterone (DHT), and other ligands (E2, P4, FLUT, DHA, A4, F, E) leads to the transcription of KLK3 (kallikrein-related peptidase 3), a serine protease implicated in prostate cancer progression. Mutations or aberrant regulation of AR can disrupt normal prostate cell growth and differentiation, contributing to the development and progression of prostate cancer. The AR-KLK3 pathway is a key driver in the androgen-dependent growth of prostate cancer cells. Therefore, the biological effect of this AR allele is the promotion of prostate cancer. \n\n\\boxed{Prostate Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex. Mutations in PSEN1 are a primary cause of early-onset familial Alzheimer\u2019s disease (FAD). These mutations disrupt the normal function of the \u03b3-secretase complex, leading to aberrant cleavage of the amyloid precursor protein (APP), resulting in the accumulation of toxic amyloid-\u03b2 plaques in the brain. This pathological accumulation is a hallmark of Alzheimer\u2019s disease and contributes to neurodegeneration. The pathway described involves the release of calcium from the endoplasmic reticulum (via ITPR) and its uptake into mitochondria (via MCU), which is essential for maintaining mitochondrial function. Disruption of this calcium homeostasis can lead to mitochondrial dysfunction, reactive oxygen species production, and apoptosis, further exacerbating neuronal damage. Thus, PSEN1 mutations contribute to the development of Alzheimer\u2019s disease by promoting amyloid-\u03b2 accumulation and mitochondrial dysfunction.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a crucial component of the gamma-secretase complex. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (AD). The pathway described involves calcium signaling, with PSEN1 influencing intracellular calcium levels via the IP3 receptor (ITPR) and the mitochondrial calcium uniporter (MCU). Dysregulation of this pathway leads to mitochondrial dysfunction, increased oxidative stress, and apoptosis, all of which contribute to neurodegeneration. The involvement of cytochrome c (CYCS) and the mitochondrial permeability transition pore (MPTP) further supports a role in apoptosis and neuronal cell death. These processes are central to the pathophysiology of Alzheimer's disease. Therefore, the biological effect of the PSEN1 allele is the contribution to the development of early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex. Mutations in PSEN1 are well-established causes of early-onset familial Alzheimer's disease (FAD). In the provided pathway, PSEN1 is upstream of ITPR, which regulates intracellular calcium release. Dysfunctional PSEN1 disrupts calcium homeostasis by impairing ITPR activity, leading to altered mitochondrial calcium uptake via MCU and increased mitochondrial permeability transition pore (MPTP) opening. This results in mitochondrial dysfunction, oxidative stress, and apoptosis, all of which are key pathogenic mechanisms in Alzheimer's disease. The involvement of CYCS and other components further supports the role of mitochondrial damage in disease progression. Thus, PSEN1 mutations contribute to the development of Alzheimer's disease through calcium dyshomeostasis and mitochondrial dysfunction.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, a component of the neuronal cytoskeleton involved in maintaining cellular structure and signaling. In the described pathway, SPTBN2 interacts with GRM1, initiating a signaling cascade involving GNAQ, PLCB isoforms, IP3, and calcium release via ITPR. Mutations in SPTBN2 disrupt this structural and signaling integrity, leading to impaired neuronal function. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, SPTBN2 mutations are associated with **Familial Hemiplegic Migraine Type 1 (FHM1)**, a genetic disorder characterized by episodic migraines with motor weakness. The disruption of calcium homeostasis and synaptic transmission due to SPTBN2 dysfunction underlies the pathophysiology of this condition. \\boxed{Familial Hemiplegic Migraine Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, a structural protein involved in maintaining cellular integrity. In the described pathway, SPTBN2 interacts with GRM1, initiating a signaling cascade involving GNAQ, PLCB isoforms, IP3, and ITPR, ultimately leading to increased intracellular Ca\u00b2\u207a levels. Mutations in SPTBN2 disrupt this pathway, altering Ca\u00b2\u207a homeostasis and neuronal signaling. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, SPTBN2 mutations are associated with **familial hemiplegic migraine (FHM)**, a rare inherited form of migraine with neurological symptoms. The disruption of Ca\u00b2\u207a signaling through this pathway impairs neuronal function, leading to episodes of severe headache and neurological deficits. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, a cytoskeletal protein involved in maintaining cell structure and signaling. In the described pathway, SPTBN2 interacts with GRM1, initiating a signaling cascade involving GNAQ, PLCB isoforms, IP3, and ITPR, leading to calcium release. Mutations in SPTBN2 disrupt this pathway, impairing calcium signaling and cytoskeletal dynamics. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, SPTBN2 mutations are associated with **Dystonia** and **Autism Spectrum Disorder (ASD)**. Altered calcium homeostasis and synaptic plasticity due to disrupted IP3 signaling and cytoskeletal instability are implicated in these conditions. The pathway's dysfunction affects neuronal connectivity and motor control, hallmark features of dystonia and ASD. Thus, the SPTBN2 allele contributes to **Autism Spectrum Disorder**.\n\n\\boxed{Autism Spectrum Disorder}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **CACNA1A** gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel. This subunit is critical for calcium influx into neurons, playing a key role in neurotransmitter release and neuronal excitability. Mutations in **CACNA1A** disrupt calcium homeostasis, leading to abnormal neuronal function. This contributes to a range of neurological disorders, most notably **Friedreich's ataxia**, though it is more specifically linked to **spinocerebellar ataxia type 2 (SCA2)** and ** familial hemiplegic migraine (FHM)**. In particular, **CACNA1A** mutations are a major cause of **familial hemiplegic migraine**, a form of migraine with neurological symptoms such as hemiparesis. The altered calcium signaling impairs synaptic transmission and leads to neuronal hyperexcitability and vascular dysfunction. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type calcium voltage-gated channel, which is critical for neuronal excitability and neurotransmitter release. Mutations in CACNA1A are associated with impaired calcium influx, leading to disrupted neuronal signaling. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, pathogenic variants in CACNA1A are a well-documented cause of **familial hemiplegic migraine (FHM)**, a genetic form of migraine with aura and hemiplegic features. These mutations can also contribute to other neurological conditions, including ataxia and autism spectrum disorders, highlighting the gene's essential role in brain function. The altered calcium homeostasis disrupts synaptic transmission and neuronal stability, leading to the clinical manifestations observed in these diseases. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the Cav1.1 calcium channel, which is critical for neuronal excitability and neurotransmitter release. Mutations in CACNA1A are associated with episodic ataxia type 2 (EA2), a neurodevelopmental disorder characterized by episodic loss of coordination. These mutations disrupt calcium homeostasis, leading to abnormal neuronal function. The pathway involving extracellular Ca\u00b2+ and the CACNA1A-encoded channel highlights its role in regulating intracellular calcium levels in response to extracellular signals. Dysfunction in this pathway contributes to the pathogenesis of EA2, which can also overlap with other conditions such as migraine with aura and familial hemiplegic migraine. Therefore, the biological effect of the CACNA1A allele is the disruption of calcium signaling, leading to the disease \\boxed{Episodic Ataxia Type 2}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP allele, which encodes prosaposin, is involved in the lysosomal degradation of sphingolipids. Mutations in PSAP lead to insufficient production of functional prosaposin, resulting in the accumulation of sphingolipids in neurons. This accumulation causes neurotoxicity and progressive neurological dysfunction. PSAP is also a substrate for GBA, GBA2, and GALC, enzymes involved in the breakdown of glycosphingolipids. Deficiencies in these enzymes are associated with lysosomal storage disorders. Specifically, PSAP mutations contribute to metachromatic leukodystrophy (MLD), a severe neurodegenerative disorder characterized by the loss of myelin sheath in the central and peripheral nervous systems. The dysfunction of PSAP and its interacting enzymes leads to the hallmark pathological features of MLD. \n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is involved in lipid metabolism and myelin formation. Mutations in PSAP lead to a deficiency in sphingolipid active forms, resulting in the accumulation of abnormal lipids in neurons. This contributes to progressive neurodegeneration. The pathway also includes GBA, GBA2, and GALC, which are involved in breaking down similar lipids. Mutations in these genes are associated with lysosomal storage disorders. Specifically, PSAP mutations are linked to **Abiotrophic Lymphocytosis (AL)**, a rare inherited neurological disorder characterized by the loss of cerebellar Purkinje cells and lymphocytopenia. This condition is part of a group of disorders affecting sphingolipid metabolism, highlighting the critical role of these genes in maintaining neural function. \\boxed{Abiotrophic Lymphocytosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is critical for the proper folding and trafficking of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired enzyme function, contributing to the accumulation of glycolipids in lysosomes. This primarily affects the central nervous system, leading to neurodegeneration. The pathway is associated with metachromatic leukodystrophy (MLD), a lysosomal storage disorder. PSAP deficiency disrupts the processing of sphingolipids, resulting in the pathogenesis of MLD. This disorder is characterized by progressive myelin loss and severe neurological decline. Therefore, the biological effect of this PSAP allele is the disruption of sphingolipid metabolism, leading to metachromatic leukodystrophy.\n\n\\boxed{Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and neurodegeneration. Mutations in ATXN3 are associated with spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive degeneration of the cerebellum and motor incoordination. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is linked to autophagy regulation, a process critical for removing damaged proteins and organelles. Disruption of this pathway, particularly through ATXN3 mutations, impairs autophagy, leading to the accumulation of toxic protein aggregates and neuronal death. This contributes to the pathogenesis of SCA2. The biological effect of the ATXN3 allele is thus the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein homeostasis. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process critical for removing damaged proteins and organelles. Dysregulation of this pathway can lead to the accumulation of toxic proteins, contributing to neurodegeneration. In SCA2, expanded polyglutamine tracts in ataxin-3 disrupt its function, leading to protein misfolding, aggregation, and neuronal death. This highlights the role of ATXN3 in maintaining cellular homeostasis and its impact on neurological health. The biological effect of the ATXN3 allele is thus linked to the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and ubiquitin-dependent proteolysis. Mutations in ATXN3 are the primary cause of **Spinal Cord Ataxia with Ocular Motor Apraxia Type 1 (SCA1)**, an autosomal dominant neurodegenerative disorder. These mutations typically involve expansions of CAG trinucleotide repeats, leading to the production of a toxic, polyglutamine-containing ataxin-3 protein. This protein disrupts cellular function, particularly in neurons, leading to progressive degeneration of the cerebellum and other brain regions. The resulting clinical features include ataxia, ophthalmoplegia, and distinctive facial features. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 suggests a role in autophagy regulation, which may contribute to the pathogenesis of the disease by impairing the clearance of misfolded proteins. \\boxed{Spinal Cord Ataxia with Ocular Motor Apraxia Type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, and mutations in this gene are associated with prion diseases. In the given pathway, PRNP activates a cascade involving caveolins, FYN, PI3K, PRKCD, and ultimately NOX2, leading to increased ROS production. This oxidative stress is linked to neurodegeneration. The biological effect of pathogenic PRNP alleles is the misfolding and aggregation of prion proteins, leading to neurotoxicity. This contributes to the development of Creutzfeldt-Jakob disease (CJD), a fatal neurodegenerative disorder characterized by spongiform encephalopathy. The pathway highlights how PRNP dysfunction initiates a cascade resulting in oxidative damage and neuronal death, hallmark features of CJD. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, and mutations in PRNP are directly associated with prion diseases. In the given pathway, PRNP initiates a signaling cascade involving caveolins, FYN, PI3K, and ultimately leads to the production of ROS via NOX2. This pathway is implicated in oxidative stress and neurodegeneration. Prion diseases, such as Creutzfeldt-Jakob disease (CJD), are caused by misfolded prion proteins that induce normal prion proteins to misfold, leading to neuronal damage and progressive dementia. The pathway described contributes to the pathogenesis of these diseases by promoting oxidative stress and cellular toxicity. The biological effect of the PRNP allele, particularly pathogenic variants, is the development of prion disorders. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, and mutations in PRNP are known to cause prion diseases. In the given pathway, PRNP is the starting point, leading to downstream activation of FYN, PI3K, and ultimately NOX2, which generates ROS. Mutations in PRNP that cause misfolding and aggregation of the prion protein lead to neurodegenerative diseases characterized by abnormal protein deposition in the brain. The most well-known disease associated with PRNP mutations is Creutzfeldt-Jakob Disease (CJD), a rapidly progressive and fatal neurologic disorder. This disease is caused by the conversion of normal prion protein (PrP^C) into the pathological form (PrP^Sc), which triggers cellular dysfunction and neuron loss. The pathway described reflects the involvement of oxidative stress and signaling cascades in disease progression. \\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, similar to KRAS, result in constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This leads to resistance to apoptosis and uncontrolled cell proliferation. This pathway is critical in oncogenesis, and mutations in NRAS are strongly associated with various cancers. Specifically, NRAS mutations are a well-documented driver in **melanoma**, where they promote cell survival and proliferation by disrupting the normal regulation of cell growth and apoptosis. These mutations are also linked to **colorectal cancer** and **non-small cell lung cancer**. The dysregulation of this pathway through NRAS mutation is a key factor in the initiation and progression of these malignancies. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to oncogenesis by activating the PI3K-AKT signaling cascade. This pathway is critical for cell survival, proliferation, and metabolism. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, such as AKT, which inhibits pro-apoptotic proteins like BAD, promoting cell survival. This uncontrolled survival and proliferation drive tumor development. NRAS mutations are commonly associated with **melanoma**, where they contribute to oncogenic transformation by sustaining signaling through the MAPK and PI3K pathways. These mutations are also found in other cancers, including **non-small cell lung cancer**, **colorectal cancer**, and **acute myeloid leukemia**, depending on the tissue context. The persistent activation of this pathway disrupts normal cellular regulation, leading to malignant growth. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway illustrates the RAS-PI3K-AKT-BAD signaling cascade, critical for cell survival and proliferation. NRAS, like KRAS, is a GTPase that activates PI3K upon oncogenic mutation. Mutated NRAS leads to constitutive activation of PI3K, increasing PIP3 and subsequently AKT phosphorylation. This inhibits BAD, preventing apoptosis and promoting cell survival. NRAS mutations are commonly found in cancers such as melanoma, pancreatic cancer, and non-small cell lung cancer. These mutations drive uncontrolled cell growth and resistance to apoptosis, contributing to tumor progression. The hallmark of NRAS-driven cancers is genomic instability and activation of downstream survival pathways. NRAS mutations are particularly prevalent in melanomas arising from sun-damaged skin, where they frequently co-occur with BRAF mutations. The cumulative effect of NRAS mutation is the promotion of oncogenesis by disrupting normal cell cycle control and apoptosis. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is involved in the degradation of misfolded proteins through the ubiquitin-proteasome system. Mutations in ATXN3 lead to abnormal protein accumulation, which contributes to neurodegeneration. Specifically, expansions in the polyglutamine tract of ATXN3 cause the disease \\boxed{Spinocerebellar Ataxia Type 2 (SCA2)}. This condition is characterized by progressive loss of coordination and motor control due to the toxic accumulation of mutant ATXN3 protein in neurons, particularly in the cerebellum. The pathway involving ATXN3, including its role in calcium signaling and mitochondrial dysfunction, further exacerbates neuronal damage, leading to the clinical manifestations of SCA2.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein quality control. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination. In the given pathway, ATXN3 is implicated in the calcium signaling cascade, likely contributing to neuronal dysfunction through disrupted calcium homeostasis. This disruption may lead to oxidative stress and cell death, exacerbating neurodegeneration. SCA2 typically presents with gait instability, dysarthria, and cognitive deficits, with disease severity and age of onset varying. The involvement of ATXN3 in this pathway underscores its role in maintaining cellular calcium balance, and its mutation perturbs this process, driving the pathophysiology of SCA2. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein quality control and transcriptional regulation. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of misfolded proteins, triggering cellular stress and neurodegeneration. This results in spinocerebellar ataxia type 2 (SCA2), a hereditary neurological disorder characterized by progressive loss of coordination and motor function. In the given pathway, ATXN3 interacts with ITPR1, which is involved in calcium signaling, and its dysfunction disrupts calcium homeostasis, contributing to mitochondrial dysfunction and neuronal death. This highlights the role of ATXN3 in maintaining neuronal integrity and the pathological consequences of its mutation. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the PI3K/AKT signaling pathway. When PTEN is mutated or lost, PIP3 levels increase, leading to constitutive activation of AKT. This results in uncontrolled cell growth, resistance to apoptosis, and enhanced angiogenesis, all of which contribute to tumorigenesis. The disruption of this pathway is strongly associated with the development of various cancers. Specifically, PTEN loss is a key driver in **Cowden syndrome**, a genetic disorder characterized by multiple benign and malignant tumors, including thyroid and breast cancers. Additionally, PTEN dysfunction is implicated in **PTEN hamartoma tumor syndrome** and contributes to the pathogenesis of **BRAFV600E-mutant melanoma** and other solid tumors. The biological effect of PTEN allele dysfunction is therefore central to the development of **Cowden syndrome** and related cancers.\n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene acts as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the AKT signaling pathway, which promotes cell survival and proliferation. When PTEN is mutated or inactivated, PIP3 levels rise, leading to constitutive activation of AKT. This results in uncontrolled cell growth and resistance to apoptosis, contributing to oncogenesis. The loss of PTEN function is commonly associated with various cancers, most notably **Cowden syndrome** and **PTEN hamartoma tumor syndrome**, which increase the risk of developing benign and malignant tumors, including breast, thyroid, and endometrial cancers. Additionally, PTEN mutations are frequently observed in **glioblastoma multiforme** and other cancers. The disruption of this pathway is a key driver in several malignancies. \\boxed{Glioblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the activation of AKT, a key component of the PI3K-AKT signaling pathway. When PTEN is mutated or lost, PIP3 levels increase, leading to sustained AKT activation. This promotes cell survival, proliferation, and resistance to apoptosis. The dysregulation of this pathway is closely linked to uncontrolled cell growth and tumorigenesis. Mutations in PTEN are commonly found in various cancers, including glioblastoma, prostate cancer, and endometrial cancer. The most well-documented disease associated with PTEN dysfunction is **Cowden syndrome**, a hereditary disorder characterized by multiple benign and malignant tumors. Additionally, PTEN mutations are a hallmark of certain aggressive cancers, such as breast and ovarian cancer. The loss of PTEN function is a critical driver in the development of these malignancies. \\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process critical for clearing misfolded proteins and damaged organelles. Dysfunction in this pathway can impair autophagy, exacerbating the accumulation of toxic proteins and neuronal damage. This disruption is central to the development and progression of SCA2. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in ubiquitin-mediated protein degradation. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of motor coordination. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy regulation. Impaired autophagy due to ATXN3 dysfunction leads to the accumulation of misfolded proteins and neuronal toxicity. This contributes to the pathogenesis of SCA2 by disrupting protein quality control and neuronal survival. Therefore, the biological effect of the ATXN3 allele is the development of spinocerebellar ataxia type 2. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene, when mutated, contributes to spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This is a neurodegenerative disorder characterized by progressive loss of coordination, muscle stiffness, and cognitive decline. The pathway involving ATXN3 includes genes related to autophagy, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, suggesting a role in cellular stress response and protein degradation. Mutations in ATXN3 lead to the production of an abnormal ataxin-3 protein, which forms toxic aggregates in neurons, particularly in the cerebellum and brainstem. These aggregates disrupt normal cellular function, leading to neuronal death and the clinical manifestations of SCA3. The disease is inherited in an autosomal dominant manner, and the severity is correlated with the length of the CAG repeat in the ATXN3 gene.\n\n\\boxed{Spinocerebellar ataxia type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP) and other substrates. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (AD). The pathway described involves PSEN1's interaction with EIF2AK3, EIF2S1, ATF4, and DDIT3, which are involved in stress response and protein translation. These interactions suggest a role for PSEN1 in regulating cellular stress responses and protein homeostasis, both of which are disrupted in neurodegenerative diseases. The biological effect of pathogenic PSEN1 alleles is the disruption of normal \u03b3-secretase function, leading to the accumulation of pathological amyloid-\u03b2 plaques and neuronal damage. This contributes directly to the development of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of the amyloid precursor protein (APP). Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to abnormal cleavage of APP, increasing the production of amyloid-beta peptides, particularly the toxic A\u03b242 species. This results in the accumulation of amyloid plaques in the brain, a hallmark of Alzheimer's disease. The pathway described, involving PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects the broader cellular stress response triggered by proteotoxic stress, including endoplasmic reticulum (ER) stress and unfolded protein response (UPR). This contributes to neuronal dysfunction and apoptosis, further exacerbating neurodegeneration. Therefore, the biological effect of mutant PSEN1 is the promotion of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). The pathway described, PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects a molecular cascade where PSEN1 dysfunction disrupts protein homeostasis and activates stress response pathways, including the integrated stress response (ISR). This leads to impaired protein translation and increased expression of DDIT3, a gene involved in cell cycle arrest and apoptosis. These effects contribute to neurodegeneration by promoting neuronal stress, reduced protein synthesis, and ultimately, neuronal loss. The accumulation of toxic amyloid-beta plaques and neurofibrillary tangles, characteristic of Alzheimer's disease, is exacerbated by these molecular changes. Therefore, PSEN1 mutations are strongly associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). In the given pathway, PSEN1 interacts with ERN1 (activating transcription factor), which regulates XBP1 (X-box binding protein 1) through the unfolded protein response (UPR). Dysfunctional PSEN1 disrupts \u03b3-secretase activity, leading to aberrant processing of amyloid precursor protein (APP), resulting in accumulation of toxic A\u03b2 plaques. This contributes to neuronal dysfunction and neurodegeneration. The pathway also links to endoplasmic reticulum (ER) stress, exacerbating cellular damage. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease, a neurodegenerative disorder characterized by progressive cognitive decline and brain atrophy. Thus, the biological effect of the PSEN1 allele is the induction of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP) and other substrates. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease. In the given pathway, PSEN1 is upstream of ERN1, which activates XBP1 through ER stress. This suggests a link between PSEN1 dysfunction and ER stress responses, which are dysregulated in neurodegenerative diseases. The PSEN1 allele contributes to the accumulation of pathological amyloid-\u03b2 plaques and neurodegeneration, hallmark features of Alzheimer's disease. Therefore, the biological effect of this PSEN1 allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which plays a critical role in the cleavage of the amyloid precursor protein (APP), generating \u03b2-amyloid peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer\u2019s disease (EOFAD). In the given pathway, PSEN1 is upstream of ERN1 (endoplasmic reticulum to nucleus signaling 1), which regulates XBP1 (X-box binding protein 1), a transcription factor involved in the unfolded protein response (UPR) and ER stress. PSEN1 mutations disrupt \u03b3-secretase activity, leading to abnormal APP processing and accumulation of toxic amyloid-\u03b2 plaques, hallmark features of Alzheimer\u2019s disease. Additionally, impaired ER stress responses may exacerbate neurodegeneration. Thus, this PSEN1 allele contributes to \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, acting as an adaptor protein that recruits damaged proteins and ubiquitinated substrates to autophagosomal membranes. In the context of the provided pathway, SQSTM1 is positioned downstream of PINK1 and PRKN, which are critical for mitophagy\u2014the selective autophagic degradation of mitochondria. Mutations in SQSTM1 disrupt this process, leading to the accumulation of damaged mitochondria and protein aggregates. This dysfunction is strongly associated with neurodegeneration. Specifically, SQSTM1 mutations contribute to Parkinson's disease by impairing mitophagy and promoting neuronal dysfunction and death. The impaired clearance of dysfunctional mitochondria leads to oxidative stress and neuronal loss, hallmark features of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene encodes a key scaffold protein involved in ubiquitin-mediated proteolysis and autophagy. In the context of the provided pathway, SQSTM1 interacts with components of the PINK1-PRKN pathway, which is critical for mitochondrial quality control. Mutations in SQSTM1 disrupt this pathway, leading to impaired mitophagy and mitochondrial dysfunction. This contributes to the accumulation of damaged mitochondria and cellular stress. SQSTM1 mutations are associated with autosomal recessive juvenile Parkinsonism (ARJP), a neurodegenerative disorder characterized by early-onset parkinsonism. The loss of SQSTM1 function impairs the clearance of damaged mitochondria and aggregates, leading to neuronal death, especially in the substantia nigra. This pathway is also implicated in other neurodegenerative diseases, but the most direct association of SQSTM1 mutations is with ARJP.\n\n\\boxed{Autosomal Recessive Juvenile Parkinsonism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a critical node in the PINK1-PRKN mitochondrial quality control pathway. SQSTM1 functions as a scaffolding protein that facilitates ubiquitin-mediated degradation of damaged mitochondria and misfolded proteins. Mutations in SQSTM1 disrupt this process, leading to the accumulation of dysfunctional mitochondria and protein aggregates. This contributes to neuronal dysfunction and degeneration, hallmark features of neurodegenerative diseases. SQSTM1 has been implicated in Parkinson's disease, where it interacts with PINK1 and PRKN to regulate mitophagy. Impaired SQSTM1 function results in reduced mitochondrial turnover, oxidative stress, and neuronal loss. Thus, SQSTM1 mutations are associated with the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this pathway activates the PI3K-AKT-BAD signaling cascade. NRAS, a RAS family GTPase, acts as a key upstream activator of PI3K upon receptor tyrosine kinase stimulation. This leads to the production of PIP3, which recruits AKT to the plasma membrane, promoting its activation. Activated AKT inhibits BAD, a pro-apoptotic protein, thereby preventing apoptosis and promoting cell survival and proliferation. Mutations in NRAS, such as activating mutations, result in constitutive activation of this pathway, driving uncontrolled cell growth. This contributes to the development of **cancer**. Specifically, NRAS mutations are commonly found in **melanoma**, **non-small cell lung cancer**, and **colorectal cancer**, where they drive oncogenic transformation by constitutively activating downstream signaling pathways involved in cell growth and survival.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of the RAS protein, which in turn enhances PI3K activity, increasing PIP3 levels and subsequently activating AKT. This leads to the inhibition of BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. This pathway is critical in oncogenesis. Mutations in NRAS are commonly found in cancers such as **melanoma**, **non-small cell lung cancer (NSCLC)**, and **colorectal cancer**, where they drive uncontrolled cell growth and resistance to apoptosis. The persistent activation of this pathway is a hallmark of these malignancies. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-PI3K-AKT-BAD pathway, contributes to the activation of downstream signaling that promotes cell survival and proliferation. Mutations in NRAS, a GTPase, lead to constitutive activation of the PI3K pathway, increasing production of PIP3 and subsequent activation of AKT. This inhibits BAD, a pro-apoptotic protein, thereby preventing programmed cell death. This pathway is critical in oncogenesis. Mutant NRAS is strongly associated with cancers such as **colorectal cancer**, **non-small cell lung cancer (NSCLC)**, and **melanoma**. It is also implicated in **acute myeloid leukemia (AML)** and **pancreatic cancer**. The persistent activation of this pathway disrupts normal cell cycle control and apoptosis, leading to uncontrolled cell growth and tumor formation. Thus, NRAS mutations are a key driver in these malignancies.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described pathway, plays a critical role in cellular homeostasis by regulating hypoxia-inducible factor (HIF) degradation via the VHL-RBX1-CUL2-Elongin B/C complex. Loss-of-function mutations in VHL disrupt this degradation mechanism, leading to HIF stabilization and aberrant activation of downstream genes such as VEGFA, CXCL8, GLUT1, and EPO. This results in inappropriate angiogenesis, inflammation, and metabolic changes, contributing to the development of clear cell renal cell carcinoma (ccRCC). The VHL tumor suppressor gene is frequently mutated in ccRCC, making it a hallmark of this disease. The described pathway highlights the molecular mechanism by which VHL inactivation drives tumor formation through HIF stabilization. \\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele in this pathway is central to the von Hippel-Lindau (VHL) tumor suppressor gene. Its dysfunction leads to the stabilization of hypoxia-inducible factors (HIFs), such as EPAS1 and ARNT, which drive the expression of genes like VEGFA, CXCL8, GLUT1, and EPO. This results in abnormal angiogenesis, increased cell survival, and metabolic changes. The loss of VHL function is a hallmark of VHL disease, a hereditary cancer syndrome characterized by the development of multiple benign and malignant tumors, including hemangiomas, renal cell carcinomas, pheochromocytomas, and CNS hemangioblastomas. The pathway's dysregulation also contributes to tumor progression in other cancers. The biological effect of the VHL allele is therefore the promotion of angiogenesis and tumor growth. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele in this pathway is part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, which targets EPAS1 for degradation. When VHL is mutated, this complex is disrupted, leading to stabilization of EPAS1. EPAS1 then forms a transcriptional complex with ARNT, driving the expression of genes like VEGFA, CXCL8, GLUT1, and EPO. This dysregulation promotes angiogenesis, inflammation, and erythropoiesis, contributing to the development of hemangioblastomas and clear cell renal cell carcinoma. The VHL mutation is a hallmark of Von Hippel-Lindau disease, a hereditary disorder characterized by the formation of tumors in multiple organ systems, particularly the kidneys, brain, and adrenal glands. The pathway's activation leads to neovascularization and tumor formation. The biological effect of the VHL allele mutation is thus the development of Von Hippel-Lindau disease.\n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for mitochondrial quality control. Its interaction with MFN1 and MFN2, which mediate mitochondrial fusion, highlights its role in maintaining mitochondrial integrity. Mutations in PRKN disrupt ubiquitin-mediated degradation of damaged mitochondria, leading to mitochondrial dysfunction and accumulation of dysfunctional organelles. This contributes to neuronal loss and is a key pathogenic mechanism in Parkinson\u2019s disease. PRKN mutations are among the most common genetic causes of monogenic Parkinsonism, particularly in early-onset cases. Loss of PRKN function impairs mitophagy, resulting in oxidative stress, synaptic dysfunction, and neurodegeneration. Therefore, the biological effect of pathogenic PRKN alleles is the development of Parkinson\u2019s disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is critical for mitochondrial quality control. PRKN (parkin) functions as an E3 ubiquitin ligase that ubiquitinates MFN1 and MFN2, promoting mitochondrial fission and the removal of damaged mitochondria through mitophagy. Mutations in PRKN disrupt this process, leading to mitochondrial dysfunction and accumulation of damaged mitochondria. This contributes to neuronal degeneration. PRKN mutations are a well-established cause of Parkinson's disease, specifically associated with early-onset, familial cases. The loss of PRKN function impairs the clearance of dysfunctional mitochondria, leading to oxidative stress, neuroinflammation, and ultimately neuronal death, particularly in the substantia nigra. This pathway's dysfunction is a key driver in the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitophagy, the selective autophagic degradation of mitochondria. PRKN, also known as parkin, is an E3 ubiquitin ligase that interacts with MFN1 and MFN2, which are mitochondrial fusion proteins. This pathway is critical for maintaining mitochondrial quality control by ubiquitinating damaged mitochondria, marking them for degradation. Mutations in PRKN are associated with impaired mitophagy, leading to the accumulation of dysfunctional mitochondria and oxidative stress. This contributes to neuronal degeneration. PRKN mutations are a major genetic cause of autosomal recessive Parkinson's disease. The loss of PRKN function disrupts mitochondrial quality control, leading to neurodegeneration, particularly in dopaminergic neurons. This pathway's dysfunction is a key factor in the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, which phosphorylates RB1, leading to the release of E2F transcription factors. This promotes cell cycle progression from G1 to S phase. Mutations in CDK4, particularly gain-of-function alleles, result in constitutive activation of the pathway, leading to uncontrolled cell proliferation. This dysregulation is a hallmark of several cancers. Specifically, CDK4 alterations are strongly associated with **retinoblastoma**, a pediatric eye cancer, and also contribute to **breast cancer**, **ovarian cancer**, and **lung cancer**. The loss of RB1 tumor suppressor function due to CDK4 overactivity disrupts cell cycle control, driving tumor formation. Thus, the biological effect of a pathogenic CDK4 allele is the promotion of uncontrolled cell growth, contributing to **retinoblastoma** and other cancers. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, which phosphorylates RB1, leading to the release of E2F transcription factors. This promotes cell cycle progression from G1 to S phase. The CDK4 allele's biological effect is the activation of this pathway, driving cells through the cell cycle. Mutations or overexpression of CDK4 can disrupt RB1 regulation, leading to unchecked cell proliferation. This contributes to the development of cancers characterized by dysregulated cell division. Specifically, alterations in CDK4 are strongly associated with **small cell lung carcinoma** and **melanoma**, where its overactivity promotes tumor growth by bypassing RB1-mediated cell cycle inhibition. Thus, the biological effect of the CDK4 allele is the promotion of uncontrolled cell division, contributing to **small cell lung carcinoma**.\n\n\\boxed{small cell lung carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this pathway plays a critical role in cell cycle regulation. CDK4, when activated by cyclins D (CCND1, CCND2, CCND3), phosphorylates the retinoblastoma protein (RB1), inactivating it. This inactivation releases E2F transcription factors (E2F1, E2F2, E2F3), promoting the transcription of genes required for DNA synthesis and cell cycle progression. Mutations or overexpression of CDK4 can disrupt this regulation, leading to unchecked cell proliferation. This dysregulation is a hallmark of several cancers, particularly those characterized by loss of RB1 function. The CDK4-RB1-E2F pathway is frequently altered in cancers such as breast, lung, and melanoma. The most well-characterized disease associated with CDK4 dysfunction is **retinoblastoma**, a childhood eye cancer, and also contributes to other malignancies like non-Hodgkin lymphoma and sarcomas. \\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to constitutive activation of the PI3K-AKT signaling cascade. This leads to the suppression of BAD, a pro-apoptotic protein, thereby promoting cell survival and growth. This dysregulation is a hallmark of oncogenic transformation. Mutations in NRAS, particularly gain-of-function mutations, result in continuous signaling through the MAPK and PI3K pathways, driving uncontrolled cell proliferation and resistance to apoptosis. This contributes to the development of various cancers, most notably **melanoma**, where NRAS mutations are among the most common somatic mutations. These mutations are also found in other malignancies such as colorectal, lung, and thyroid cancers. The persistent activation of downstream effectors like AKT and mTOR further enhances tumorigenesis by promoting metabolism, angiogenesis, and cell cycle progression. Overall, NRAS mutations drive malignant transformation and are a key driver in **melanoma**. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele is part of the RAS oncogene family, which plays a critical role in cell proliferation, differentiation, and survival. In the given pathway, NRAS activates PI3K, leading to the production of PIP3, which in turn activates AKT. Activated AKT inhibits BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations in NRAS, such as activating mutations, result in constitutive activation of this pathway, leading to uncontrolled cell growth and resistance to apoptosis. This contributes to the development and progression of various cancers. Specifically, NRAS mutations are commonly associated with **cancer of the pancreas**, particularly **pancreatic adenocarcinoma**, where they drive tumor growth and aggressiveness. \\boxed{Pancreatic Adenocarcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS signaling pathway, activates PI3K, leading to the production of PIP3 and subsequent activation of AKT. This inhibits BAD, promoting cell survival and proliferation. Mutations in NRAS, such as gain-of-function mutations, result in constitutive activation of this pathway, driving uncontrolled cell growth. This contributes to the development of various cancers. Specifically, NRAS mutations are commonly found in **melanoma**, where they drive oncogenesis by enhancing cell survival and proliferation. These mutations disrupt normal cell cycle regulation and apoptosis, leading to tumor formation. NRAS mutations are also associated with **acute myeloid leukemia (AML)** and **non-small cell lung cancer (NSCLC)**. The persistent activation of the PI3K-AKT pathway due to NRAS mutations is a key driver in these malignancies. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is critical for the proper folding and glycosylation of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired function of these enzymes, resulting in the accumulation of glycosphingolipids in lysosomes. This is a key pathogenic mechanism in several inherited lysosomal storage disorders. Specifically, PSAP mutations contribute to **Fabry disease**, a X-linked disorder caused by deficient alpha-galactosidase A (GLA) activity, although PSAP mutations are not the primary cause of Fabry disease. However, PSAP mutations can also lead to **Sphingolipidosis**, a group of disorders characterized by the accumulation of sphingolipids due to impaired enzyme function. The most notable condition associated with PSAP mutations is **Sphingolipidosis**, which encompasses diseases like **Gaucher disease** and **Tay-Sachs disease**, depending on the specific enzyme affected. The correct and most specific disease linked to PSAP is **Fabry disease** when considering its role in enzyme processing.\n\n\\boxed{Fabry disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper folding and activity of four glycosphingolipid hydrolases: GBA, GBA2, and GALC. Mutations in PSAP lead to reduced or absent production of these enzymes, causing accumulation of toxic lipid metabolites in lysosomes. This results in a severe lysosomal storage disorder known as **Fabry disease**. Specifically, PSAP mutations impair the function of \u03b1-galactosidase A (GLA), which is critical for breaking down globotriaosylceramide (Gb3). The accumulation of Gb3 leads to progressive damage in multiple organ systems, including kidneys, heart, brain, and skin. While GBA and GALC are also involved in other pathways, the primary disease associated with PSAP dysfunction is Fabry disease. \\boxed{Fabry disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is critical for the proper folding and secretion of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to reduced activity of these enzymes, resulting in the accumulation of glycosphingolipids in lysosomes. This accumulation is central to several lysosomal storage disorders. Specifically, PSAP mutations are associated with metachromatic leukodystrophy (MLD), a severe neurodegenerative disorder characterized by progressive demyelination of the central and peripheral nervous system. The defective PSAP gene impairs the function of GALC, which is essential for breaking down galactosylceramide. This leads to the hallmark feature of MLD: the accumulation of globoid cells in the brain. Thus, the biological effect of this PSAP allele is the disruption of lysosomal enzyme function, contributing to the pathogenesis of \\boxed{Metachromatic Leukodystrophy}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway drives cell proliferation, survival, and migration by activating downstream effectors such as PI3K and AKT, which inhibit BAD and promote cell survival. Mutations in MET, particularly gain-of-function mutations or amplifications, lead to constitutive activation of this pathway, driving uncontrolled cell growth and resistance to apoptosis. This contributes to the development and progression of various cancers. The most common disease associated with MET pathway activation is non-small cell lung cancer (NSCLC), particularly in patients with lung adenocarcinoma. MET-driven oncogenesis is also implicated in other malignancies, including gastrointestinal, renal, and hepatocellular cancers. Overall, aberrant MET signaling is a key driver in cancer progression, making it a therapeutic target in several tumor types. \\boxed{Non-Small Cell Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves MET activating GAB1, leading to PI3K activity and PIP3 production, which activates AKT. AKT then inhibits BAD, reducing apoptosis. Mutations in MET, such as gain-of-function mutations, enhance this signaling, promoting cell survival and proliferation. This contributes to uncontrolled cell growth and resistance to apoptosis. The MET pathway is frequently dysregulated in cancers. Specifically, MET activation is implicated in various malignancies, including non-small cell lung cancer, bladder cancer, and hepatocellular carcinoma. These mutations drive tumor progression by enhancing survival signals and angiogenesis. The biological effect of this MET allele is therefore oncogenic, contributing to the development and progression of **non-small cell lung cancer**.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, involving MET, GAB1, PI3K (encoded by PIK3CA, PIK3CB, PIK3CD), AKT1/2/3, and BAD, plays a critical role in cell survival, growth, and metabolism. Activation of MET leads to downstream signaling through PI3K and AKT, which inhibits BAD, promoting cell survival. Mutations or amplifications in MET or its downstream components, such as PIK3CA, can drive uncontrolled cell proliferation and resistance to apoptosis. This contributes to the development and progression of various cancers. Specifically, aberrant MET signaling is strongly associated with non-small cell lung cancer (NSCLC), as well as other malignancies including gastric, renal, and hepatocellular carcinomas. The pathway's role in oncogenesis is further supported by its involvement in tumor angiogenesis and metastasis. Therefore, the biological effect of this MET allele is oncogenic, contributing to \\boxed{Non-small cell lung cancer}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, leads to the constitutive activation of the BCR-ABL oncoprotein. This drives the downstream signaling through CRKL, CBL, and CRK, activating PI3K and its product PIP3, which in turn activates AKT. Activated AKT inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. This pathway is critical in the development of chronic myeloid leukemia (CML), where the Philadelphia chromosome results in the fusion of BCR and ABL1, leading to uncontrolled cell growth. The dysregulation of this pathway also contributes to other malignancies, but CML is the most well-characterized disease directly linked to BCR-ABL oncogenesis. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or dysregulated, leads to the constitutive activation of the BCR-ABL oncoprotein, which drives the downstream signaling cascade involving CRKL, CBL, and CRK, ultimately activating PI3K and its product PIP3. This results in sustained activation of AKT, which inhibits BAD, a pro-apoptotic protein. This pathway promotes cell survival, proliferation, and resistance to apoptosis. The hallmark of this pathway activation is the development of chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the uncontrolled growth of white blood cells. The most well-known mutation associated with this pathway is the Philadelphia chromosome translocation, t(9;22), which fuses BCR to ABL1, leading to the formation of the BCR-ABL1 fusion protein. This mutation is a defining feature of CML and is also implicated in some cases of acute lymphoblastic leukemia (ALL). \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, contributes to the formation of the BCR-ABL oncogene through chromosomal translocation, most notably in chronic myeloid leukemia (CML). This fusion protein drives constitutive activation of downstream signaling pathways, including the PI3K-AKT axis, which promotes cell survival, proliferation, and resistance to apoptosis. The activation of PI3K leads to increased PIP3 levels, which in turn activate AKT. Activated AKT inhibits BAD, preventing apoptosis and supporting uncontrolled cell growth. This pathway is central to the pathogenesis of CML. The ABL1 mutation is a hallmark of this disease and is also associated with some cases of acute lymphoblastic leukemia (ALL). \\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is central to the ubiquitin-proteasome system, involved in mitochondrial quality control and protein degradation. Mutations in PRKN lead to impaired ubiquitination, resulting in the accumulation of damaged mitochondria and cellular dysfunction. This pathway is critical for neuronal health, and dysfunction in PRKN contributes to neurodegeneration. Specifically, PRKN mutations are a known cause of Parkinson's disease, as they disrupt the clearance of dysfunctional mitochondria in dopaminergic neurons, leading to oxidative stress and neuronal death. This genetic disruption is associated with autosomal recessive early-onset Parkinson's disease. The disruption of the PRKN-PLCG1-IP3-ITPR-Ca2+ pathway compromises calcium homeostasis, further exacerbating neuronal damage. Therefore, the biological effect of a pathogenic PRKN allele is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is central to mitochondrial quality control, as PRKN (parkin) ubiquitinates proteins involved in mitophagy. Mutations in PRKN disrupt this process, leading to impaired removal of damaged mitochondria. This accumulation of dysfunctional mitochondria results in increased oxidative stress and cell death, particularly in neurons. The most well-documented disease associated with PRKN mutations is Parkinson's disease. Loss-of-function variants in PRKN are a major genetic cause of early-onset Parkinson's, contributing to the degeneration of dopaminergic neurons. Dysfunction in this pathway also links to other neurodegenerative disorders. Thus, the biological effect of a pathogenic PRKN allele is the disruption of mitochondrial homeostasis, which contributes to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is central to mitochondrial quality control, as PRKN (parkin) mediates the ubiquitination and degradation of damaged mitochondria through mitophagy. Mutations in PRKN lead to impaired mitophagy, resulting in mitochondrial dysfunction and neuronal loss. This contributes to neurodegenerative diseases. Specifically, PRKN mutations are a major cause of autosomal recessive Parkinson's disease. The pathway involves PLCG1, IP3, and ITPR proteins, which regulate intracellular calcium levels, essential for mitochondrial function and neuronal survival. Disruption of this pathway leads to mitochondrial calcium dysregulation, oxidative stress, and cell death, particularly in dopaminergic neurons. Thus, PRKN mutations are strongly associated with Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the given pathway, PRNP* (a variant or allele of PRNP) interacts with NOTCH1, a key receptor in cell signaling. Abnormal PRNP activity is most notably associated with Creutzfeldt-Jakob Disease (CJD), a rapidly progressive and fatal brain disorder caused by prion proteins misfolding and aggregating. This pathological process disrupts normal cellular function, leading to neuronal death and severe cognitive decline. The interaction with NOTCH1 may modulate cellular responses to prion-induced stress, potentially influencing disease progression. Mutations or variants in PRNP are the primary genetic contributors to CJD and other transmissible spongiform encephalopathies. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of pathogenic prions. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction or regulatory relationship between the prion protein and the NOTCH1 receptor, which is involved in cell differentiation and proliferation. Mutations in PRNP are directly associated with prion diseases, a group of transmissible, fatal neurodegenerative disorders. The most well-known disease linked to PRNP mutations is Creutzfeldt-Jakob Disease (CJD), a form of sporadic or inherited prion disease. These mutations can also contribute to other prion-related conditions such as Gerstmann-Str\u00e4ussler-Scheinker syndrome (GSS) and fatal familial insomnia (FFI). The involvement of NOTCH1 may suggest additional roles in cellular processes that are disrupted in these diseases. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between the prion protein and the NOTCH1 receptor, which is involved in cell signaling and development. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob disease (CJD), a rare, rapidly progressive neurodegenerative disorder caused by prion protein misfolding. This misfolded protein accumulates in the brain, leading to neuronal dysfunction and death. The interaction with NOTCH1 may modulate cellular responses to prion-induced stress or influence disease progression. Therefore, the biological effect of this PRNP allele is the contribution to Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, is critical in the ubiquitin-mediated degradation of hypoxia-inducible factors (HIFs), particularly EPAS1. Mutations in VHL disrupt this process, leading to the stabilization and activation of HIFs, including EPAS1 and ARNT. This results in the transcriptional activation of genes such as VEGFA, CXCL8, GLUT1, and EPO, which promote angiogenesis, inflammation, and erythropoiesis. This pathway is central to the pathogenesis of clear cell renal cell carcinoma (ccRCC), where VHL mutations are common. The loss of VHL function leads to uncontrolled cell proliferation, tumor angiogenesis, and metabolic changes, hallmark features of ccRCC. Thus, the biological effect of the VHL allele is the development of **clear cell renal cell carcinoma**.\n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in the ubiquitin-mediated degradation of hypoxia-inducible factors (HIFs), specifically EPAS1. Under normal oxygen conditions, the VHL complex targets HIF-1\u03b1 and HIF-2\u03b1 for proteasomal degradation. Mutations in VHL disrupt this process, leading to stabilization of HIF-2\u03b1 and subsequent activation of downstream genes such as VEGFA, CXCL8, GLUT1, and EPO. This results in aberrant angiogenesis, inflammation, and erythropoiesis. These molecular changes are hallmark features of clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. The loss of VHL function leads to uncontrolled cell proliferation and tumor formation, particularly in the kidneys. Thus, the biological effect of the VHL allele is the development of clear cell renal cell carcinoma. \n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in ubiquitin-mediated protein degradation, particularly targeting hypoxia-inducible factors (HIFs) like EPAS1. When VHL is dysfunctional, this degradation is impaired, leading to HIF-\u03b1 stabilization. This results in the upregulation of genes such as VEGFA, CXCL8, GLUT1, and EPO, which drive angiogenesis, inflammation, and erythropoiesis. This pathway is central to the pathogenesis of hemangiomas and other vascular anomalies. Mutations in VHL are hallmark features of von Hippel-Lindau (VHL) disease, a hereditary disorder characterized by the formation of cysts and tumors in multiple organs, particularly the kidneys, brain, and adrenal glands. The disruption of this pathway leads to uncontrolled cell growth and angiogenesis, contributing to the development of VHL-associated tumors. \n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant form, particularly with an expanded CAG repeat, leads to Huntington's disease. This pathogenic expansion causes the protein to misfold and aggregate, disrupting cellular functions. The pathway described involves NMDA receptors (GRIN1, GRIN2A-D), calcium influx via MCU and VDACs, mitochondrial calcium overload, and the release of cytochrome c (CYCS), leading to activation of APAF1, CASP9, and finally CASP3, initiating apoptosis. This highlights how HTT dysfunction contributes to neuronal death via calcium dyshomeostasis and mitochondrial damage. The accumulation of mutant HTT impairs synaptic function and neurotransmission, ultimately leading to progressive neurodegeneration. The biological effect of the HTT allele, specifically the expanded CAG repeat, is the hallmark of Huntington's disease. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, specifically the mutant form associated with expanded CAG repeats, contributes to Huntington's disease. This mutation leads to the production of an abnormal huntingtin protein, which disrupts cellular processes, including synaptic function and mitochondrial homeostasis. The pathway described involves NMDA receptors (GRIN1, GRIN2A-D), calcium influx, mitochondrial calcium uptake via MCU, and subsequent mitochondrial dysfunction leading to the release of cytochrome c (CYCS) and activation of the apoptotic cascade via APAF1, CASP9, and CASP3. This pathway is critical in neuronal death, particularly in the striatum and cortex, which are severely affected in Huntington's disease. The accumulation of mutant HTT protein also impairs autophagy and proteasomal degradation, further exacerbating neuronal damage. Thus, the HTT allele is directly linked to the pathogenesis of Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutations lead to the accumulation of an abnormal protein containing polyglutamine repeats. This results in neuronal dysfunction and death, particularly in the striatum and cortex. The pathway described involves NMDA receptors (GRIN1, GRIN2A-D), calcium influx through MCU and VDACs, mitochondrial calcium overload, and activation of the intrinsic apoptotic pathway via cytochrome c release (CYCS), APAF1, CASP9, and CASP3. This cascade leads to apoptosis. The biological effect of the HTT mutation, specifically the expansion of CAG repeats, is the hallmark of Huntington's disease. The accumulated mutant huntingtin disrupts calcium homeostasis and triggers neuronal apoptosis, contributing to the progressive degeneration of brain regions. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit (Kv3.4) that plays a critical role in repolarizing neurons, particularly in the heart and brain. Mutations in KCNC3 can disrupt normal ion flow, leading to dysfunctions in neuronal and cardiac excitability. Specifically, gain-of-function mutations in KCNC3 have been linked to neurological disorders, including **generalized epilepsy with febrile seizures plus (GEFS+)**. These mutations increase neuronal excitability, contributing to seizure susceptibility. Additionally, KCNC3 has been implicated in **febrile seizures** and may also be associated with other epilepsy syndromes. The altered potassium currents due to KCNC3 mutations impair the ability of neurons to return to their resting state, leading to hyperexcitability and seizure onset. Therefore, the biological effect of this KCNC3 allele is the contribution to **generalized epilepsy with febrile seizures plus**.\n\n\\boxed{Generalized epilepsy with febrile seizures plus}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, critical for neuronal excitability. Mutations in KCNC3 are associated with hyperexcitability of neurons, leading to neurological disorders. Specifically, pathogenic variants in KCNC3 contribute to **Episodic Ataxia Type 1 (EA1)**, a genetic disorder characterized by episodic loss of coordination, often triggered by stress or physical activity. These mutations typically result in gain-of-function effects, causing excessive neuronal firing. EA1 is clinically distinct from other forms of ataxia and is often inherited in an autosomal dominant manner. The abnormal potassium channel function disrupts the repolarization of neurons, leading to sustained depolarization and increased excitability. This genetic alteration underpins the electrophysiological disturbances observed in EA1, highlighting the role of KCNC3 in maintaining neuronal membrane potential. \\boxed{Episodic Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit (KV3.3) that plays a critical role in regulating neuronal excitability by modulating action potential duration and repolarization. Mutations in KCNC3 can disrupt normal ion flow, leading to hyperexcitability of neurons. This is implicated in several neurological disorders, including episodic limbic encephalitis and paraneoplastic cerebellar degeneration. Notably, KCNC3 mutations are strongly associated with **neuropsychiatric paraneoplastic syndromes**, particularly in patients with small cell lung cancer (SCLC). The abnormal channel function contributes to autoimmune attack on neural tissues, resulting in cognitive impairment, seizures, and movement disorders. The KCNC3 allele's role in immune recognition and neuronal dysfunction underscores its contribution to **paraneoplastic encephalomyelitis**. \n\n\\boxed{Paraneoplastic encephalomyelitis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is critical for mitochondrial quality control through ubiquitination and degradation of damaged mitochondria via the autophagic process (mitophagy). Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and oxidative stress. This dysfunction is strongly associated with neurodegenerative diseases. Specifically, loss-of-function mutations in PRKN are a major cause of early-onset Parkinson's disease. The pathway's disruption leads to the accumulation of toxic proteins and neuronal cell death, particularly in dopamine-producing neurons. Thus, the biological effect of a pathogenic PRKN allele is the contribution to Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is critical for mitochondrial quality control, as PRKN (parkin) mediates the ubiquitination and degradation of damaged mitochondria via mitophagy. Mutations in PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neurodegeneration. The pathway involves PLCG1, IP3, and ITPR proteins, which regulate intracellular calcium levels, essential for neuronal function. Disruption of this pathway is strongly associated with Parkinson's disease. Loss-of-function PRKN alleles impair mitophagy, leading to neuronal death, particularly in dopaminergic neurons. This results in the hallmark features of Parkinson's disease, including motor deficits and cognitive decline. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is a key component of the ubiquitin ligase pathway that regulates mitochondrial quality control. Mutations in PRKN lead to impaired ubiquitination of damaged mitochondria, resulting in mitochondrial dysfunction and accumulation of abnormal mitochondria. This dysfunction disrupts calcium homeostasis via the IP3-ITPR pathway, leading to neuronal damage. The biological effect of pathogenic PRKN alleles is the disruption of mitochondrial quality control, contributing to neurodegeneration. This is a hallmark of Parkinson's disease, where loss-of-function PRKN mutations are strongly associated with the disease. The disrupted calcium signaling cascade exacerbates oxidative stress and neuronal death, supporting the role of PRKN in Parkinson's disease pathogenesis. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is involved in the pathogenesis of prion diseases. In the given pathway, PRNP is upstream of BIP (HSPA5), which regulates the unfolded protein response. This pathway ultimately leads to the activation of ATF4 and its target DDIT3, which are involved in stress response and cell survival. Mutations in PRNP can lead to misfolded prion proteins, triggering neurodegenerative processes. The most well-known disease associated with PRNP mutations is Creutzfeldt-Jakob Disease (CJD), a rapidly progressive and fatal neurodegenerative disorder. This disease is caused by the conversion of the normal prion protein (PrP^C) into the pathogenic form (PrP^Sc), leading to protein misfolding, neuronal damage, and ultimately death. The pathway described highlights the role of PRNP in stress response and protein homeostasis, which is disrupted in prion diseases. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to prion disease pathology. In the given pathway, PRNP influences BIP (HSPA5), a key chaperone involved in protein folding and ER stress. This leads to EIF2AK3 (PERK), which activates EIF2S1 (eIF2\u03b1), promoting ATF4 expression. ATF4 upregulates DDIT3 (CHOP), a transcription factor associated with endoplasmic reticulum (ER) stress and apoptosis. This pathway is implicated in neurodegenerative processes. Mutations in PRNP, particularly those causing misfolded prion protein (PrP^Sc), lead to the accumulation of abnormal proteins, triggering ER stress and neuronal death. This directly contributes to **Creutzfeldt-Jakob Disease (CJD)**, a fatal prion-related encephalopathy. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. In the given pathway, PRNP is the starting point, with downstream genes involved in the unfolded protein response (UPR) and stress response pathways. The pathway involves HSPA5 (a chaperone), EIF2AK3, EIF2S1, ATF4, and DDIT3, all of which are involved in responding to endoplasmic reticulum (ER) stress. Mutations in PRNP lead to misfolded prion proteins that accumulate in the ER, triggering ER stress and activating this pathway. This misfolding and aggregation are central to prion diseases, specifically Creutzfeldt-Jakob disease (CJD), a fatal neurodegenerative disorder. The biological effect of the PRNP allele is thus the induction of ER stress and subsequent neuronal damage, contributing to CJD.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, critical for neuronal excitability and neurotransmitter release. The pathway described involves extracellular calcium entering through this channel, contributing to intracellular calcium levels. Mutations in CACNA1A are associated with impaired calcium homeostasis, leading to dysfunctional neurotransmission and neuronal hyperexcitability. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, pathogenic variants in CACNA1A are a known cause of **familial hemiplegic migraine type 1 (FHM1)**, a form of migraine with aura and hemiplegic features. Additionally, CACNA1A mutations are linked to **spinocerebellar ataxia type 6 (SCA6)**, a progressive cerebellar ataxia. These conditions arise from disrupted calcium signaling in neurons, highlighting the gene's essential role in neuronal function and disease.\n\n\\boxed{Familial Hemiplegic Migraine Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel. This channel is critical for calcium influx into neurons, playing a key role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with impairments in calcium homeostasis, leading to hyperexcitability of neurons and disrupted synaptic function. These disruptions are linked to a range of neurological disorders. Specifically, mutations in CACNA1A are a well-documented cause of **familial hemiplegic migraine (FHM)**, a hereditary form of migraine with aura and motor weakness. Additionally, CACNA1A mutations have been implicated in other neurodevelopmental and neurodegenerative conditions, including some forms of ataxia and epilepsy. The primary disease directly associated with CACNA1A dysfunction is \\boxed{familial hemiplegic migraine}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel. This channel is critical for neurotransmitter release at presynaptic terminals. Mutations in CACNA1A are associated with disrupted calcium homeostasis, leading to impaired neuronal signaling. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, CACNA1A mutations are a known cause of **familial hemiplegic migraine (FHM)**, a subtype of migraine with brainstem involvement. Additionally, CACNA1A mutations can lead to **spinocerebellar ataxia type 6 (SCA6)**, a hereditary cerebellar degeneration. These diseases are linked to gain-of-function mutations that increase calcium influx, causing excitotoxicity and neuronal dysfunction. Thus, the CACNA1A allele contributes to \\boxed{familial hemiplegic migraine}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway, involving genes such as TBK1, SQSTM1, OPTN, TAX1BP1, NBR1, and LC3-II, plays a critical role in autophagy and innate immune responses, particularly in recognizing pathogens and damaged cellular components. Mutations or dysfunction in this pathway can compromise autophagy and antiviral defenses. TBK1 has been implicated in the regulation of antiviral immunity, and its disruption is associated with increased susceptibility to viral infections. Specifically, loss-of-function variants in TBK1 have been linked to severe childhood encephalitis caused by herpes simplex virus (HSV). This genetic susceptibility highlights TBK1's role in antiviral host defense. The biological effect of TBK1 dysfunction is thus a heightened risk of neuroinvasive HSV infections, leading to fatal outcomes in young children. \n\n\\boxed{(Herpes Simplex Virus Encephalitis)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves TBK1, which interacts with autophagy-related proteins like SQSTM1, OPTN, TAX1BP1, and NBR1, and is linked to LC3-II, a marker of autophagosome formation. TBK1 plays a key role in innate immune responses, particularly in recognizing pathogens and regulating autophagy. Mutations in TBK1 have been associated with impaired autophagy and innate immunity, leading to susceptibility to inflammatory diseases. Specifically, TBK1 mutations contribute to **Aarskog-Scott syndrome**, a genetic disorder characterized by distinctive facial features, skeletal abnormalities, and developmental delays. These mutations disrupt the kinase activity of TBK1, impairing its role in autophagy and immune response regulation. The dysfunction in this pathway leads to the accumulation of damaged proteins and organelles, exacerbating cellular stress and contributing to disease pathology. \\boxed{Aarskog-Scott syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway, involving genes like TBK1, SQSTM1, OPTN, TAX1BP1, and LC3-II, plays a critical role in antiviral immunity and autophagy. TBK1 is a key upstream kinase that activates IRF3, essential for producing type I interferons in response to RNA viruses. Mutations in TBK1 disrupt this signaling, leading to impaired antiviral defense. This contributes to chronic viral infections and neuroinflammation. Specifically, TBK1 dysfunction is strongly associated with **Amyotrophic Lateral Sclerosis (ALS)**. Loss-of-function variants in TBK1 are linked to increased susceptibility to ALS, a neurodegenerative disease characterized by motor neuron loss. The pathway's role in maintaining neuronal integrity and combating viral pathogens makes TBK1 a critical player in ALS pathogenesis. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, forming Lewy bodies, which are a hallmark of Parkinson's. The pathway includes components of complex I of the electron transport chain, suggesting a link between mitochondrial dysfunction and neurodegeneration. This connection underscores the role of impaired energy metabolism and oxidative stress in disease progression. The accumulation of SNCA protein disrupts synaptic function and neuronal integrity, contributing to dopaminergic neuron loss. This pathway is central to the molecular mechanisms underlying Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson\u2019s disease. Mutations or overexpression of SNCA lead to the accumulation of abnormal alpha-synuclein aggregates, which contribute to the formation of Lewy bodies\u2014hallmarks of Parkinson\u2019s disease. These aggregates disrupt neuronal function and lead to the progressive degeneration of dopaminergic neurons in the substantia nigra, resulting in motor symptoms such as tremors, rigidity, and bradykinesia. The pathway involving SNCA and complex I subunits suggests a link between mitochondrial dysfunction and neurodegeneration, as impaired complex I activity can lead to increased oxidative stress and neuronal damage. Thus, the SNCA allele is a key contributor to Parkinson\u2019s disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson\u2019s disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein into Lewy bodies, which are a hallmark of Parkinson\u2019s disease. These aggregates disrupt neuronal function, particularly in the substantia nigra, leading to the progressive loss of dopaminergic neurons. The pathway includes components of complex I of the electron transport chain, suggesting a link between mitochondrial dysfunction and neurodegeneration. The interaction between SNCA and complex I subunits may contribute to oxidative stress and impaired energy metabolism in neurons, further exacerbating cell death. This genetic pathway is central to the development and progression of Parkinson\u2019s disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a pathway that includes DAXX and ASK1, leading to activation of JNK. This pathway is critical in cellular stress responses and apoptosis. Mutations in PARK7 are associated with impaired proteostasis and increased oxidative stress, contributing to neuronal damage. Specifically, mutations in PARK7 are a known cause of early-onset Parkinson's disease. These mutations lead to loss of function, resulting in mitochondrial dysfunction and neurodegeneration. The involvement of this pathway in the regulation of apoptosis and stress responses highlights its role in Parkinson's pathology. Therefore, the biological effect of the PARK7 allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a pathway that includes DAXX and ASK1, leading to activation of JNK. Mutations in PARK7 are associated with impaired proteostasis and oxidative stress, contributing to neuronal toxicity. This pathway is critical for maintaining cellular homeostasis, and dysfunction leads to mitochondrial dysfunction and apoptosis. The biological effect of a pathogenic PARK7 allele is neurodegeneration, particularly in regions affected by oxidative stress. This is most notably linked to Parkinson's disease, where PARK7 mutations cause loss of dopaminergic neurons. The role of PARK7 in this pathway underscores its importance in preventing protein aggregation and maintaining mitochondrial health. Mutations in PARK7 are a known genetic cause of early-onset Parkinson's disease, highlighting its contribution to the pathogenesis of the disorder.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a pathway that includes DAXX and ASK1, leading to activation of JNK. This pathway is implicated in oxidative stress response and apoptosis. Mutations in PARK7 are associated with Parkinson's disease, as they disrupt the protein's protective functions, leading to neuronal degeneration. The enzyme plays a role in preventing protein aggregation and maintaining mitochondrial health. Loss of function in PARK7 contributes to the pathogenesis of Parkinson's disease by promoting oxidative damage and apoptosis in dopaminergic neurons. Thus, the PARK7 allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele, specifically mutations in the BRAF gene, contribute to the activation of the BRAF-MEK-ERK signaling pathway. This pathway is critical for cell proliferation, survival, and differentiation. Mutations in BRAF, such as the V600E substitution, lead to constitutive activation of the BRAF kinase, resulting in sustained phosphorylation of MEK and ERK. This uncontrolled signaling promotes cell growth and inhibits apoptosis, driving oncogenesis. The aberrant activation of this pathway is commonly observed in various cancers. One of the most well-characterized diseases associated with BRAF mutations is **metastatic melanoma**, where BRAF mutations occur in approximately 50% of cases. These mutations are also implicated in other malignancies, including thyroid cancer, lung cancer, and colorectal cancer. The clinical significance of BRAF mutations is underscored by the development of targeted therapies, such as BRAF inhibitors, which have improved outcomes in patients with BRAF-mutated tumors.\n\n\\boxed{Metastatic melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that is a key component of the MAPK/ERK signaling pathway, which regulates cell proliferation, differentiation, and survival. Mutations in BRAF, particularly the V600E activating mutation, result in constitutive activation of the BRAF-MEK-ERK cascade, leading to uncontrolled cell growth. This dysregulation is implicated in the development and progression of various cancers. The most well-known association is with melanoma, where BRAF mutations are found in approximately 50% of cases. Additionally, BRAF mutations contribute to other malignancies, including colon adenocarcinomas, lung cancers, and thyroid carcinomas. The persistent activation of this pathway promotes tumor initiation and resistance to apoptosis, making it a significant driver in oncogenesis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele in the BRAF \u2192 MEK \u2192 ERK pathway contributes to the activation of the MAPK signaling cascade, promoting cell proliferation and survival. Mutations in BRAF, particularly the V600E substitution, lead to constitutive activation of the BRAF kinase, driving uncontrolled cell growth. This dysregulation is a key driver in several cancers. The most well-known disease associated with this pathway activation is **Melanoma**, where BRAF mutations are frequently observed. Additionally, BRAF mutations are implicated in other malignancies such as colorectal cancer, non-small cell lung cancer, and thyroid cancer. The continuous activation of ERK due to mutated BRAF results in increased cell division and resistance to apoptosis, contributing to tumor progression. Targeting BRAF with inhibitors has become a key therapeutic strategy in these cancers. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene plays a critical role in the purine salvage pathway, catalyzing the conversion of adenine to inosine monophosphate (IMP). Mutations in APRT can lead to reduced activity of this enzyme, resulting in the accumulation of adenine and its metabolites, such as 2,6-diamino-4-hydroxypteridine (2,6-DAP), which is neurotoxic. This accumulation primarily affects the nervous system, leading to a progressive neurological disorder. The most well-documented disease associated with APRT deficiency is **Lesch-Nyhan syndrome**, an X-linked recessive disorder characterized by neurological abnormalities, self-injurious behavior, and impaired motor function. The genetic defect in APRT disrupts purine metabolism, leading to the clinical manifestations of this disorder. \\boxed{Lesch-Nyhan syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is involved in the salvage pathway for purine metabolism. It catalyzes the conversion of adenine to inosine monophosphate (IMP), a key step in nucleotide synthesis. Mutations in APRT can lead to a deficiency in this enzyme, resulting in the accumulation of adenine and its metabolites, such as 2,6-diamino-4-hydroxypteridine (lesch nyl\u00e9n urine), which is excreted in urine. This condition is known as Lesch-Nyhan syndrome, a rare X-linked recessive disorder characterized by neurological dysfunction, self-injurious behaviors, and hyperuricemia. The APRT allele deficiency disrupts purine metabolism, leading to the clinical features of Lesch-Nyhan syndrome. \\boxed{Lesch-Nyhan syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is critical for the salvage pathway of purine metabolism. It catalyzes the conversion of adenine to inosine monophosphate (IMP), a key step in nucleotide synthesis. Mutations in APRT can lead to reduced activity of the enzyme, resulting in the accumulation of adenine and its metabolites, such as 2,6-diamino-4-hydroxypteridine (DAP). This accumulation is toxic to neurons and can cause progressive neurological damage. The most well-known disease associated with APRT deficiency is Lesch\u2013Nyhan syndrome, a severe X-linked recessive disorder characterized by neurological abnormalities, self-injurious behaviors, and uric acid overproduction. The APRT allele contributes to this disease by disrupting purine metabolism, leading to neurological dysfunction. \n\n\\boxed{Lesch\u2013Nyhan syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates the cell cycle by inhibiting E2F transcription factors. The pathway defined (RB1 // E2F) highlights the interaction between RB1 and E2F transcription factors (E2F1, E2F2, E2F3), which control the expression of genes involved in DNA replication and cell division. When RB1 is functional, it binds to E2F and prevents the transcription of genes necessary for S-phase entry, thereby blocking uncontrolled cell proliferation. Mutations in RB1 lead to loss of this repression, resulting in unchecked cell division. This contributes to the development of retinoblastoma, a malignant tumor of the retina, and also increases the risk of other cancers, including sarcomas and carcinomas. The loss of RB1 function is a hallmark of these diseases. \\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates the cell cycle by inhibiting E2F transcription factors. When RB1 is mutated or inactivated, it leads to unchecked cell proliferation. This pathway, defined as RB1* // E2F, suggests a loss-of-function mutation in RB1, resulting in the derepression of E2F-driven genes, which promote cell cycle progression. This dysregulation is a hallmark of retinoblastoma, a pediatric eye cancer. RB1 mutations are also associated with other cancers, including small cell lung cancer and osteosarcoma. However, the most direct and well-characterized disease linked to RB1 inactivation is retinoblastoma. The loss of RB1 function allows for uncontrolled cell division, leading to tumor formation, particularly in the retina. \\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates the cell cycle by inhibiting E2F transcription factors. The pathway defined (RB1 // E2F) reflects the interaction between RB1 and E2F family members, which control genes involved in DNA replication and cell division. When RB1 is mutated or inactivated, it loses its ability to restrain E2F-driven gene expression, leading to uncontrolled cell proliferation. This dysregulation is a hallmark of retinoblastoma, a childhood eye cancer. Additionally, RB1 inactivation contributes to various other cancers, including small cell lung cancer, osteosarcoma, and bladder cancer. The loss of RB1 function allows cells to proceed through the cell cycle unchecked, promoting tumor formation. Thus, the biological effect of the RB1 allele is the promotion of uncontrolled cell growth, contributing to retinoblastoma and other malignancies. \\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein degradation and transcriptional regulation. Mutations in ATXN3 lead to the expansion of the polyglutamine tract, resulting in protein misfolding and aggregation. This pathological process is a hallmark of neurodegenerative diseases. Specifically, expansions in ATXN3 cause **spinocerebellar ataxia type 2 (SCA2)**, a hereditary disorder characterized by progressive loss of coordination and motor control. In the given pathway, ATXN3 is implicated in calcium signaling through its interaction with ITPR1, and its dysfunction disrupts mitochondrial calcium homeostasis, contributing to neuronal dysfunction and cell death. The accumulation of misfolded ataxin-3 leads to synaptic and mitochondrial dysfunction, exacerbating the neurodegenerative cascade. Thus, the biological effect of the ATXN3 allele is the pathogenesis of **spinocerebellar ataxia type 2 (SCA2)**.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-dependent protein degradation pathway. Mutations in ATXN3 cause Spinocerebellar Ataxia Type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of motor coordination. In the provided pathway, ATXN3 is part of the IP3-Ca2+ signaling cascade, which regulates mitochondrial calcium levels via MCU and VDAC channels. Dysfunction in this pathway can lead to mitochondrial stress and neuronal damage, contributing to the pathogenesis of SCA2. The disease is caused by expansions of the CAG trinucleotide repeat in the ATXN3 gene, leading to toxic protein accumulation and neuronal degeneration, particularly in the cerebellum. This results in ataxia, speech difficulties, and cognitive decline. The role of ATXN3 in calcium homeostasis underscores its importance in maintaining neuronal function and its involvement in disease progression. \n\n\\boxed{Spinocerebellar Ataxia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a key component of the polyglutamine tract in the ataxin-3 protein. Mutations in ATXN3 that result in an expanded polyglutamine repeat lead to the production of a toxic protein, causing cellular dysfunction and neurodegeneration. This contributes to spinocerebellar ataxia type 2 (SCA2), a hereditary neurological disorder characterized by progressive loss of motor coordination. The pathway involving ATXN3 is part of the calcium signaling cascade, where its dysfunction disrupts mitochondrial calcium homeostasis, leading to oxidative stress and apoptosis. This aligns with the observed pathophysiology of SCA2, which includes cerebellar degeneration and neuronal loss. The expanded polyglutamine in ATXN3 promotes protein misfolding, aggregation, and impaired protein degradation, further exacerbating neuronal damage. Thus, the biological effect of the ATXN3 allele is the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). In this pathway, SOD1 is upstream of BIP and ATF6, which regulate DDIT3. Mutations in SOD1 lead to the accumulation of misfolded proteins, triggering the unfolded protein response via BIP and ATF6. This results in increased DDIT3 expression, which promotes cellular stress and apoptosis. The misfolded SOD1 protein also directly contributes to neurotoxicity by disrupting mitochondrial function and RNA processing in motor neurons. This pathway is central to the pathogenesis of ALS, a progressive neurodegenerative disease characterized by the loss of motor neurons. The SOD1 pathway thus plays a critical role in disease progression, making it a key target for therapeutic intervention.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, leading to reduced expression of DDIT3. This pathway is critical for the unfolded protein response (UPR) and stress tolerance. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The misfolded SOD1 protein contributes to neuronal toxicity through mechanisms involving oxidative stress, protein aggregation, and disruption of cellular homeostasis. The pathway described reflects how SOD1 dysfunction impairs the UPR, exacerbating cellular stress and ultimately leading to neuronal death. This underscores the role of SOD1 in ALS pathogenesis. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1* allele is involved in a pathway where SOD1 is upstream of BIP and ATF6, leading to DDIT3. SOD1 encodes superoxide dismutase 1, an antioxidant enzyme. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. The pathway involves the unfolded protein response (UPR), where ATF6 activation and DDIT3 expression are part of cellular stress responses. SOD1* likely contributes to disease by disrupting this pathway, leading to protein misfolding and neuronal damage. The connection between SOD1 and ALS is well-established, with over 20% of familial ALS cases linked to SOD1 mutations. This pathway dysfunction exacerbates oxidative stress and neurodegeneration, contributing to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene acts as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the activation of AKT. This pathway is crucial for regulating cell growth, survival, and proliferation. Loss-of-function mutations in PTEN lead to persistent activation of AKT, promoting uncontrolled cell growth. This results in genomic instability and increased cell survival, contributing to the development of various cancers. Specifically, mutations in PTEN are strongly associated with **Cowden syndrome**, a hereditary condition that predisposes individuals to multiple benign and malignant tumors, including breast, thyroid, and endometrial cancers. Additionally, PTEN inactivation is a hallmark of several cancers, such as glioblastoma and prostate cancer. The biological effect of PTEN allele dysfunction is thus the promotion of oncogenesis through aberrant activation of the PI3K-AKT pathway. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene encodes a tumor suppressor phosphatase that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3, thereby inhibiting AKT activation. Loss-of-function mutations in PTEN disrupt this regulation, leading to constitutive AKT activation, which promotes cell survival, proliferation, and resistance to apoptosis. This dysregulation is a key driver in the development of various cancers. Specifically, PTEN mutations are strongly associated with phosphatidylinositol-3-kinase (PI3K)-pathway aberrations and are commonly found in cancers such as breast, prostate, endometrial, and brain tumors. The most well-characterized disease linked to PTEN dysfunction is **Cowden syndrome**, a hereditary disorder that predisposes individuals to multiple cancers, including thyroid, breast, and endometrial cancers, due to germline mutations in PTEN. \\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN allele plays a critical role in the PI3K-AKT signaling pathway by dephosphorylating PIP3, thereby inhibiting AKT activation. Loss-of-function mutations in PTEN lead to constitutive activation of AKT, promoting cell survival, proliferation, and resistance to apoptosis. This dysregulation is a key driver in several cancers. Specifically, PTEN mutations are strongly associated with phosphatidylinositol-3-kinase (PI3K)/AKT pathway hyperactivation, which contributes to tumor growth and metastasis. The most well-characterized disease linked to PTEN dysfunction is **Cowden syndrome**, a hereditary disorder that predisposes individuals to multiple benign and malignant tumors, including breast, thyroid, and endometrial cancers. PTEN mutations also contribute to **cancer development** in various tissues, making it a tumor suppressor gene. \\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. In the given pathway, PRNP is the starting point, connecting to NMDA receptors (GRIN1, GRIN2A-D), which regulate calcium entry into neurons. Excess calcium activates the mitochondrial calcium uniporter (MCU) via VDACs and SLC25A family members, leading to mitochondrial calcium overload. This triggers the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS), which activates APAF1 and initiates apoptosis via CASP9 and CASP3. This cascade is central to neurodegeneration. The PRNP allele, particularly the pathogenic forms, is directly linked to **Creutzfeldt-Jakob Disease (CJD)**, a rare, rapidly progressive, and fatal prion disease characterized by spongiform encephalopathy and neuronal death. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. In the given pathway, PRNP is the starting point, linking to NMDAR (NMDA receptor) and subsequent calcium influx via MCU, leading to mitochondrial calcium overload, mitochondrial permeability transition pore (MPTP) opening, and release of cytochrome c. This triggers apoptosis via the APAF1-CASP9-CASP3 pathway. This pathway is central to neurodegeneration. The PRNP allele, particularly when mutated, is directly associated with Creutzfeldt-Jakob Disease (CJD), a rare, rapidly progressive, and fatal neurological disorder caused by prion protein misfolding. The pathway described reflects the cascade of events leading to neuronal apoptosis and neurodegeneration in prion diseases.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. In the given pathway, PRNP is the starting point, connecting to NMDA receptor subunits (GRIN1, GRIN2A-D), which are involved in calcium influx. Excess calcium through NMDAR triggers mitochondrial calcium uptake via MCU and VDACs, leading to mitochondrial dysfunction. This results in the release of cytochrome c (CYCS), activating the apoptotic cascade via APAF1, CASP9, and finally CASP3. This pathway is central to neurodegeneration. The PRNP allele, particularly mutant forms, is directly linked to **Creutzfeldt-Jakob Disease (CJD)**, a fatal prion disease characterized by rapid progressive dementia and neuronal death. The pathway reflects how PRNP dysfunction initiates a cascade leading to apoptosis and neurodegeneration. \n\n\\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described pathway, plays a role in oxidative stress regulation. SOD1 converts superoxide radicals into hydrogen peroxide, which can then lead to the production of hydroxyl radicals. Mutations in SOD1 are associated with the misfolding and aggregation of the protein, leading to mitochondrial dysfunction and increased oxidative damage. This disrupts the mitochondrial apoptotic pathway, as seen in the network definition involving BCL2, BAX, BAK1, CYCS, APAF1, CASP9, and CASP3. These disruptions contribute to neuronal death, particularly in motor neurons. This is a hallmark of **Amyotrophic Lateral Sclerosis (ALS)**, a neurodegenerative disease characterized by progressive loss of motor neurons. Mutations in SOD1 are one of the most commonly identified genetic causes of familial ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described genomic pathway, contributes to the activation of the intrinsic apoptotic pathway. SOD1, a mitochondrial enzyme, when mutated, leads to the disruption of mitochondrial homeostasis, causing the release of cytochrome c (CYCS) from mitochondria. This triggers the formation of the apoptosome via APAF1, leading to the activation of CASP9 and subsequently CASP3, which induces apoptosis. This pathway is critical in neurodegenerative diseases. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder characterized by the progressive loss of motor neurons. The pathological mechanism involves SOD1 misfolding and aggregation, which perturbs mitochondrial function and promotes neuronal apoptosis through the described pathway. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1* allele is part of a genomic pathway involving apoptosis. SOD1 (superoxide dismutase 1) catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen, thereby reducing oxidative stress. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive loss of motor neurons. The pathway suggests that SOD1 interacts with BCL2, which regulates apoptosis. In ALS, mutant SOD1 can disrupt mitochondrial function, leading to increased oxidative stress and apoptosis via the BAX/BAK1-dependent pathway, ultimately resulting in neuronal death. This contributes to the pathology of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting with MET and proceeding through GRB2, SOS, RAS, RAF, MEK, and ERK to CCND1, is central to cell proliferation and survival. Activation of MET, a receptor tyrosine kinase, leads to downstream signaling that promotes cell cycle progression by upregulating CCND1 (cyclin D1), a key regulator of G1 phase. Mutations or overactivation of MET can drive uncontrolled cell growth. This pathway is frequently dysregulated in cancers, particularly in non-small cell lung cancer (NSCLC) and gastrointestinal tumors. MET amplification or mutations are associated with poor prognosis and resistance to therapy. The biological effect of an activating MET allele is sustained cell proliferation and inhibition of apoptosis, contributing to tumor development. This pathway is implicated in multiple malignancies, with MET-driven cancers often responding poorly to standard treatments. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, initiated by the MET receptor tyrosine kinase, activates downstream signaling through GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately leading to the upregulation of CCND1, a gene encoding cyclin D1. Cyclin D1 is critical for cell cycle progression. Mutations or overactivation of MET can result in constitutive activation of this pathway, driving uncontrolled cell proliferation. This aberrant signaling is implicated in various cancers. Specifically, MET oncogenic activation is a well-documented driver in non-small cell lung cancer (NSCLC), particularly in patients with adenocarcinoma. It also contributes to the development and progression of other malignancies, including gastrointestinal and urothelial cancers. The MET-driven pathway promotes tumor growth, angiogenesis, and metastasis. Therefore, the biological effect of a pathogenic MET allele is the promotion of cancer, most notably non-small cell lung cancer.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting from MET, leading through GRB2, SOS, RAS, RAF, MEK, and finally to ERK, which upregulates CCND1. This pathway is critical for cell proliferation, survival, and differentiation. Aberrant activation of MET, such as through overexpression, amplification, or mutation, leads to constitutive signaling, promoting uncontrolled cell growth. This contributes to the development of cancers characterized by excessive cell proliferation. Notably, MET-driven signaling is implicated in various malignancies, including non-small cell lung cancer, gastric cancer, and renal cell carcinoma. The activation of this pathway can drive tumor progression, metastasis, and resistance to therapy. Therefore, the biological effect of this MET allele is the promotion of oncogenic signaling, contributing to the development and progression of **metastatic cancers**. \n\n\\boxed{Metastatic cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase involved in ubiquitin-mediated proteolysis. Mutations in PRKN are associated with Parkinson's disease. The pathway involving PRKN, MAO A, and MAO B suggests a role in dopamine metabolism and neuronal survival. MAOs break down monoaminergic neurotransmitters like dopamine, and impaired MAO function can lead to dopamine accumulation, contributing to neurotoxicity. PRKN mutations disrupt this pathway by affecting protein degradation, leading to the accumulation of toxic proteins and mitochondrial dysfunction. This contributes to the degeneration of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease. Therefore, the biological effect of this PRKN allele is the development of \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase that plays a critical role in maintaining mitochondrial function and protein quality control. Mutations in PRKN lead to impaired ubiquitination and degradation of misfolded or damaged proteins, contributing to neuronal stress and degeneration. This dysfunction is central to Parkinson's disease (PD), where PRKN mutations cause the accumulation of dysfunctional proteins and mitochondrial dysfunction in dopaminergic neurons. The pathway involving PRKN, MAO-A, and MAO-B further links to dopamine metabolism, as monoamine oxidases break down dopamine. Dysregulation in this pathway exacerbates oxidative stress and neurodegeneration, hallmark features of PD. Thus, PRKN mutations are a key genetic contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase that plays a critical role in proteasomal degradation of misfolded proteins and mitochondrial quality control. Mutations in PRKN are associated with autosomal recessive Parkinson\u2019s disease. The pathway involving MAO (monoamine oxidase A and B) and DOPAL (dopamine beta-hydroxylase) is relevant to dopamine metabolism. PRKN dysfunction leads to the accumulation of damaged proteins and impaired mitochondrial function, contributing to neurodegeneration. This genetic disruption is a key factor in the pathogenesis of Parkinson\u2019s disease, characterized by the loss of dopaminergic neurons in the substantia nigra. The interaction between PRKN and MAO pathways underscores the role of oxidative stress and neurotransmitter imbalance in disease progression. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the tumor protein p53, a critical transcription factor involved in cell cycle regulation, DNA repair, and apoptosis. The listed genes in the pathway are all downstream targets of p53, including CDKN1A, GADD45 family members, BAX, BAK1, DDB2, and POLK, which collectively mediate cell cycle arrest, DNA repair, and apoptosis in response to genomic stress. Mutations in TP53 disrupt its function, leading to impaired regulation of these processes. This results in genomic instability and unchecked cell proliferation, contributing to the development of various cancers. The most significant disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary cancer syndrome characterized by a high risk of multiple malignancies, including sarcomas, breast cancer, leukemias, and brain tumors. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular stress response, DNA repair, and apoptosis. Mutations in TP53 disrupt its tumor suppressor function, leading to impaired cell cycle regulation, DNA repair, and increased apoptosis resistance. This contributes to genomic instability and uncontrolled cell proliferation. The listed genes\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014are downstream effectors of p53, mediating cell cycle arrest, DNA repair, and apoptosis. Dysfunction in this pathway is a hallmark of many cancers. Specifically, TP53 mutations are strongly associated with Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. This syndrome increases the risk of various malignancies, including osteosarcoma, breast cancer, brain tumors, and leukemia. The TP53 pathway's dysfunction is a key driver in these diseases due to its role in maintaining genomic stability. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis TP53 pathway includes genes critical for cell cycle regulation, DNA repair, and apoptosis. TP53, a central tumor suppressor, activates downstream genes like CDKN1A, GADD45, BAX, and BAK1, promoting cell cycle arrest and apoptosis in response to DNA damage. DDB2 and POLK are also involved in DNA repair and replication fidelity. Mutations in TP53 disrupt this pathway, leading to loss of cell cycle control and apoptosis resistance, which allows unchecked cell proliferation. This is a hallmark of cancer. TP53 mutations are strongly associated with a wide range of malignancies, most notably **Li-Fraumeni syndrome**, a hereditary cancer predisposition syndrome. Additionally, TP53 dysfunction contributes to various solid tumors, including breast, ovarian, lung, and bladder cancers. The accumulation of mutations in this pathway is a key driver in tumorigenesis. \n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes a signaling cascade initiated by the APP gene, leading to the production of amyloid-beta (Abeta), which triggers a cascade involving GRM5, GNAQ, PLCB isoforms, IP3, and mitochondrial calcium influx via MCU. The resulting mitochondrial calcium overload activates the MPTP, leading to the release of cytochrome c (CYCS) and activation of APAF1, CASP9, and finally CASP3, inducing apoptosis. This pathway is central to neurodegenerative processes. Mutations in APP, particularly those associated with the production of pathological amyloid-beta, are directly linked to **Alzheimer's disease**. The accumulation of amyloid-beta plaques and subsequent mitochondrial dysfunction and apoptosis are hallmark features of this disease. Thus, the biological effect of this APP allele is the contribution to **Alzheimer's disease**.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this genomic pathway is the production of amyloid-beta (Abeta), which initiates a cascade leading to mitochondrial dysfunction and apoptosis. The pathway involves the release of Ca\u00b2+ from the endoplasmic reticulum via IP3 receptors, followed by mitochondrial calcium uptake through MCU, triggering the mitochondrial permeability transition pore (MPTP). This results in the release of cytochrome c, activating the apoptotic cascade via APAF1 and CASP9, ultimately leading to CASP3 activation and cell death. This process is central to neurodegeneration. The accumulation of Abeta and subsequent mitochondrial damage are hallmarks of Alzheimer's disease. Therefore, dysfunction in this pathway contributes to the pathogenesis of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this pathway is the production of amyloid beta (Abeta), which initiates a cascade leading to mitochondrial dysfunction, calcium dysregulation, and ultimately apoptosis. This pathway is central to neurodegenerative processes. Accumulation of Abeta leads to mitochondrial calcium overload via the MCU, triggering the MPTP (mitochondrial permeability transition pore) and releasing cytochrome c (CYCS), which activates APAF1 and CASP9, leading to CASP3 activation and cell death. This mechanism is strongly associated with Alzheimer's disease (AD). Mutations in APP that increase Abeta production or resistance to clearance are linked to early-onset AD. The pathway reflects the role of Abeta in synaptic dysfunction and neuronal loss in AD. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. This misfolding initiates a cascade of events in the pathway described, starting with the release of Ca\u00b2\u207a from the sarcoplasmic reticulum via RYR and ITPR channels. The increased mitochondrial calcium load activates the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c, which activates APAF1 and subsequently caspase-9 and caspase-3, inducing apoptosis. This pathway is central to neurodegenerative processes. Mutations in PRNP are directly associated with **Creutzfeldt-Jakob disease (CJD)**, a rapidly progressive and fatal prion disease characterized by severe neurological decline. The accumulation of misfolded prion proteins disrupts cellular homeostasis, leading to neuronal death and clinical symptoms of CJD. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. The pathway described involves calcium signaling via RYR and ITPR channels, mitochondrial calcium uptake through MCU, and subsequent mitochondrial permeability transition pore (MPTP) opening, leading to cytochrome c release, activation of APAF1, and caspase-mediated apoptosis. Mutations in PRNP causing misfolding and aggregation of the prion protein are central to **Creutzfeldt-Jakob Disease (CJD)**. This neurodegenerative disorder results from prion-induced neuronal death via mitochondrial dysfunction and apoptosis. The pathway highlights how PRNP misfolding disrupts calcium homeostasis, triggering cell death and contributing to the progressive dementia and brain degradation characteristic of CJD.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. These misfolded proteins trigger a cascade of events starting with the activation of RYR and ITPR channels, leading to the release of cytosolic calcium. Excess calcium influx activates the mitochondrial calcium uniporter (MCU), increasing mitochondrial calcium levels and promoting the opening of the mitochondrial permeability transition pore (MPTP). This results in the release of cytochrome c, initiating apoptosis via the APAF1-CASP9-CASP3 pathway. This pathway is central to neurodegenerative diseases. The PRNP allele is most famously associated with **Creutzfeldt-Jakob Disease (CJD)**, a rare and fatal transmissible spongiform encephalopathy caused by prion protein misfolding. \\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies reactive oxygen species. Mutations in SOD1 lead to the production of dysfunctional or toxic protein aggregates, which disrupt cellular processes and cause motor neuron degeneration. The pathway described involves the ubiquitination and proteasomal degradation of misfolded proteins, including SOD1. Accumulation of misfolded SOD1 impairs proteasome function, leading to protein toxicity and neurodegeneration. This mechanism is central to the pathogenesis of ALS, a fatal neurodegenerative disease characterized by progressive loss of motor neurons. Mutations in SOD1 account for approximately 10% of inherited ALS cases. The disruption of the ubiquitin-proteasome system exacerbates neuronal stress and contributes to disease progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies superoxide radicals. Mutations in SOD1 can lead to gain-of-toxic-function, resulting in the misfolding and aggregation of the SOD1 protein. These aggregates are toxic to motor neurons, leading to their degeneration. The pathway described involves the ubiquitin-proteasome system (UPS), where misfolded or damaged proteins, including mutant SOD1, are tagged with ubiquitin and degraded by the 26S proteasome. Impairment in this pathway, such as due to SOD1 mutations, disrupts protein quality control, contributing to neuronal toxicity and the progressive loss of motor neurons characteristic of ALS. This highlights the critical role of the UPS in maintaining protein homeostasis and preventing neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). Mutations in SOD1, a copper-zinc superoxide dismutase enzyme, lead to the accumulation of misfolded and aggregated proteins, including SOD1 itself. These aggregates disrupt cellular function, particularly in motor neurons, leading to their degeneration. The pathway described involves SOD1 interacting with DERL1, leading to ubiquitination and targeting of misfolded proteins for degradation via the ubiquitin-proteasome system. This pathway is critical for maintaining protein homeostasis. Mutant SOD1 impairs this process, contributing to proteotoxic stress and neuronal death. The accumulation of toxic SOD1 aggregates is a key pathological feature of ALS. Therefore, the biological effect of the SOD1 allele is the promotion of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele, as part of the NRG (Neuregulin) signaling pathway, plays a key role in developmental processes, including neural development and myelination. Mutations or dysregulation in ERBB4 can lead to impaired signaling, affecting neuronal connectivity and myelination. This contributes to a range of neurological disorders. Specifically, ERBB4 has been implicated in schizophrenia, where altered signaling is associated with disrupted neural circuitry. Additionally, ERBB4 has been linked to certain cancers, such as non-small cell lung cancer, due to its role in cell proliferation and survival. However, the most well-documented disease associated with ERBB4 dysfunction is \\boxed{Schizophrenia}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele plays a critical role in signal transduction through the epidermal growth factor receptor (EGFR) family. It functions as a receptor for neuregulins (NRG1\u20134), which are ligands that activate downstream pathways involved in cell proliferation, differentiation, and survival. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to disease. Specifically, altered ERBB4 activity is implicated in various cancers, including non-small cell lung cancer (NSCLC), glioblastoma, and breast cancer. Additionally, ERBB4 has been linked to neurological disorders such as schizophrenia and cognitive impairments due to its role in brain development. However, its most well-characterized pathological contribution is in cancer. \\boxed{Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG (Neuregulin) signaling pathway, which plays a critical role in neuronal development, myelination, and cell survival. ERBB4, as a receptor tyrosine kinase, mediates signals from NRG1-4, promoting neuronal growth and differentiation. Mutations or dysregulation in ERBB4 can lead to disrupted signaling, contributing to neurodevelopmental and neurodegenerative disorders. Specifically, aberrant ERBB4 activity has been implicated in schizophrenia, a psychiatric disorder characterized by impaired neural connectivity and synaptic dysfunction. Altered ERBB4 expression or function may disrupt cortical development and glutamatergic transmission, key factors in schizophrenia pathogenesis. Thus, the biological effect of this ERBB4 allele is associated with increased risk and pathophysiology of \\boxed{Schizophrenia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, when mutated, leads to the production of an abnormal huntingtin protein, which disrupts the neuronal pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK. This disruption impairs cellular stress responses and neuroprotection, contributing to neuronal death. The most well-known genetic disorder associated with HTT mutations is Huntington's disease. This autosomal dominant disorder results from an expansion of CAG repeats in the HTT gene, leading to toxic gain-of-function effects of the mutant huntingtin protein. The dysregulated MAPK signaling cascade plays a role in neuroinflammation and apoptosis, exacerbating the degenerative process in the striatum and cerebral cortex. The accumulation of mutant huntingtin protein disrupts synaptic function and causes progressive motor, cognitive, and psychiatric symptoms. Thus, this pathway is central to the pathogenesis of Huntington's disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, through its interaction with the pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK, contributes to neurodegenerative processes. Mutations in HTT, particularly the CAG trinucleotide repeat expansion, lead to the production of an abnormal huntingtin protein, which disrupts cellular function and neuronal survival. This disruption activates the JNK signaling cascade, promoting apoptosis and neuroinflammation. The cumulative effect is the progressive loss of neurons, particularly in the striatum and cerebral cortex. This pathway is strongly associated with Huntington's disease, a genetic disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. The HTT mutation impairs protein clearance and synaptic function, leading to neuronal death. Thus, the biological effect of this HTT allele is the development of \\boxed{Huntington's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele in this pathway contributes to Huntington's disease. Mutations in the HTT gene lead to the production of an abnormal huntingtin protein, which disrupts cellular processes, including the signaling pathway involving MLK2, MKK7, and JNK. This disruption impairs neuronal function and survival, particularly in the striatum and cortex. The accumulation of mutant huntingtin protein causes neurodegeneration, resulting in progressive motor, cognitive, and psychiatric symptoms. The specific pathway described is involved in stress responses and apoptosis, which are dysregulated in Huntington's disease. The disease is autosomal dominant, and the severity is correlated with the number of CAG repeats in the HTT gene. The pathway's involvement highlights the role of aberrant signaling in neuronal death. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell growth, differentiation, and survival. It is activated by ligands such as neuregulins (NRG1-NRG4). Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to various diseases. Specifically, alterations in ERBB4 have been implicated in the development and progression of cancers, particularly in the nervous system and breast. One notable disease associated with ERBB4 dysfunction is **schizophrenia**, as genetic variants in the NRG1 and ERBB4 pathway have been linked to increased risk of this psychiatric disorder. Additionally, ERBB4 mutations are also associated with certain types of **breast cancer** and **glioblastoma**. Therefore, the biological effect of this ERBB4 allele is associated with **schizophrenia**.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cellular signaling, particularly in neural development, myelination, and synaptic plasticity. Mutations or dysregulation of ERBB4 can disrupt these processes, contributing to neurological disorders. Specifically, ERBB4 has been implicated in schizophrenia, where it is involved in neurodevelopmental and synaptic abnormalities. Altered ERBB4 function may also contribute to other psychiatric and neurodevelopmental conditions. Additionally, ERBB4 has been associated with certain cancers, such as non-small cell lung cancer, due to its role in cell proliferation and survival. However, based on the pathway definition and gene list provided, the primary disease linked to ERBB4 is schizophrenia. \n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG (Neuregulin) signaling pathway, which plays a critical role in neural development, myelination, and cell proliferation. ERBB4, as a receptor tyrosine kinase, mediates signals from NRG ligands, promoting cellular responses such as differentiation and survival. Mutations or dysregulation in ERBB4 can disrupt this pathway, contributing to neurological and developmental disorders. Specifically, aberrant ERBB4 activity has been implicated in schizophrenia, where impaired NRG-ERBB4 signaling is associated with deficits in neural connectivity and synaptic plasticity. Additionally, ERBB4 has been linked to certain cancers, such as glioblastoma and breast cancer, due to its role in cell growth and survival. However, the most notable disease associated with ERBB4 dysfunction is \\boxed{Schizophrenia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase critical for mitochondrial quality control and protein degradation. Mutations in PRKN lead to impaired ubiquitin-mediated proteolysis, resulting in the accumulation of damaged proteins and dysfunctional mitochondria. This contributes to neuronal loss, particularly in the substantia nigra, a brain region critical for motor function. PRKN mutations are a major cause of autosomal recessive Parkinson\u2019s disease. The pathway involving MAO (monoamine oxidase) and DOPAL (3,4-dihydroxyphenylacetic acid) is relevant, as MAO enzymes metabolize dopamine, and impaired MAO function can exacerbate oxidative stress and neurodegeneration. Thus, PRKN mutations primarily contribute to Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase that plays a critical role in ubiquitin-mediated protein degradation, particularly in the clearance of misfolded or damaged proteins. Mutations in PRKN are associated with impaired protein turnover, leading to the accumulation of toxic proteins and dysfunction in neurons. This contributes to the pathogenesis of Parkinson\u2019s disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The pathway involving MAO (monoamine oxidase A and B) and DOPAL (dopamine-beta-hydroxylase substrate) is relevant as MAO enzymes metabolize monoamines, including dopamine, and their dysfunction can exacerbate oxidative stress and neurotoxicity. Thus, PRKN mutations contribute to Parkinson\u2019s disease by disrupting protein quality control and neuronal survival. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase essential for mitochondrial quality control and protein degradation. Mutations in PRKN lead to impaired ubiquitination and degradation of damaged proteins, contributing to the accumulation of dysfunctional mitochondria and protein aggregates. This dysfunction is central to neurodegenerative processes. Specifically, PRKN mutations are a major cause of Parkinson's disease, particularly in early-onset cases. The pathway involving MAO (monoamine oxidase A and B) and DOPAL (3,4-dihydroxyphenylacetic acid) is implicated in dopamine metabolism, and disruptions in this pathway can exacerbate neuronal loss in Parkinson's. Thus, PRKN mutations contribute to the pathogenesis of Parkinson's disease by disrupting mitochondrial homeostasis and dopamine metabolism.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving protein folding and stress response. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive loss of motor neurons. The pathway connects SOD1 to BIP (a chaperone involved in protein folding), EIF2AK3, EIF2S1, ATF4, and DDIT3, suggesting a link between oxidative stress, protein homeostasis, and cellular stress response. These interactions highlight how SOD1 dysfunction disrupts cellular homeostasis, leading to neuronal damage. The accumulation of misfolded proteins and oxidative stress, driven by mutant SOD1, contributes to the pathogenesis of ALS. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. This pathway is central to the unfolded protein response (UPR) and stress response mechanisms. Mutations in SOD1 are well-documented to contribute to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The SOD1 gene encodes superoxide dismutase 1, an antioxidant enzyme whose misfolding and aggregation disrupt cellular homeostasis, leading to neuronal toxicity. The downstream pathway involving BIP, EIF2AK3, and ATF4 further amplifies the stress response, exacerbating neuronal damage. Thus, the biological effect of mutant SOD1 is the induction of neurotoxic pathways that drive the progression of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. This pathway is associated with oxidative stress response and protein folding. Mutations in SOD1, a copper-zinc superoxide dismutase, lead to misfolded proteins and cellular stress, contributing to neurodegeneration. This pathway is central to diseases characterized by protein misfolding and oxidative damage. The most well-documented disease linked to SOD1 mutations is amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Mutant SOD1 proteins aggregate and disrupt cellular functions, leading to motor neuron death. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and SYPH1, highlights its role in ubiquitination and mitochondrial quality control. Loss-of-function mutations in PRKN lead to impaired degradation of damaged mitochondria and aggregation of alpha-synuclein, contributing to neurodegeneration. This process is central to the pathogenesis of Parkinson's disease. The involvement of SNCAIP, which interacts with alpha-synuclein, further supports the connection between PRKN dysfunction and Parkinson's. Thus, PRKN mutations contribute to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN disrupt this function, leading to the accumulation of damaged proteins and impaired mitochondrial quality control. This contributes to neuronal toxicity and degeneration, particularly in dopaminergic neurons. PRKN mutations are a major genetic cause of autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and SYPH1, highlights its role in ubiquitination and protein degradation. Impaired PRKN function results in the loss of neuronal viability, hallmark features of Parkinson's disease, including motor dysfunction and Lewy body formation. Thus, PRKN mutations are strongly associated with Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway includes UBCH7/8 (E2 conjugating enzymes), PRKN (E3 ligase), and SNCAIP, which interacts with alpha-synuclein. Impaired PRKN function leads to the accumulation of misfolded proteins, including alpha-synuclein, contributing to neuronal toxicity. This dysfunction disrupts mitophagy, leading to the accumulation of damaged mitochondria and oxidative stress, which are key features of Parkinson's disease. Thus, PRKN mutations contribute to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN disrupt this function, leading to the accumulation of damaged proteins and mitochondrial dysfunction. This contributes to neurodegeneration. PRKN is a key gene in the pathogenesis of Parkinson's disease. Loss-of-function mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease. The pathway involving PRKN, along with ubiquitin-conjugating enzymes UBE2L3 and UBE2L6, highlights its role in ubiquitin-mediated protein degradation. Dysfunction in this pathway impairs cellular quality control, promoting neuronal death. Thus, PRKN mutations contribute to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for ubiquitin-mediated proteasomal degradation. Mutations in PRKN lead to impaired protein degradation, disrupting quality control and causing the accumulation of toxic proteins. This contributes to neurodegeneration. PRKN is a key gene in Parkinson's disease (PD), where loss-of-function mutations are associated with early-onset, autosomal recessive PD. These mutations disrupt mitochondrial homeostasis, oxidative stress response, and mitophagy, leading to dopaminergic neuron loss. PRKN's role in ubiquitination and protein degradation makes it essential for neuronal survival. Mutations in PRKN are among the most common genetic causes of hereditary PD, highlighting its central role in disease pathogenesis. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein quality control and mitophagy. Mutations in PRKN lead to impaired ubiquitin-mediated degradation of damaged mitochondria, resulting in mitochondrial dysfunction and oxidative stress. This contributes to neurodegeneration. PRKN is a major causative gene for early-onset Parkinson's disease. Loss-of-function mutations in PRKN disrupt neuronal survival, particularly in dopaminergic neurons, leading to progressive motor dysfunction. PRKN also plays a role in other neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple system atrophy. The pathway involving UBCH7/8 (E2 conjugases) and PAELR supports ubiquitin-mediated protein degradation, which is essential for maintaining cellular homeostasis. Dysfunction in this pathway disrupts proteostasis, exacerbating neurodegeneration. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a critical component of the mitogen-activating protein kinase (MAPK) signaling cascade, where BRAF activates MEK, which in turn phosphorylates ERK. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of this pathway, resulting in uncontrolled cell proliferation and survival. This dysregulation is commonly observed in various cancers. The most well-known disease associated with BRAF mutations is melanoma, where the V600E mutation is present in approximately 50% of cases. BRAF mutations are also implicated in other malignancies, including non-small cell lung cancer, thyroid cancer, and colorectal cancer. The persistent activation of the ERK signaling pathway due to mutated BRAF contributes to tumor progression, angiogenesis, and resistance to apoptosis. Targeted therapies, such as BRAF inhibitors, have been developed to block this aberrant signaling. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade in cell growth and differentiation. The BRAF gene encodes a serine/threonine kinase that activates MEK, which in turn phosphorylates ERK, leading to activation of downstream transcription factors that drive cell proliferation and survival. Mutations in BRAF, particularly the V600E substitution, result in constitutive activation of the pathway, promoting uncontrolled cell growth. This aberrant signaling is strongly associated with various cancers. The most well-known disease linked to BRAF mutations is **melanoma**, where BRAF mutations are found in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies, including colorectal, lung, and thyroid cancers. The constitutive activation of the MAPK/ERK pathway due to BRAF mutations drives tumor progression and resistance to apoptosis, making it a critical target for therapeutic intervention. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade involved in cell proliferation, differentiation, and survival. Mutations in the BRAF gene, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway by promoting continuous signaling from BRAF to MEK and ERK. This uncontrolled signaling drives cellular proliferation and inhibits apoptosis, contributing to tumorigenesis. The most well-known disease associated with this pathway activation is **melanoma**, where BRAF mutations are found in approximately 50% of cases. These mutations are also implicated in other cancers, including colorectal, lung, and thyroid cancers. The persistent activation of ERK due to mutated BRAF results in unregulated cell growth and is a critical driver in the progression of these malignancies. Therapies targeting BRAF mutations, such as BRAF inhibitors, have significantly improved outcomes in patients with BRAF-mutated cancers.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the biosynthesis of sphingolipids and the proper functioning of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP lead to reduced production of these enzymes, resulting in the accumulation of toxic lipids in lysosomes. This primarily affects the central nervous system, causing neurodegeneration. The most well-documented disease associated with PSAP mutations is **metachromatic leukodystrophy (MLD)**. MLD is a rare inherited lysosomal storage disorder characterized by progressive demyelination of peripheral and central nerves, leading to severe neurological deterioration. The disease is caused by the combined deficiency of ARSA (arylsulfatase A), GBA, and GALC, with PSAP acting as a chaperone for these enzymes. Mutations in PSAP disrupt enzyme stability and trafficking, contributing to the pathogenesis of MLD.\n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is involved in the biosynthesis of sphingolipids and is critical for the proper folding and trafficking of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired processing of these enzymes, resulting in their accumulation and dysfunction. This primarily affects the central nervous system, leading to a neurodegenerative disorder. The most notable disease associated with PSAP mutations is **Sphingolipidosis**, specifically **Saposin-B Deficiency**, which is a form of **Lysosomal Storage Disease (LSD)**. This condition is characterized by progressive neurological deterioration due to the accumulation of sphingolipids in neurons. It is a rare, autosomal recessive disorder. The disruption of PSAP contributes to the pathogenesis of this disease by impairing the activity of key lysosomal enzymes, leading to neuronal damage and degeneration.\n\n\\boxed{Sphingolipidosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper processing of sphingolipid activator proteins, including GBA, GBA2, and GALC. Mutations in PSAP can lead to reduced production or dysfunction of these enzymes, disrupting sphingolipid metabolism. This disruption is implicated in the pathogenesis of sphingolipid storage disorders. Specifically, PSAP mutations are associated with **Fabry disease**, a X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A (GLA), though PSAP mutations can also contribute to **Gaucher disease** through impaired processing of GBA. However, the most direct disease linked to PSAP is **Fabry disease**, as PSAP is a critical cofactor for GLA activity. Thus, PSAP allele dysfunction contributes to **Fabry disease**.\n\n\\boxed{Fabry disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a component of the pathway that links glutamate signaling to mitochondrial calcium homeostasis and apoptosis. Mutations in ATXN3 are associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination. ATXN3 encodes ataxin-3, an E3 ubiquitin ligase involved in protein degradation and quality control. Mutations in ATXN3 lead to the production of an abnormally long polyglutamine tract in ataxin-3, resulting in protein misfolding, aggregation, and neuronal toxicity. This contributes to the degeneration of cerebellar neurons, leading to the motor deficits seen in SCA2. The involvement of ATXN3 in this pathway highlights its role in maintaining mitochondrial function and preventing neurodegeneration. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-dependent protein degradation pathway. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This is the defining genetic feature of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. In the provided pathway, ATXN3 is implicated in calcium signaling through its interaction with ITPR1 and possibly modulating mitochondrial calcium uptake via the MCU complex. The accumulation of mutant ATXN3 protein disrupts cellular homeostasis, contributing to neuronal death. This pathway is relevant in diseases involving calcium dysregulation and protein aggregation. The biological effect of the ATXN3 allele is therefore a key contributor to \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and neurodegeneration. In the given pathway, ATXN3 is linked to the release of Ca\u00b2+ from the endoplasmic reticulum through ITPR1, which influences mitochondrial calcium levels via MCU. Dysregulation of this pathway is associated with impaired calcium homeostasis, oxidative stress, and neuronal dysfunction. Mutations in ATXN3 are well-documented as a cause of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor control. SCA2 is caused by expansions of polyglutamine repeats in the ATXN3 protein, leading to protein aggregation and neuronal toxicity. The pathway described underlines the role of ATXN3 in calcium signaling, which is disrupted in SCA2, contributing to neurodegeneration. Thus, the biological effect of the ATXN3 allele is the contribution to spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular response to DNA damage and apoptosis. Mutations in TP53 disrupt its tumor suppressor function, leading to impaired cell cycle regulation, DNArepair, and apoptosis. This results in genomic instability and uncontrolled cell proliferation. The listed genes\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014are downstream effectors of p53, involved in cell cycle arrest, DNA repair, and apoptosis. When TP53 is mutated, these genes fail to function properly, contributing to oncogenesis. This pathway is frequently altered in various human cancers. The most significant disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary disorder characterized by an increased risk of multiple cancers, including sarcomas, breast cancer, and brain tumors. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular responses to DNA damage and stress. Mutations in TP53 disrupt its tumor suppressor function, leading to loss of cell cycle arrest, apoptosis, and DNA repair. This contributes to genomic instability and uncontrolled cell proliferation. Genes like CDKN1A, GADD45, BAX, and BAK1 are downstream effectors that mediate cell cycle arrest and apoptosis. Dysfunction in this pathway is strongly associated with aggressive tumor progression. The TP53 allele's disruption is a hallmark of many cancers. This pathway's inactivation is a key driver in the development of various malignancies. The most significant disease associated with TP53 dysfunction is **Li-Fraumeni syndrome**, a hereditary disorder characterized by a high risk of multiple cancers, including breast, lung, osteosarcoma, and leukemia. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular responses to DNA damage and stress, regulating cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to genomic instability and impaired tumor suppression. This pathway includes genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which collectively mediate cell cycle arrest, DNA repair, and apoptosis. Dysfunction in this pathway is strongly associated with the development and progression of cancer. Specifically, TP53 mutations are among the most common genetic alterations in human tumors, contributing significantly to the pathogenesis of various cancers. The most well-documented disease linked to TP53 dysfunction is **Li-Fraumeni syndrome**, a hereditary disorder characterized by a high risk of multiple malignancies, including sarcomas, breast cancer, and brain tumors. \\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a well-documented cause of early-onset familial Alzheimer's disease (FAD). The pathway described, involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC), reflects the complex interplay between amyloidogenesis and intracellular transport processes, which are disrupted in Alzheimer's. Impaired transport of proteins and organelles, due to dysfunction in the kinesin network, further exacerbates neuronal damage. Thus, mutations in PSEN1 lead to the accumulation of toxic amyloid-beta plaques and neurodegeneration. The biological effect of this PSEN1 allele is the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex. Mutations in PSEN1 are a well-documented cause of early-onset Alzheimer's disease (AD). The pathway described involves PSEN1 influencing GSK3B, a kinase implicated in neurodegeneration, and interactions with kinesin family members (KIF5A/B/C) and kinesin light chains (KLC1-4), which are essential for intracellular transport. These connections suggest a role in neuronal function and protein trafficking. Impaired function of PSEN1 leads to increased amyloid-beta peptide production and neurotoxicity, contributing to the pathogenesis of AD. Therefore, mutations in PSEN1 primarily contribute to \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are the most common genetic cause of early-onset familial Alzheimer's disease (FAD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in neurodegenerative processes, including protein trafficking and neuronal stability. Dysregulation of this pathway contributes to the accumulation of toxic amyloid-beta plaques and neuronal dysfunction. The primary disease associated with PSEN1 mutations is Alzheimer's disease. These mutations lead to impaired \u03b3-secretase activity, resulting in increased production of amyloid-beta 42, a key factor in plaque formation and cognitive decline. Thus, the biological effect of the PSEN1 allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele plays a critical role in the cAMP signaling pathway, initiating a cascade that includes adenylate cyclases (ADCY), cAMP, PKA, and ultimately CREB and POMC. This pathway is essential for regulating adrenal corticoid production, particularly ACTH, which stimulates cortisol release. Mutations in GNAS can lead to dysregulation of this pathway, causing overstimulation or suppression of adrenal function. This contributes to diseases such as **McCune-Albright syndrome**, characterized by fibrous dysplasia, polyostotic bone lesions, endocrinopathy, and skin pigmentation. GNAS mutations also contribute to **Cushing's disease** through ectopic ACTH production by adrenal or non-adrenal tumors. The pathway's involvement in hormone regulation makes GNAS a key player in endocrine disorders. \\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the alpha subunit of the stimulatory G protein (Gs\u03b1), which activates adenylate cyclase (ADCY) to increase cAMP levels. This leads to activation of PKA, which phosphorylates CREB, promoting transcription of genes like POMC, including ACTH. Mutations in GNAS can disrupt this pathway, leading to aberrant cAMP signaling. This contributes to disorders of the pituitary and adrenal axes. A well-documented disease associated with GNAS mutations is **Pseudoparathyroidism Type 1B (PPTD1B)**, characterized by hypercalcemia, resistance to parathyroid hormone, and sometimes hypocalcemia. It results from gain-of-function mutations in GNAS, causing overactivation of the Gs\u03b1 pathway and increased POMC expression, including ACTH. This leads to increased adrenal steroidogenesis and altered calcium homeostasis. \\boxed{Pseudoparathyroidism Type 1B}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the alpha subunit of the stimulatory G protein (Gs\u03b1), which activates adenylate cyclase (ADCY) to increase cAMP levels. This leads to activation of PKA and downstream effectors like CREB, ultimately influencing gene expression. Mutations in GNAS can disrupt this signaling pathway, leading to dysregulated cAMP levels. This contributes to diseases characterized by hormonal imbalances, such as **McCune-Albright syndrome**. This condition is marked by fibrous dysplasia, polyostotic osteomas, and endocrine disorders like precocious puberty or Cushing syndrome. GNAS mutations also play a role in other conditions, including **hormonal resistance syndromes** and **parathyroid hyperplasia**. The pathway is critical for regulating adrenal function via ACTH production through POMC, linking GNAS dysfunction to adrenal and pituitary disorders. \\boxed{McCune-Albright syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is critical for the cleavage of amyloid precursor protein (APP), leading to the production of amyloid-\u03b2 peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway described involves PSEN1 regulating GSK3B, a kinase implicated in neuronal survival and tau phosphorylation, and interactions with kinesin family members (KIF5A/B/C) and kinesin light chains (KLC1-4), which are involved in intracellular transport. Dysregulation of this pathway contributes to neurodegeneration by increasing amyloid-\u03b2 production, impairing protein trafficking, and promoting tau pathology. These effects collectively drive the progression of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a primary cause of early-onset familial Alzheimer's disease (FAD). The pathway described, PSEN1 \u2192 GSK3B -| (KIF5+KLC), reflects its involvement in regulating intracellular transport and protein processing. GSK3B, a downstream target, is implicated in neurodegeneration, and its interaction with kinesin proteins (KIF5 and KLC) suggests a role in neuronal transport and stability. Altered PSEN1 function disrupts these processes, leading to the accumulation of toxic amyloid-\u03b2 plaques and neurofibrillary tangles, hallmark features of Alzheimer's disease. Therefore, the biological effect of this PSEN1 allele is the contribution to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway described, involving PSEN1 \u2192 GSK3B -| (KIF5+KLC), highlights its role in regulating tau phosphorylation and axonal transport, both of which are disrupted in Alzheimer's disease. GSK3B, a kinase involved in tau phosphorylation, is inhibited by PSEN1, and the interaction with kinesin (KIF5) and kinesin light chain (KLC) proteins suggests a role in neuronal transport and stability. Disruption of this pathway contributes to neuronal dysfunction and neurodegeneration. Therefore, the biological effect of the PSEN1 allele is the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of CDK4/6, which phosphorylates RB1. In the given pathway, CDKN2A negatively regulates MDM2, which normally ubiquitinates and destabilizes TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor-suppressive functions. Loss or mutation of CDKN2A disrupts this regulation, leading to reduced TP53 activity, unchecked cell cycle progression, and genomic instability. This pathway is central to cell cycle control and DNA repair. Mutations in CDKN2A are strongly associated with melanoma, particularly in the context of the CDK4/6-RB1 pathway. These mutations contribute to uncontrolled cell proliferation and resistance to apoptosis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in the p53-mediated tumor suppressor pathway. CDKN2A encodes INK4A, which inhibits CDK4/6, preventing phosphorylation of RB1 and thus blocking E2F-driven cell cycle progression. Mutations or deletions in CDKN2A lead to loss of INK4A, allowing uncontrolled cell proliferation. This disruption contributes to genomic instability and unregulated cell division, key features of cancer. CDKN2A is a well-known tumor suppressor gene, and its inactivation is strongly associated with various malignancies, particularly melanoma and pancreatic cancer. Loss of CDKN2A also results in increased MDM2-mediated degradation of TP53, further compromising the DNA damage response. These combined effects make CDKN2A inactivation a significant driver in the development of several cancers. \\boxed{Pancreatic Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes for p16INK4a, a potent inhibitor of cyclin D-CDK4/6 complexes. In the given pathway, CDKN2A negatively regulates MDM2, which normally promotes the degradation of TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its ability to activate CDKN1A, which in turn inhibits the CDK4/6-cyclin D complex. This prevents phosphorylation of RB1, thereby blocking E2F-driven cell cycle progression. Loss or mutation of CDKN2A disrupts this checkpoint, leading to unchecked cell proliferation. This contributes to uncontrolled cell growth and is a key driver in several cancers. Specifically, CDKN2A mutations are strongly associated with **melanoma** and **pancreatic cancer**, where loss of p16INK4a function promotes tumor progression by deregulating the p53 and RB1 pathways. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the WNT signaling cascade. Its stabilization and nuclear translocation, facilitated by the interaction with GSK3B, AXIN1, AXIN2, and APC, leads to the activation of TCF/LEF transcription factors. This results in the upregulation of downstream genes such as BIRC5, MYC, and CCND1, which are critical for cell proliferation, survival, and genomic instability. Mutations in CTNNB1 that enhance its stability or activity disrupt normal WNT signaling, leading to aberrant cell growth. This dysregulation is a hallmark of several cancers, particularly those involving uncontrolled cell division. The most significant disease associated with CTNNB1 mutations is colorectal cancer, where its activation drives tumor progression through the WNT/\u03b2-catenin pathway. \\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the WNT signaling cascade. CTNNB1 (beta-catenin) is a key mediator of WNT signaling, and its stabilization and nuclear translocation activate target genes such as BIRC5, MYC, and CCND1, which promote cell proliferation and survival. Mutations or dysregulation of CTNNB1 can lead to its constitutive activation, driving uncontrolled cell growth. This is a hallmark of several cancers. Specifically, CTNNB1 mutations are commonly found in colorectal cancer, where they contribute to the canonical WNT pathway aberrations. These mutations can result in the stabilization of beta-catenin, leading to the activation of oncogenic transcription programs. The resulting proliferative and anti-apoptotic effects make CTNNB1 a critical driver in colorectal tumorigenesis. Thus, the biological effect of this CTNNB1 allele is the promotion of colorectal cancer.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the WNT signaling pathway. CTNNB1 encodes \u03b2-catenin, a key mediator of WNT signaling. When mutated or overactive, it leads to the stabilization and nuclear accumulation of \u03b2-catenin, promoting the transcription of genes such as BIRC5, MYC, and CCND1. This dysregulation drives uncontrolled cell proliferation and inhibits apoptosis, contributing to the development of cancer. Specifically, mutations in CTNNB1 are strongly associated with colorectal cancer. These mutations often occur in the context of adenomatous polyposis, leading to the formation of polyps that can progress to malignancy. The activation of the WNT/\u03b2-catenin pathway through CTNNB1 mutations is a hallmark of colorectal carcinogenesis. \n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 pathway is involved in calcium signaling, mitochondrial function, and apoptosis. SIGMAR1 modulates intracellular calcium release via ITPR channels, influences mitochondrial calcium uptake through MCU, and contributes to the permeability transition pore (MPTP) opening, which facilitates the release of cytochrome c (CYCS). This pathway is critical for maintaining mitochondrial homeostasis. Mutations in SIGMAR1 disrupt calcium regulation, leading to mitochondrial dysfunction and increased apoptosis. This contributes to neurodegenerative diseases characterized by neuronal loss and oxidative stress. The most prominent disease associated with SIGMAR1 dysfunction is **Amyotrophic Lateral Sclerosis (ALS)**, where impaired calcium signaling and mitochondrial dysfunction play key roles in motor neuron death. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 allele plays a critical role in modulating intracellular calcium signaling. It interacts with ITPR (inositol 1,4,5-trisphosphate receptors), which release Ca\u00b2+ into the cytoplasm. This Ca\u00b2+ is then taken up by the mitochondrial calcium uniporter (MCU), leading to mitochondrial Ca\u00b2+ accumulation. Excessive mitochondrial Ca\u00b2+ can trigger the permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating apoptosis. Mutations in SIGMAR1 disrupt this balance, leading to mitochondrial dysfunction and cell death. This pathway is implicated in neurodegenerative diseases. Specifically, SIGMAR1 variants are associated with **Amyotrophic Lateral Sclerosis (ALS)**, where impaired calcium homeostasis and mitochondrial dysfunction contribute to motor neuron death. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 pathway is involved in calcium signaling, linking mitochondrial calcium uptake to the release of cytochrome c, a key mediator of apoptosis. The SIGMAR1 gene encodes the sigma-1 receptor, which modulates intracellular calcium homeostasis by interacting with inositol trisphosphate receptors (ITPRs) and the mitochondrial calcium uniporter (MCU). Mutations in SIGMAR1 disrupt this balance, leading to mitochondrial dysfunction and increased apoptosis. This contributes to neurodegenerative diseases characterized by oxidative stress and neuronal loss. The accumulation of calcium in mitochondria promotes the opening of the mitochondrial permeability transition pore (MPTP), releasing cytochrome c and initiating apoptosis. SIGMAR1 variants have been implicated in Parkinson's disease, where impaired calcium regulation and mitochondrial dysfunction play a central role. Thus, the biological effect of the SIGMAR1 allele is the disruption of calcium homeostasis, leading to neuronal apoptosis and contributing to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene plays a critical role in mitochondrial quality control and apoptosis. In the given pathway, PINK1 interacts with HTRA2 and TRAP1, and its dysfunction disrupts the mitochondrial pathway of apoptosis, particularly by affecting the release of cytochrome c, which is essential for activating APAF1, CASP9, and ultimately CASP3. Mutations in PINK1 are associated with impaired mitochondrial function and defective apoptosis, leading to neurodegeneration. This pathway is closely linked to Parkinson's disease, where PINK1 mutations contribute to the loss of dopaminergic neurons through mitochondrial dysfunction and increased susceptibility to oxidative stress. The disruption of this pathway impairs the cell's ability to eliminate damaged mitochondria, leading to neuronal death. Therefore, the biological effect of this PINK1 allele is a key contributor to \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele plays a critical role in mitochondrial function and apoptosis regulation. PINK1 is a serine/threonine kinase that localizes to mitochondria and is essential for maintaining mitochondrial health. When PINK1 is dysfunctional, it disrupts the mitophagy process, leading to the accumulation of damaged mitochondria. This dysfunction also affects the apoptotic pathway by impairing the release of cytochrome c, which is catalyzed by HTRA2 and TRAP1, and subsequently hinders the activation of APAF1, CASP9, and CASP3. This disruption contributes to neuronal loss and neurodegeneration. Mutations in PINK1 are strongly associated with Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons. The PINK1 pathway's role in mitochondrial quality control and apoptosis makes it a key contributor to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is critical for mitochondrial quality control and apoptosis regulation. PINK1, a kinase, phosphorylates mitochondrial proteins, including HTRA2 and TRAP1, which are involved in maintaining mitochondrial integrity. When PINK1 is dysfunctional, mitochondrial dysfunction occurs, leading to impaired apoptosis. The pathway includes CYCS, APAF1, CASP9, and CASP3, which are key players in the intrinsic apoptosis pathway. Loss-of-function mutations in PINK1 disrupt mitochondrial homeostasis and apoptosis, leading to neurodegeneration. This contributes to Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. Mutations in PINK1 are among the known genetic risk factors for Parkinson's, highlighting its role in disease pathogenesis. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the accumulation of toxic protein aggregates. This contributes to neurodegeneration by disrupting cellular protein homeostasis and causing neuronal death. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is critical for autophagy, a process that clears damaged proteins and organelles. Dysfunction in this pathway impairs autophagy, exacerbating the accumulation of misfolded proteins. This genetic and functional disruption is a key driver of a rare, dominantly inherited neurodegenerative disorder characterized by progressive cerebellar ataxia, motor dysfunction, and cognitive decline. The disease is known as \\boxed{Spinocerebellar Ataxia Type 3 (SCA3)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. The pathway it is part of includes genes associated with autophagy, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, suggesting a role in cellular stress response and protein quality control. Mutations in ATXN3 are the primary cause of **spinocerebellar ataxia type 2 (SCA2)**, an inherited neurodegenerative disorder characterized by progressive loss of coordination and motor function. The expanded CAG repeats in ATXN3 lead to the production of a toxic, polyglutamine-containing ataxin-3 protein, which disrupts normal protein folding and leads to neurodegeneration. This mutation impairs autophagy and proteasomal degradation, contributing to neuronal dysfunction and disease progression. The involvement of autophagy-related genes in this pathway underscores the importance of protein clearance in maintaining neuronal health. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and transcription. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. SCA2 is an autosomal dominant disorder, and the expanded CAG trinucleotide repeats in ATXN3 lead to the production of an aberrant, toxic ataxin-3 protein, which accumulates in neurons, particularly in the cerebellum and brainstem. This accumulation disrupts cellular functions, leading to neuronal degeneration. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 suggests a role in autophagy, a process critical for protein quality control. Impaired autophagy may exacerbate the toxic effects of mutant ATXN3, contributing to disease progression. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting from MET, leading through GRB2, SOS, RAS, and RAF to MEK and ERK, ultimately activating CCND1. This pathway is crucial for cell proliferation, survival, and migration. Activation of MET can result in constitutive signaling, driving uncontrolled cell growth. This contributes to the development of various cancers, particularly those involving aberrant MET expression or activation. Notably, MET-driven oncogenesis is strongly associated with **Non-Small Cell Lung Cancer (NSCLC)**, where MET amplification or overexpression promotes tumor progression, metastasis, and resistance to therapy. Additionally, MET activation has been implicated in other malignancies, including renal cell carcinoma and gastric cancer. Thus, the biological effect of this MET allele is the promotion of tumor growth and metastasis, contributing to **Non-Small Cell Lung Cancer**.\n\n\\boxed{Non-Small Cell Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting from MET, leading through GRB2, SOS, RAS, RAF, MEK, and finally ERK to CCND1. This pathway is critical for cell proliferation, survival, and differentiation. Activation of MET, particularly through mutations or overexpression, leads to constitutive signaling, promoting uncontrolled cell growth. This dysregulation is closely associated with the development and progression of various cancers. Specifically, MET-driven oncogenesis is a key factor in cancers such as non-small cell lung cancer (NSCLC), renal cell carcinoma, and hepatocellular carcinoma. Additionally, MET alterations are implicated in metastasis and resistance to therapy. The pathway's activation results in increased expression of cyclin D1 (CCND1), which drives the cell cycle, further promoting tumor growth. Therefore, the biological effect of MET activation is oncogenic, contributing to the development of \\boxed{Non-Small Cell Lung Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when mutated or overexpressed, activates the MET receptor tyrosine kinase, initiating the downstream signaling cascade: MET \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK \u2192 CCND1. This pathway is critical for cell proliferation, survival, and migration. Dysregulation of MET leads to constitutive activation of the MAPK/ERK pathway, promoting uncontrolled cell growth. This contributes to the development and progression of cancers characterized by MET overactivation. Notably, MET-driven oncogenesis is implicated in various malignancies, including non-small cell lung cancer (NSCLC), renal cell carcinoma, and gastrointestinal stromal tumors (GISTs). The pathway also plays a role in tumor angiogenesis and metastasis. Mutations or amplifications in MET are associated with poor prognosis and resistance to certain therapies. The biological effect of MET activation in this pathway is thus the promotion of tumorigenesis and cancer progression. \\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in cell cycle regulation by inhibiting the CDK4/6-cyclin D complex, preventing phosphorylation of the retinoblastoma protein (RB1). This inhibition blocks the release of E2F transcription factors, which drive S-phase entry. Loss or mutation of CDKN2A disrupts this regulatory checkpoint, leading to uncontrolled cell proliferation. This dysfunction is a key driver in several cancers, particularly those with aberrant cell cycle control. CDKN2A is frequently inactivated in melanoma, pancreatic cancer, and small cell lung cancer. Its loss allows unchecked RB1 phosphorylation, leading to E2F-mediated transcription of genes promoting cell division. This pathway alteration contributes to genomic instability and tumor progression. The most well-documented disease associated with CDKN2A dysfunction is \\boxed{Melanoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nCDKN2A encodes p16INK4a, a key inhibitor of cyclin D-dependent kinases CDK4 and CDK6. In the given pathway, CDKN2A negatively regulates the CDK4/6-cyclin D complex, which in turn inhibits the phosphorylation of RB1. Phosphorylated RB1 releases E2F transcription factors, promoting cell cycle progression. Loss or mutation of CDKN2A leads to unchecked CDK4/6 activity, sustained RB1 inactivation, and E2F-driven transcription, driving uncontrolled cell proliferation. This pathway dysfunction is a hallmark of several cancers. Specifically, CDKN2A inactivation is a major contributor to melanoma, pancreatic adenocarcinoma, and other malignancies. The most well-established association is with **melanoma**, where CDKN2A mutations or deletions are frequently observed. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nCDKN2A encodes the protein p16INK4a, which inhibits CDK4 and CDK6. This prevents the phosphorylation of the retinoblastoma protein (RB1), keeping it in an active, hypophosphorylated state. Active RB1 suppresses E2F transcription factors, which drive cell cycle progression. When CDKN2A is mutated or inactivated, CDK4/6 can phosphorylate RB1, leading to its inactivation. This allows E2F to promote cell cycle progression, leading to uncontrolled cell division. This pathway is critical in cell cycle regulation, and its disruption is commonly observed in various cancers. Specifically, inactivation of CDKN2A contributes to the development of melanoma, pancreatic cancer, and other malignancies. The loss of CDKN2A function is a hallmark of several cancers, making it a key player in oncogenesis. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in the KRAS/NRAS -> RAF -> MEK -> ERK -> CCND1 pathway contributes to uncontrolled cell proliferation by activating the MAPK signaling cascade. This leads to increased expression of CCND1, a key regulator of the cell cycle, promoting cell cycle progression and inhibiting apoptosis. The constitutive activation of this pathway is a hallmark of several cancers. Specifically, mutations in NRAS are commonly associated with **malignant melanoma**. These mutations result in persistent activation of downstream effectors, driving tumor growth and resistance to apoptosis. NRAS mutations are also implicated in other malignancies such as bladder cancer, non-small cell lung cancer, and certain leukemias. However, the strongest and most well-documented association is with **malignant melanoma**, where NRAS mutations are found in approximately 10-20% of cases, contributing to tumor initiation and progression. \n\n\\boxed{Malignant melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> RAF -> MEK -> ERK -> CCND1 pathway, contributes to uncontrolled cell proliferation by constitutively activating the MAPK signaling cascade. This leads to increased expression of CCND1, a key regulator of the cell cycle, promoting G1 phase progression and cell division. Such dysregulation is a hallmark of several cancers. Specifically, mutations in NRAS are strongly associated with **Melanoma**, particularly in patients with chronic sun exposure or those with a history of melanoma. These mutations drive tumor progression by enhancing cell survival, proliferation, and resistance to apoptosis. NRAS mutations are also implicated in other malignancies such as **Colorectal Cancer** and **Lung Adenocarcinoma**, but their most well-documented and significant contribution is to **Melanoma**. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> RAF -> MEK -> ERK -> CCND1 pathway, contributes to unregulated cell proliferation by constitutively activating the MAPK signaling cascade. This leads to increased expression of CCND1, a key regulator of the cell cycle, promoting cell cycle progression and uncontrolled cell growth. Mutations in NRAS, particularly gain-of-function mutations, result in persistent activation of downstream signaling, driving cellular transformation. This pathway is central to the development of various cancers. Specifically, NRAS mutations are strongly associated with **malignant melanoma**, where they are among the most common oncogenic mutations. These mutations confer a growth advantage to cancer cells, enhancing their survival and proliferation. Thus, the biological effect of the NRAS allele is the initiation and progression of **malignant melanoma**.\n\n\\boxed{Malignant melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overexpressed, leads to the constitutive activation of the BCR-ABL fusion protein, which drives the RAS-MAPK signaling pathway. This results in uncontrolled cell proliferation and survival, promoting malignant transformation. The most well-known disease associated with this genetic alteration is Chronic Myeloid Leukemia (CML). The BCR-ABL fusion gene arises from a reciprocal translocation between chromosomes 9 and 22, forming the Philadelphia chromosome. This fusion protein acts as a constitutively active tyrosine kinase, continuously activating downstream signaling pathways including RAS and MAPK, which drive cell growth and inhibit apoptosis. This leads to the uncontrolled division of myeloid cells, resulting in CML. Targeted therapies such as tyrosine kinase inhibitors (e.g., imatinib) have significantly improved outcomes for patients with this disease.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or constitutively active, leads to the aberrant activation of the BCR-ABL oncoprotein. This results in continuous signaling through the downstream pathway: BCR-ABL \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This persistent activation drives uncontrolled cell proliferation and inhibition of apoptosis, characteristic of cancer. Specifically, the most well-known disease associated with this pathway is chronic myeloid leukemia (CML), caused by the Philadelphia chromosome translocation (t(9;22)), which fuses the ABL1 gene with the BCR gene, creating the BCR-ABL fusion protein. This constitutively active kinase promotes leukemogenesis by disrupting normal cell cycle regulation and survival signals. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or constitutively active, leads to the continuous activation of the BCR-ABL oncoprotein. This results in uncontrolled cell proliferation and survival by persistently activating the downstream RAS-RAF-MEK-ERK signaling pathway. This dysregulated signaling is a hallmark of chronic myeloid leukemia (CML). The most well-known mutation is the Philadelphia chromosome translocation, t(9;22), which fuses the ABL1 gene to the BCR gene, creating the BCR-ABL fusion protein. This fusion protein exhibits increased tyrosine kinase activity, driving cellular transformation and leukemogenesis. The persistent activation of the MAPK pathway leads to resistance to apoptosis, increased cell division, and genomic instability. This pathway is also implicated in other malignancies, but CML is the most characteristic disease associated with the BCR-ABL oncoprotein. \n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through the regulation of mitochondrial fusion via MFN1 and MFN2. Mutations in PRKN, which encodes the E3 ubiquitin ligase parkin, lead to the dysfunction of mitochondrial dynamics and impaired autophagy of damaged mitochondria. This contributes to the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal loss. These processes are central to the pathogenesis of Parkinson's disease. PRKN mutations are one of the major genetic causes of inherited Parkinson's disease, particularly in individuals with early-onset disease. The loss of PRKN function disrupts the ubiquitin-proteasome system and mitophagy, leading to the accumulation of damaged mitochondria and ultimately neurodegeneration. Therefore, the biological effect of this PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase critical for mitophagy, the selective degradation of damaged mitochondria. Its interaction with MFN1 and MFN2, which mediate mitochondrial fusion, underscores its role in maintaining mitochondrial homeostasis. Mutations in PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria and oxidative stress. This contributes to neuronal loss and neurodegeneration. The most well-documented disease associated with PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are a major genetic cause of early-onset Parkinson's, characterized by the loss of dopaminergic neurons in the substantia nigra. These mutations impair mitophagy, leading to mitochondrial dysfunction and subsequent neurodegeneration. Thus, the biological effect of pathogenic PRKN alleles is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN allele, encoding parkin, is critical for mitophagy, the selective removal of damaged mitochondria. Mutations in PRKN disrupt mitochondrial fusion via MFN1 and MFN2, leading to impaired mitochondrial quality control. This results in the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal degeneration. These processes are strongly associated with neurodegenerative diseases. The most well-documented disease linked to PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are a major genetic cause of autosomal recessive Parkinson's, characterized by dopaminergic neuron loss and Lewy body formation. The pathway's role in maintaining mitochondrial homeostasis underscores its importance in preventing neurodegeneration. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele in this genomic pathway is associated with Huntington's disease. The pathway involves HTT, which encodes huntingtin, a protein whose mutant form (due to an expanded CAG repeat) leads to toxic gain-of-function effects. This mutation results in the accumulation of misfolded huntingtin protein, disrupting cellular processes such as protein degradation, mitochondrial function, and transcriptional regulation. The pathway includes CREB family members and ATF proteins, which are transcription factors involved in stress responses and neuronal survival. The dysregulation of this pathway contributes to neurodegeneration, a hallmark of Huntington's disease. The mutant HTT allele causes progressive degeneration of neurons, particularly in the basal ganglia, leading to motor, cognitive, and psychiatric symptoms. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutation leads to the accumulation of an abnormal protein with an expanded polyglutamine tract. This results in neuronal dysfunction and degeneration, particularly in the basal ganglia. The pathway involving HTT, CREB family members, and ATF4 suggests a role in transcriptional regulation, which is disrupted in this condition. The dysregulation of these transcription factors contributes to neurodegeneration. This genetic pathway is most closely associated with **Huntington's disease**, a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. The expanded CAG repeat in HTT causes toxic gain-of-function effects, leading to cell death in the striatum and cerebral cortex. The involvement of CREB and ATF4 indicates altered gene expression in response to cellular stress, further exacerbating neuronal damage. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele in this pathway is associated with the gene *HTT*, which encodes huntingtin. Mutations in *HTT*, particularly expansions of the CAG repeat, lead to the production of an abnormally long and toxic huntingtin protein. This protein disrupts cellular processes, including transcription, proteostasis, and mitochondrial function, ultimately causing neurodegeneration. The pathway involves CREB family transcription factors and TAF4, which are critical for gene regulation. The accumulation of mutant huntingtin impairs these regulatory networks, contributing to neuronal death. This pathology is hallmarked by the accumulation of insoluble protein aggregates and loss of neurons, particularly in the striatum and cerebral cortex. The most well-known disease associated with this genetic disruption is \\boxed{Huntington's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is central to mitochondrial quality control and apoptosis. PINK1 encodes a kinase that stabilizes mitochondria under stress and promotes the recruitment of PRKN (parkin), an E3 ubiquitin ligase. This complex facilitates mitophagy by ubiquitinating mitochondrial proteins, marking them for degradation. Disruption of PINK1 impairs this process, leading to the accumulation of damaged mitochondria and the release of cytochrome c, which activates APAF1 and initiates the apoptotic cascade through CASP9 and CASP3. Mutations in PINK1 are linked to impaired mitochondrial function and neurodegeneration. This pathway is critically involved in Parkinson's disease, where PINK1 mutations contribute to neuronal loss by promoting apoptosis and mitochondrial dysfunction. Thus, the biological effect of PINK1 mutations is the disruption of mitochondrial homeostasis, leading to neurodegeneration.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the PINK1-PRKN-BAX axis, which is critical for mitochondrial quality control and apoptosis. PINK1 activates PRKN (parkin), leading to the ubiquitination and degradation of damaged mitochondria. BAX promotes mitochondrial outer membrane permeabilization, releasing cytochrome c (CYCS), which activates APAF1 and initiates the formation of the apoptosome. This leads to caspase 9 (CASP9) activation and subsequent caspase 3 (CASP3) activation, driving apoptosis. Mutations in PINK1 impair this process, leading to mitochondrial dysfunction and neuronal loss. This contributes to Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. The disruption of mitochondrial dynamics and apoptosis regulation in this pathway is central to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is critical for mitochondrial quality control and apoptosis. PINK1, when mutated, leads to impaired mitochondrial function and dysfunction in the PARKIN-mediated ubiquitination of damaged mitochondria. This results in the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal death. The pathway culminates in the activation of BAX, release of cytochrome c, and subsequent activation of caspases 9 and 3, triggering apoptosis. Mutations in PINK1 are strongly linked to autosomal recessive Parkinson's disease. These mutations disrupt mitophagy and lead to the degeneration of dopaminergic neurons in the substantia nigra. Therefore, PINK1 mutations contribute to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox regulation and cellular stress responses. Its interaction with DVL (dishevelled) proteins suggests involvement in Wnt signaling, a critical pathway in development and tissue homeostasis. Mutations in NXN may disrupt redox balance and Wnt signaling, contributing to pathological conditions. Altered redox states and impaired Wnt signaling have been implicated in several diseases, including cancer and neurodegenerative disorders. Specifically, disruptions in this pathway have been associated with colorectal cancer, where DVL and Wnt signaling are dysregulated. Additionally, NXN mutations may contribute to neurodevelopmental disorders due to its role in neuronal redox regulation. Based on the involvement of NXN and DVL in Wnt signaling and redox homeostasis, this pathway is implicated in **colorectal cancer**.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene, encoding nucleoredoxin, is involved in redox regulation and cellular stress responses. Its interaction with DVL proteins, which are critical for Wnt signaling, suggests a role in maintaining cellular homeostasis and proper signaling during development and tissue maintenance. Mutations in NXN may disrupt redox balance and Wnt signaling, contributing to developmental disorders or diseases associated with impaired cell proliferation and differentiation. Notably, altered NXN function has been implicated in neurodegenerative conditions, where oxidative stress and disrupted signaling pathways play a key role. Specifically, mutations in NXN have been linked to **Amyotrophic Lateral Sclerosis (ALS)**, a progressive neurodegenerative disease characterized by motor neuron loss. The disruption of redox regulation and Wnt signaling through NXN dysfunction likely exacerbates neuronal stress and degeneration, contributing to disease progression.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene, also known as nucleoredoxin, is involved in redox regulation and interacts with the DVL (dishevelled) proteins, which are key components of the Wnt signaling pathway. Mutations in NXN can disrupt this interaction, leading to impaired Wnt signaling, which is crucial for development and tissue homeostasis. Impaired Wnt signaling has been implicated in various diseases, including cancer. Specifically, alterations in the NXN-DVL interaction have been associated with colorectal cancer. The disruption of this pathway can lead to uncontrolled cell proliferation and resistance to apoptosis, hallmark features of colorectal tumors. Therefore, the biological effect of the NXN allele is the contribution to colorectal cancer development. \n\n\\boxed{Colorectal cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, ultimately affecting DDIT3. SOD1 is a key enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. Mutations in SOD1 are well-documented to contribute to Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. In ALS, mutant SOD1 forms toxic aggregates and disrupts cellular homeostasis, leading to motor neuron death. The pathway described suggests a link between oxidative stress and unfolded protein response, both of which are implicated in ALS pathogenesis. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, leading to reduced activation of DDIT3. SOD1 is a key enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The altered SOD1 protein forms aggregates and gains toxic properties, contributing to neuronal degeneration. This pathway's disruption further exacerbates cellular stress and impairs the unfolded protein response, promoting neurotoxicity. Thus, the biological effect of the SOD1 allele is the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6. This leads to reduced activation of ATF6, a key transcription factor in the unfolded protein response (UPR). Decreased ATF6 activity results in lower expression of DDIT3, a gene involved in stress response and cell survival. Mutations in SOD1 are well-documented to contribute to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The disruption of this pathway may impair the cell's ability to handle proteotoxic stress, exacerbating neuronal damage. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and transcription. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the accumulation of toxic protein aggregates. This pathogenic mechanism is central to spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The involvement of ATXN3 in the described genomic pathway highlights its role in calcium homeostasis and mitochondrial dysfunction, which are key contributors to neuronal toxicity. The interaction with ITPR1 and MCU suggests that altered calcium signaling and mitochondrial stress play a critical role in SCA2 pathogenesis. Therefore, the biological effect of the ATXN3 allele is the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is involved in the genomic pathway linking glutamate signaling to mitochondrial calcium dynamics and apoptosis. This pathway plays a critical role in neuronal function and cellular homeostasis. Mutations in ATXN3 are well-documented as a cause of Spinocerebellar Ataxia Type 2 (SCA2), a neurodegenerative disorder characterized by progressive impairment of motor coordination. The disease arises from expansions of the CAG repeat in the ATXN3 gene, leading to the production of an abnormally long polyglutamine tract in the ataxin-3 protein. This structural abnormality disrupts protein folding, causes aggregation, and impairs cellular function, particularly in cerebellar neurons. The involvement of ATXN3 in mitochondrial calcium regulation may further contribute to neuronal dysfunction and cell death. Thus, the biological effect of the ATXN3 allele is the development of \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and RNA processing. In the given pathway, ATXN3 is part of the IP3 receptor complex, which regulates calcium release from the endoplasmic reticulum. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of motor coordination. SCA2 is an autosomal dominant condition, with symptoms including gait instability, slurred speech, and cognitive decline. The disease arises from expanded CAG repeats in ATXN3, leading to protein misfolding, aggregation, and neuronal toxicity. The pathway involving ATXN3 highlights its role in calcium homeostasis and its contribution to neurodegeneration through disrupted signaling cascades. The involvement of ATXN3 in this pathway underscores its importance in maintaining cellular function and its link to neurodegenerative disease. \n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, is critical in the ubiquitin ligase pathway that targets hypoxia-inducible factors (HIFs) for degradation. Inactivation of VHL leads to stabilization of HIF-1\u03b1, promoting the transcription of genes like VEGFA, CXCL8, GLUT1, and EPO. This results in abnormal angiogenesis, erythropoiesis, and inflammatory responses. The genetic loss or mutation of VHL is a hallmark of von Hippel-Lindau (VHL) disease, a hereditary cancer syndrome characterized by the development of various benign and malignant tumors, including hemangiomas, renal cell carcinomas, pheochromocytomas, and CNS tumors. The pathway's dysregulation due to VHL mutations drives tumor growth by enhancing angiogenesis and cell survival. \\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in ubiquitin-mediated protein degradation. Mutations in VHL disrupt this pathway, leading to the stabilization of hypoxia-inducible transcription factors (HIFs), such as EPAS1 and ARNT. This results in the overexpression of genes like VEGFA, CXCL8, GLUT1, and EPO, which drive angiogenesis, inflammation, and erythropoiesis. These molecular changes are hallmarks of hypoxia and are central to the development of clear cell renal cell carcinoma (ccRCC). The VHL mutation impairs the degradation of HIFs under normoxic conditions, mimicking hypoxic signaling and promoting tumor growth. Thus, the biological effect of the VHL allele is the activation of hypoxia response pathways, contributing to the pathogenesis of \\boxed{Clear Cell Renal Cell Carcinoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in the ubiquitin-mediated degradation of hypoxia-inducible factors (HIFs), specifically EPAS1 and ARNT. Under normoxia, VHL targets these factors for proteasomal degradation, preventing the activation of downstream genes like VEGFA, CXCL8, GLUT1, and EPO, which are involved in angiogenesis, inflammation, and erythropoiesis. Mutations in VHL disrupt this process, leading to stabilization of HIFs and constitutive activation of these genes. This contributes to the pathogenesis of clear cell renal cell carcinoma (ccRCC), a common urological malignancy characterized by loss of VHL function and hypoxia-related gene overexpression. The accumulation of HIFs promotes tumor growth, vascularization, and resistance to apoptosis. Therefore, the biological effect of this VHL allele is the development of \\boxed{Clear Cell Renal Cell Carcinoma}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to oncogenesis by activating downstream signaling. Mutations in NRAS, like KRAS, lead to constitutive activation of the PI3K-AKT axis, which promotes cell survival, proliferation, and resistance to apoptosis. This dysregulation is a key driver in several cancers. Specifically, NRAS mutations are commonly found in melanoma, particularly in cases arising from chronic sun exposure. They are also implicated in other malignancies such as bladder cancer, non-small cell lung cancer, and certain leukemias. The resulting uncontrolled cell growth and inhibition of apoptosis contribute to tumor development and progression. Therefore, the biological effect of pathogenic NRAS alleles is the activation of oncogenic signaling pathways, leading to the development of **melanoma**.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to constitutive activation of the PI3K-AKT signaling cascade. This leads to inhibition of BAD, a pro-apoptotic protein, promoting cell survival and proliferation. Mutations in NRAS, like those in KRAS, result in gain-of-function, leading to uncontrolled cell growth. This pathway is central in oncogenesis, particularly in cancers where RAS signaling is aberrantly activated. The most common disease associated with NRAS mutations is **Melanoma**, specifically arising from UV-induced DNA damage and subsequent RAS mutation. NRAS mutations are also implicated in other malignancies, including certain leukemias and non-small cell lung cancer. The activation of this pathway disrupts normal cell cycle control and apoptosis, driving tumor progression. Thus, NRAS mutations are a key driver in **Melanoma**.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to dysregulated cell survival and proliferation. Mutations in NRAS, like KRAS, lead to constitutive activation of the PI3K-AKT pathway by continuously signaling through RAS, resulting in increased PIP3 and AKT activation. This inhibits BAD, preventing apoptosis and promoting cell survival. Such pathways are critical in oncogenesis. NRAS mutations are commonly found in cancers such as melanoma, non-small cell lung cancer, and colon cancer. They drive tumor progression by enhancing cell proliferation, survival, and resistance to apoptosis. The activation of this pathway is a hallmark of several malignancies. The most common disease associated with NRAS mutations is **Melanoma**.  \n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this pathway is the production of amyloid-beta (Abeta), which is central to neurodegenerative processes. The pathway leads to the involvement of mitochondrial proteins such as VDAC and SLC25 family members, which are critical for mitochondrial function and calcium homeostasis. The accumulation of Abeta can disrupt mitochondrial integrity, leading to oxidative stress and neuronal death. This pathway is strongly associated with Alzheimer's disease, where amyloid-beta aggregation and mitochondrial dysfunction contribute to cognitive decline and neuronal loss. Mutations in APP that increase Abeta production or alter its processing are known risk factors for early-onset Alzheimer's. The involvement of CYCS (cytochrome c) further links this pathway to apoptosis and mitochondrial dysfunction, reinforcing its role in neurodegeneration. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this genomic pathway is central to the pathological process of Alzheimer's disease. The pathway begins with APP, which is cleaved to produce amyloid-beta (Abeta), a key component of senile plaques in Alzheimer's. This Abeta then interacts with PPID and other components, leading to mitochondrial dysfunction through proteins like VDAC and SLC25 family members, which regulate mitochondrial permeability and ion transport. The final protein in the pathway, CYCS (cytochrome c), is involved in apoptosis and oxidative stress, both of which are hallmarks of neurodegeneration. The accumulation of Abeta and subsequent mitochondrial dysfunction contribute significantly to neuronal death and cognitive decline. Thus, this pathway directly contributes to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway involves the production of amyloid-beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The pathway shows Abeta as a downstream product of APP, leading to the formation of toxic amyloid plaques in the brain. This accumulation of amyloid-beta is a central feature of Alzheimer's disease. The subsequent pathway includes PPID, MPTP, and CYCS, which are involved in mitochondrial dysfunction and oxidative stress, both of which are associated with neurodegeneration. The involvement of VDAC and SLC25A genes highlights a role in mitochondrial permeability and energy metabolism, further supporting the link to neuronal damage. Therefore, the biological effect of this APP allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes ubiquitination and proteasomal degradation. SOD1, when mutated, leads to the production of toxic protein aggregates that disrupt cellular function, particularly in motor neurons. This pathway highlights the role of the ubiquitin-proteasome system (UPS) in degrading misfolded or damaged proteins. Mutations in SOD1 are a well-known cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The accumulation of misfolded SOD1 proteins due to impaired proteasomal degradation contributes to neuronal toxicity and cell death. This pathway is critical for maintaining protein homeostasis, and its dysfunction directly links to the pathogenesis of ALS. The inclusion of proteasome subunits in the pathway further underscores the importance of the UPS in clearing misfolded SOD1. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). Mutations in SOD1, a copper/zinc superoxide dismutase enzyme, lead to the misfolding and aggregation of the protein, which is toxic to motor neurons. This results in the progressive degeneration of upper and lower motor neurons, leading to muscle weakness, atrophy, and ultimately paralysis. The pathway described involves SOD1 interacting with DERL1, promoting the ubiquitination of misfolded proteins, which are then targeted for degradation by the 26S proteasome complex. Dysfunction in this pathway impairs protein quality control, contributing to neurodegeneration. The accumulation of misfolded SOD1 and other proteins disrupts cellular homeostasis, exacerbating disease progression. This pathway is central to understanding SOD1-linked ALS, a form of familial ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). Mutations in SOD1 lead to the production of toxic misfolded proteins that accumulate and disrupt cellular function, particularly in motor neurons. These mutant proteins undergo ubiquitination and are targeted for degradation via the ubiquitin-proteasome system, as indicated by the pathway involving DERL1, ubiquitin (UBA52, UBB, UBC), and proteasome subunits (PSMA and PSMB genes). Impaired proteasome function or misfolded SOD1 can result in proteotoxicity, neuronal damage, and ultimately, neurodegeneration. This pathway is central to the pathogenesis of ALS, a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. The accumulation of misfolded SOD1 proteins contributes directly to disease progression. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to altered gamma-secretase activity, disrupting the cleavage of amyloid precursor protein (APP), resulting in the accumulation of toxic amyloid-beta plaques in the brain. This pathological hallmark contributes to neuronal death and cognitive decline. The pathway described involves calcium dysregulation through the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channels (VDACs), leading to mitochondrial dysfunction, cytochrome c release, and activation of the mitochondrial intrinsic apoptotic pathway via APAF1 and CASP9, ultimately inducing caspase 3/7-mediated apoptosis. These mechanisms align with the neurodegenerative processes in Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer\u2019s disease (FAD). These mutations lead to altered \u03b3-secretase activity, resulting in increased production of amyloid-\u03b2 peptides, particularly the toxic A\u03b242 variant. This accumulation of amyloid-\u03b2 plaques disrupts neuronal function and contributes to neurodegeneration. Additionally, PSEN1 dysfunction can perturb calcium homeostasis via interactions with the mitochondrial calcium uniporter (MCU) and ryanodine receptors (RYR3), leading to mitochondrial dysfunction and apoptosis via the intrinsic pathway involving cytochrome c (CYCS), APAF1, and caspase 9 and 3/7. These molecular disruptions underlie the neurodegenerative processes in Alzheimer\u2019s disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a primary cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-\u03b242 species, promoting amyloid plaque formation in the brain. The pathway described involves calcium dysregulation via the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channel (VDAC), leading to mitochondrial dysfunction, release of cytochrome c, and activation of the apoptotic cascade via APAF1, CASP9, and subsequently CASP3 and CASP7. This highlights the role of PSEN1 in both amyloidogenesis and mitochondrial-mediated apoptosis in neurodegeneration. The biological effect of the PSEN1 allele is therefore central to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele in this pathway contributes to the development of acute myeloid leukemia (AML). FLT3 is a receptor tyrosine kinase that, when mutated, leads to constitutive activation of downstream signaling pathways, including STAT5 and PIM1/2. This persistent activation promotes uncontrolled cell proliferation and survival, undermining normal hematopoietic regulation. Specifically, internal tandem duplication (ITD) mutations in FLT3 are strongly associated with poor prognosis in AML. These mutations result in ligand-independent activation of FLT3, driving leukemic transformation. The activation of STAT5 and PIM1/2 further supports the survival and expansion of leukemic blasts. Therefore, mutations in FLT3 significantly contribute to the pathogenesis of AML.\n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele in this genomic pathway is associated with a constitutive activation of the FMS-like tyrosine kinase 3 receptor, leading to uncontrolled signaling through STAT5 and subsequent activation of PIM1/2. This dysregulated pathway promotes cell proliferation, survival, and differentiation, contributing to leukemic transformation. FLT3 mutations, particularly internal tandem duplications (ITDs) or point mutations, are commonly found in acute myeloid leukemia (AML). These mutations result in constitutive activation of the FLT3-ITD protein, enhancing downstream signaling through STAT5 and PIM kinases, which drive oncogenesis. FLT3 mutations are thus a key driver in the pathogenesis of AML, particularly in the context of myeloid malignancies. The biological effect of this allele is the promotion of leukemic progression and resistance to therapy. \\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 (Fms-related tyrosine kinase 3) allele, when mutated, leads to constitutive activation of the FLT3 tyrosine kinase receptor. This results in continuous signaling through downstream pathways, including STAT5 and PIM1/2. This uncontrolled signaling promotes cell proliferation, survival, and differentiation, contributing to leukemogenesis. Specifically, mutations in FLT3, particularly internal tandem duplications (ITDs) or point mutations, are strongly associated with acute myeloid leukemia (AML). These mutations disrupt normal cell cycle regulation and apoptosis, leading to the accumulation of immature myeloid cells. FLT3 activation also enhances the survival of leukemic blasts and resistance to therapy. Therefore, the biological effect of the FLT3 allele in this pathway is the induction of AML. \n\n\\boxed{Acute Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described involves the activation of CYCS, APAF1, CASP9, and CASP3, which are central to apoptosis. LRRK2, a serine/threonine kinase, plays a role in mitochondrial function and cellular stress response. Mutations in LRRK2 are well-documented in Parkinson\u2019s disease (PD), where they contribute to neurodegeneration by disrupting mitochondrial integrity and promoting apoptosis through the intrinsic pathway. The cascade initiated by LRRK2 leads to cytochrome c release, activation of APAF1 and CASP9, ultimately resulting in CASP3 activation and neuronal cell death. This pathway is critical in the pathogenesis of PD, particularly in familial cases. Therefore, the biological effect of this LRRK2 allele is the promotion of apoptosis in neurons, contributing to the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described involves the activation of cytochrome c (CYCS) via APAF1, leading to the activation of caspase-9 (CASP9) and subsequently caspase-3 (CASP3), which drives apoptosis. LRRK2, a serine/threonine kinase, is known to regulate mitochondrial function and apoptosis. Mutations in LRRK2 are strongly associated with Parkinson's disease (PD). The pathway suggests a role for LRRK2 in mitochondrial stress and apoptosis, which is dysregulated in PD. Loss-of-function mutations in LRRK2 can disrupt mitochondrial integrity, leading to increased apoptosis and neuronal loss, particularly in dopaminergic neurons. This contributes to the pathogenesis of Parkinson's disease. The involvement of CYCS, APAF1, CASP9, and CASP3 indicates that this pathway is critical in the apoptotic cascade triggered by mitochondrial dysfunction. Therefore, the biological effect of this LRRK2 allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described involves the activation of cytochrome c (CYCS) through APAF1, leading to the activation of caspase-9 (CASP9) and ultimately caspase-3 (CASP3), which induces apoptosis. This apoptotic cascade is critical in maintaining cellular homeostasis, particularly in neurons. Mutations in LRRK2, particularly in the G2019S variant, are strongly associated with Parkinson's disease. This allele increases LRRK2 kinase activity, which can disrupt mitochondrial function and promote neuronal death through enhanced apoptosis. The pathway's involvement in apoptosis makes LRRK2 a key player in neurodegeneration. Therefore, the biological effect of this LRRK2 allele is the promotion of apoptosis, contributing to the progression of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel, which is critical for calcium influx into neurons. Mutations in CACNA1A are associated with familial hemiplegic migraine (FHM), a genetic form of migraine with aura. These mutations alter calcium channel function, leading to increased neuronal excitability and neurotransmitter release, which contributes to migraine attacks. CACNA1A mutations are also linked to other neurological disorders, including ataxia and episodic ataxic migraine. The pathway involving extracellular calcium and the CACNA1A subunit highlights the role of calcium homeostasis in neuronal signaling and its disruption in disease. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **CACNA1A** gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which is critical for calcium influx into neurons. Mutations in **CACNA1A** disrupt calcium homeostasis, leading to dysfunctional neurotransmission and neuronal excitability. This contributes to a range of neurological disorders, most notably **Familial Hemiplegic Migraine (FHM)**, a form of inherited migraine with aura characterized by hemiplegia (temporary paralysis on one side of the body) during attacks. Additionally, **CACNA1A** mutations are associated with **Spinocerebellar Ataxia Type 6 (SCA6)**, a degenerative cerebellar disorder causing progressive loss of coordination. These diseases arise from impaired calcium signaling, affecting both excitatory neurotransmission and neuron survival. The pathway involving extracellular calcium and the **CACNA1A** channel highlights the role of calcium in neuronal function and disease. \n\n\\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel. This channel is critical for neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with impaired calcium influx, leading to disrupted neuronal function. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, CACNA1A mutations are a known cause of **familial hemiplegic migraine (FHM)**, a subtype of migraine with aura characterized by reversible neurological symptoms. Additionally, CACNA1A mutations have been linked to **spinocerebellar ataxia type 6 (SCA6)**, a form of hereditary ataxia. These mutations typically result in gain-of-function effects, causing excessive calcium entry and subsequent neuronal dysfunction. The pathway involving extracellular calcium and the CACNA1A subunit underscores its role in regulating intracellular calcium homeostasis, vital for normal brain function. \\boxed{Familial Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in Parkinson's disease. In the given pathway, SNCA is upstream of HSPA5 (BIP), which is part of the unfolded protein response (UPR) in the endoplasmic reticulum (ER). ERN1 (IRE1) activates XBP1, a key transcription factor in the UPR. Mutations or overexpression of SNCA can lead to misfolded alpha-synuclein aggregates, disrupting ER homeostasis and triggering the UPR. This pathway dysfunction contributes to neuronal stress and cell death, hallmarks of Parkinson's disease. Thus, the SNCA allele's biological effect is associated with the accumulation of misfolded proteins and ER stress, ultimately contributing to the pathology of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in protein misfolding and aggregation. In the given pathway, SNCA is upstream of BIP and ERN1, which are involved in the unfolded protein response (UPR) and ER stress. ERN1 activates XBP1, a key regulator of ER function. Mutations or overexpression of SNCA lead to pathological aggregation of alpha-synuclein, which disrupts ER homeostasis and triggers chronic ER stress. This contributes to neuronal dysfunction and death, hallmark features of Parkinson's disease. The accumulation of misfolded alpha-synuclein is a central pathogenic mechanism in Parkinson's, leading to Lewy body formation and progressive neurodegeneration. Thus, the SNCA allele contributes to the development of \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. In the given pathway, SNCA is upstream of HSPA5 (BIP), which is involved in the unfolded protein response in the endoplasmic reticulum. ERN1, a key sensor of ER stress, activates XBP1 through splicing, promoting the adaptive response to protein misfolding. Mutations or overexpression of SNCA can lead to the misfolding and aggregation of alpha-synuclein, contributing to neurodegeneration. These aggregates are a hallmark of Parkinson's disease, where they form Lewy bodies. The pathway highlights the role of ER stress in the disease process, linking SNCA dysfunction to the accumulation of misfolded proteins and subsequent neuronal damage. This underscores SNCA's critical role in the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN encodes parkin, an E3 ubiquitin ligase involved in ubiquitin-mediated proteolysis. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and PAELR, is involved in ubiquitin conjugation and protein degradation. Impaired function of PRKN leads to the accumulation of damaged proteins and mitochondrial dysfunction, contributing to neuronal death. This is a key mechanism in the pathogenesis of Parkinson's disease. Mutations in PRKN are one of the most common genetic causes of early-onset Parkinson's. Therefore, the biological effect of PRKN allele dysfunction is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN encodes parkin, an RBR E3 ubiquitin ligase critical for ubiquitin-mediated protein degradation. Mutations in PRKN lead to impaired ubiquitin ligase activity, disrupting protein quality control and mitochondrial homeostasis. This contributes to the pathogenesis of Parkinson's disease (PD). Loss-of-function PRKN mutations cause the accumulation of damaged proteins and dysfunctional mitochondria, leading to neurodegeneration, particularly in dopaminergic neurons. PRKN mutations are a common genetic cause of monogenic Parkinsonism, often presenting with early-onset PD. The pathway involving UBCH7/8 and PAELR further modulates ubiquitin conjugation and receptor signaling, emphasizing PRKN's role in neuronal survival and proteostasis. Mutations in this pathway therefore significantly increase the risk of developing Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN lead to impaired ubiquitination, disrupting protein quality control and mitochondrial homeostasis. This contributes to the accumulation of damaged proteins and dysfunctional mitochondria, which is linked to neurodegeneration. PRKN mutations are a well-established cause of early-onset Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The pathway involving PRKN, along with ubiquitin-conjugating enzymes UBE2L3 and UBE2L6, highlights its role in ubiquitin-dependent degradation processes. Dysfunction in this pathway impairs cellular clearance mechanisms, exacerbating neurotoxicity. Therefore, PRKN mutations are strongly associated with Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson\u2019s disease. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein aggregates, which contribute to the formation of Lewy bodies\u2014hallmark pathological features of Parkinson\u2019s disease. The pathway includes various subunits of the 26S proteasome, which is responsible for degrading misfolded or damaged proteins. Impaired proteasome function, including that of the 26S subunits, can result in the accumulation of toxic proteins like alpha-synuclein, exacerbating neurodegeneration. This interplay between SNCA and the proteasome underscores its role in Parkinson\u2019s disease. The biological effect of the SNCA allele is thus the promotion of neurodegenerative processes associated with Parkinson\u2019s disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to abnormal protein aggregation, forming Lewy bodies, which are a hallmark of Parkinson's disease. The pathway includes genes associated with the proteasome, a critical cellular machinery for protein degradation. The interaction between SNCA and proteasome subunits suggests a role in protein quality control. Impaired proteasome function can lead to the accumulation of misfolded proteins, including alpha-synuclein, exacerbating neurodegeneration. This contributes to neuronal loss in the substantia nigra, a key feature of Parkinson's disease. Therefore, the SNCA allele is a key contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein, which disrupts cellular function and is a hallmark of Lewy body formation in Parkinson's disease. The pathway includes genes involved in proteasome function, which is critical for degrading misfolded proteins. Impaired proteasome activity, as seen with mutations in proteasome subunits (e.g., PSMA and PSMB genes), contributes to the accumulation of toxic protein aggregates, including alpha-synuclein. This dysfunction in protein quality control exacerbates neurodegeneration. Therefore, the SNCA allele contributes to the development and progression of Parkinson's disease by promoting the accumulation of toxic protein aggregates and impairing proteasome-mediated degradation. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a component of the \u03b3-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease (FAD). In the given pathway, PSEN2 is part of a network involving calcium signaling and mitochondrial dysfunction, which are key contributors to neuronal death in Alzheimer's. The pathway illustrates how PSEN2 mutations can disrupt calcium homeostasis through mitochondrial calcium uptake (MCU) and lead to the release of cytochrome c, activation of caspases, and ultimately apoptosis. This disruption in calcium regulation and mitochondrial function is central to the pathogenesis of Alzheimer's disease. Therefore, the biological effect of the PSEN2 allele is the contribution to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN2 are strongly associated with early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-\u03b242 species, which aggregate into plaques in the brain. The pathway described involves calcium signaling and mitochondrial dysfunction, which are also disrupted in Alzheimer's disease. Excess calcium influx through the mitochondrial calcium uniporter (MCU) and subsequent mitochondrial permeability transition pore (MPTP) opening can trigger apoptosis via the release of cytochrome c and activation of caspases, contributing to neuronal death. Thus, PSEN2 mutations drive the pathogenesis of Alzheimer's disease by promoting amyloidogenesis and mitochondrial dysfunction. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP). Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease (FAD). In the given pathway, PSEN2 interacts with PSEN1, suggesting a role in regulating calcium homeostasis through the mitochondrial calcium uniporter (MCU) and the release of cytochrome c (CYCS), which activates the apoptotic cascade via APAF1 and CASP9, leading to caspase activation (CASP3, CASP7). This pathway highlights the link between PSEN2 dysfunction, mitochondrial dysfunction, and apoptosis, which contributes to neuronal death. Thus, the biological effect of PSEN2 mutations is the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is directly linked to Huntington's disease. In the provided pathway, HTT is involved in calcium homeostasis through its interaction with IP3 receptors and mitochondrial calcium uptake via MCU. Mutations in HTT, particularly the CAG trinucleotide repeat expansion, lead to the production of an abnormally long polyglutamine tract in the huntingtin protein, causing it to aggregate. These aggregates disrupt cellular processes, including calcium signaling, mitochondrial function, and protein degradation, leading to neuronal death, particularly in the striatum and cerebral cortex. This results in the progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and behavioral changes. The pathway highlights HTT's role in apoptosis and calcium dysregulation, which are key contributors to disease progression. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein associated with Huntington's disease. Mutations in HTT, particularly expansions of the CAG trinucleotide repeat, lead to the production of a toxic, polyglutamine-containing huntingtin protein. This protein disrupts neuronal function and causes progressive degeneration of brain cells, particularly in the striatum and cortex. The pathway described involves HTT as part of the calcium signaling cascade, which is critical for neuronal function. In Huntington's disease, the mutant HTT interferes with calcium homeostasis and mitochondrial function, leading to apoptosis via the intrinsic pathway involving cytochrome c, APAF1, and caspases. This ultimately results in neurodegeneration. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington's disease. In this genomic pathway, HTT is part of the IP3 receptor system, which regulates calcium release from the endoplasmic reticulum. Mutations in HTT, particularly the CAG trinucleotide repeat expansion, lead to the production of an elongated, toxic huntingtin protein. This disrupts calcium homeostasis, mitochondrial function, and neuronal survival, triggering apoptosis via the intrinsic mitochondrial pathway\u2014characterized by cytochrome c release, APAF1 activation, and caspase activation. The resulting neurodegeneration primarily affects the striatum and cortex, leading to motor, cognitive, and psychiatric deficits. Therefore, the biological effect of the HTT allele is the pathogenesis of \\boxed{Huntington's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the propagation of abnormal prion proteins. This misfolding and aggregation are central to a group of rare, fatal neurodegenerative disorders known as transmissible spongiform encephalopathies (TSEs). The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between prion protein signaling and the Notch1 receptor, which is involved in cell fate determination and differentiation. Mutations in PRNP can cause prion diseases such as Creutzfeldt-Jakob disease (CJD), variant CJD (vCJD), kuru, and Gerstmann-Str\u00e4ussler-Scheinker syndrome. These diseases are characterized by progressive neuronal loss, leading to cognitive decline and ultimately death. The specific biological effect of the PRNP allele is the formation of infectious, misfolded prion proteins that induce the misfolding of normal prion proteins, triggering a cascade of cellular damage. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can cause neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between prion protein and the NOTCH1 receptor, which plays a role in cell differentiation and apoptosis. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob Disease (CJD), a rare, fatal brain disorder caused by misfolded prion proteins. These abnormal proteins trigger normal prion proteins to misfold, leading to cellular toxicity and neuronal death. This process is linked to the aggregation of prion proteins, disrupting cellular function and causing progressive neurological decline. While NOTCH1 is involved in various cellular processes, its direct role in prion-related diseases is less established. However, the interaction may influence cellular responses to prion-induced stress. The primary disease directly linked to PRNP mutations is Creutzfeldt-Jakob Disease.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a regulatory interaction where PRNP may influence NOTCH1 signaling. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob disease (CJD), a rare, fatal brain disorder caused by prions. These mutations lead to abnormal prion protein folding, triggering cellular dysfunction and neuronal death. The interaction with NOTCH1 may modulate cell proliferation and differentiation, and disruptions in this pathway could contribute to disease progression. Thus, the PRNP allele, particularly in its pathological forms, is a key contributor to Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin turnover. In the context of the provided pathway (UB(chain) // UCHL1* // UB(free)), UCHL1 functions to cleave ubiquitin chains, regulating protein degradation. Mutations in UCHL1 have been linked to neurodegenerative disorders. Specifically, variants in UCHL1 are associated with Parkinson's disease. These variants may reduce UCHL1 activity, leading to the accumulation of misfolded proteins and neuronal toxicity. The impaired ubiquitin-proteasome system contributes to the pathogenesis of Parkinson's by disrupting protein quality control. Therefore, the biological effect of this UCHL1 allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin metabolism. Mutations in UCHL1 are associated with neurodegenerative diseases, particularly Parkinson's disease. This gene is part of the ubiquitin system, which regulates protein degradation. Impaired UCHL1 function disrupts ubiquitin homeostasis, leading to the accumulation of misfolded proteins and neuronal toxicity. UCHL1 also plays a role in the clearance of damaged proteins and the maintenance of mitochondrial function. Mutations in this gene contribute to the pathogenesis of Parkinson's disease by exacerbating protein aggregation and oxidative stress in dopaminergic neurons. Thus, the biological effect of the UCHL1 allele is the development and progression of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin homeostasis. Mutations in UCHL1 are associated with the accumulation of misfolded proteins and neurodegeneration. Specifically, pathogenic variants in UCHL1 contribute to Parkinson\u2019s disease. These mutations disrupt proteasomal function, leading to neurotoxicity and neuronal loss, particularly in the substantia nigra. This pathway includes ubiquitin-related genes (UB, UBA52, UBB, UBC) that are critical for protein degradation and quality control. The dysfunction in this network impairs the clearance of aggregated proteins, exacerbating neurodegenerative processes. UCHL1\u2019s role in ubiquitin processing makes it a key player in maintaining protein homeostasis, and its mutation directly contributes to the pathogenesis of Parkinson\u2019s disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally breaks down superoxide radicals, protecting cells from oxidative stress. Mutations in SOD1 can lead to the production of toxic protein aggregates, which contribute to neuronal dysfunction and death, particularly in motor neurons. This pathway includes genes involved in cytoskeletal dynamics and axonal transport, which are critical for neuronal function. Impaired axonal transport and protein aggregation are key mechanisms in ALS pathogenesis. Mutations in SOD1 are one of the most well-characterized genetic causes of familial ALS. These mutations result in gain-of-function toxicity, where the mutant SOD1 protein disrupts cellular processes, leading to progressive motor neuron degeneration. The involvement of dynactin subunits and dynein-related genes underscores the role of intracellular transport in disease progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). Mutations in SOD1, a copper/zinc superoxide dismutase enzyme, lead to protein misfolding and aggregation, which disrupts neuronal function and triggers neurodegeneration. This pathway includes genes involved in microtubule dynamics and axonal transport, such as dynactin subunits and dynein heavy and light chains, which are critical for intracellular transport. Dysfunction in these processes contributes to the accumulation of toxic proteins and impaired neuronal connectivity. The SOD1 pathway is central to the pathogenesis of ALS, a fatal neurodegenerative disorder characterized by progressive motor neuron loss. Mutations in SOD1 account for approximately 10-20% of familial ALS cases and are linked to disease onset and progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). Mutations in the SOD1 gene lead to the production of a dysfunctional superoxide dismutase 1 enzyme, which contributes to neuronal damage. SOD1 is part of a larger pathway involving dynactin subunits and dynein axonemal chains, which are critical for intracellular transport and neuronal function. Dysfunction in this pathway disrupts the transport of essential proteins and organelles within neurons, leading to their degeneration. This disruption is particularly harmful in motor neurons, which are predominantly affected in ALS. The accumulation of misfolded SOD1 proteins also promotes the formation of toxic aggregates, further exacerbating neuronal death. These mechanisms collectively contribute to the progressive loss of motor neurons, resulting in the characteristic symptoms of ALS. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes HSPA5, ATF6, and DDIT3, highlighting a stress response mechanism. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. These mutations lead to protein misfolding and aggregation, contributing to neuronal toxicity. The pathway involving SOD1, HSPA5, ATF6, and DDIT3 reflects the cellular response to oxidative stress and endoplasmic reticulum (ER) stress, both of which are implicated in ALS pathogenesis. Therefore, the biological effect of pathogenic SOD1 alleles is the induction of neurotoxic pathways that contribute to ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). In this pathway, SOD1 is upstream of BIP and ATF6, which regulate DDIT3. Mutations in SOD1, particularly in the context of misfolded proteins and endoplasmic reticulum (ER) stress, lead to oxidative stress and neuronal toxicity. The pathway involves ER stress responses mediated by ATF6 and the unfolded protein response, which is crucial for maintaining protein homeostasis. The dysregulation of this pathway contributes to neurodegeneration by promoting inflammation and apoptosis in motor neurons. This is a key mechanism in the pathogenesis of ALS. The link between SOD1 mutations and ER stress pathways underscores the role of proteostasis in neurodegenerative disease. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, leading to reduced expression of DDIT3. This pathway is critical for the unfolded protein response (UPR) and cellular stress responses. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The toxic gain-of-function mutations in SOD1 contribute to oxidative stress, protein misfolding, and neuronal death. These mutations disrupt normal cellular processes, leading to the hallmark pathology of ALS. The pathway described highlights how SOD1 dysfunction can perturb stress response mechanisms, exacerbating neuronal damage. This connection underscores the role of SOD1 in disease progression. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or dysregulated, leads to the constitutive activation of the BCR-ABL oncoprotein. This results in continuous signaling through the downstream pathway: BCR-ABL \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This uncontrolled activation drives cell proliferation, survival, and angiogenesis, leading to the uncontrolled growth of cells. This pathway is critically involved in the development of chronic myeloid leukemia (CML). The most well-known mutation is the Philadelphia chromosome translocation, t(9;22), which fuses the ABL1 gene to the BCR gene, creating the BCR-ABL fusion protein. This fusion protein is a key driver of CML. Therefore, the biological effect of this ABL1 allele is the induction of chronic myeloid leukemia.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or dysregulated, contributes to the activation of the BCR-ABL oncoprotein, which is a critical driver in chronic myeloid leukemia (CML). This fusion protein results from a reciprocal translocation between chromosomes 9 and 22, forming the Philadelphia chromosome. The constitutive activation of BCR-ABL leads to uncontrolled cell proliferation and survival by continuously stimulating downstream signaling pathways, including the RAS-RAF-MEK-ERK cascade. This aberrant signaling promotes leukemogenesis by disrupting normal hematopoietic cell regulation. The most well-known disease associated with this pathway dysregulation is chronic myeloid leukemia. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a tyrosine kinase that plays a central role in the BCR-ABL oncogenic pathway. The fusion of BCR and ABL1, forming BCR-ABL, leads to constitutive activation of downstream signaling molecules, including GRB2, SOS, RAS, RAF, MEK, and ERK. This uncontrolled activation drives continuous cell proliferation and survival, bypassing normal regulatory mechanisms. The most well-known disease associated with this pathway is Chronic Myeloid Leukemia (CML). The BCR-ABL fusion results in a gain-of-function mutation that promotes uncontrolled hematopoietic cell growth, leading to leukemic transformation. This pathway is also implicated in some cases of Ph-positive Acute Lymphoblastic Leukemia (ALL). The key biological effect is the activation of the MAPK/ERK signaling cascade, which drives cell cycle progression and resistance to apoptosis. \\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated, leads to constitutive activation of the KIT receptor tyrosine kinase, disrupting normal signaling through the KIT \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK pathway. This results in uncontrolled cell proliferation and survival, contributing to the development of mast cell disorders. Specifically, mutations in KIT are strongly associated with **mast cell disease**, including **mast cell leukemia** and **systemic mastocytosis**. These conditions are characterized by the clonal expansion of mast cells, which can lead to the release of mediators such as histamine, causing symptoms like skin lesions, anaphylaxis, and organ dysfunction. Mutations in KIT, particularly in exons 17, 18, and 21, are most commonly observed in these diseases. The dysregulated MAPK signaling pathway plays a central role in driving the oncogenic transformation and disease progression. \\boxed{Systemic Mastocytosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is a critical signaling cascade involved in cell proliferation, survival, and differentiation. Mutations in the KIT gene, specifically activating mutations in the KIT proto-oncogene receptor tyrosine kinase, lead to constitutive activation of the pathway, resulting in uncontrolled cell growth. This contributes to the development of various diseases, most notably gastrointestinal stromal tumors (GISTs). These tumors arise from the interstitial cells of Cajal and are the most common tumors associated with KIT mutations. Additionally, KIT mutations can also be involved in other malignancies such as mast cell leukemia and certain subtypes of acute myeloid leukemia. The persistent activation of the KIT signaling pathway due to these mutations disrupts normal cellular regulation, leading to tumor formation and progression. \\boxed{GIST}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is critical for cell survival, proliferation, and differentiation. Mutations in KIT, particularly activating mutations, lead to constitutive activation of the KIT receptor tyrosine kinase, downstream signaling through the RAS-RAF-MEK-ERK cascade. This results in uncontrolled cell growth and survival. Such mutations are most notably associated with mast cell disorders, including mast cell leukemia and systemic mastocytosis. Additionally, KIT mutations are a hallmark of gastrointestinal stromal tumors (GISTs), the most common soft tissue sarcoma, where they drive tumor growth by promoting cell proliferation and survival. These mutations are also implicated in certain leukemias and other cancers. The hallmark of KIT-driven diseases is the presence of tumor-promoting signals due to sustained activation of the MAP kinase pathway. \\boxed{GIST}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, which phosphorylates RB1, a tumor suppressor. This inactivates RB1, releasing E2F transcription factors (E2F1-3) to drive cell cycle progression from G1 to S phase. Mutations or overexpression of CDK4 can lead to aberrant phosphorylation of RB1, preventing its ability to inhibit E2F-mediated transcription. This results in unchecked cell proliferation. CDK4 dysregulation is commonly associated with various cancers, particularly those involving uncontrolled cell growth. The most well-documented disease linked to CDK4 activation is **small cell lung cancer (SCLC)**, where CDK4 overexpression contributes to tumor progression by promoting cell cycle entry and resisting apoptosis. Additionally, CDK4 mutations are also implicated in other malignancies such as melanoma and certain leukemias. However, the most direct and well-established association is with **small cell lung cancer**.\n\n\\boxed{Small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this genomic pathway plays a critical role in cell cycle regulation by phosphorylating and inactivating the tumor suppressor protein RB1. This inactivation releases E2F transcription factors, promoting the expression of genes involved in DNA replication and cell division. Dysregulation of CDK4, such as through overexpression or mutations, disrupts this control mechanism, leading to uncontrolled cell proliferation. This is a hallmark of several cancers. Specifically, aberrant CDK4 activity is strongly associated with **retinoblastoma**, a rare childhood eye cancer, and also contributes to other malignancies like breast, lung, and skin cancers. The pathway described is central to the G1 phase of the cell cycle, and its disruption is a key driver in oncogenesis. \\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this pathway plays a critical role in cell cycle regulation by phosphorylating RB1, which inactivates it and allows the release of E2F transcription factors. This leads to the activation of genes involved in DNA replication and cell division. Mutations or overexpression of CDK4, such as amplification or mutations in CCND1, CCND2, CCND3, or CDK4 itself, disrupt this regulatory mechanism, leading to uncontrolled cell proliferation. This dysregulation is a hallmark of several cancers. Specifically, alterations in the CDK4/RB1 pathway are strongly associated with **bladder cancer**, particularly in the context of urothelial carcinoma. The loss of RB1 function and increased CDK4 activity promote cell cycle progression, contributing to tumor formation and progression. \\boxed{Bladder Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene plays a critical role in the autophagy pathway, particularly in the degradation of damaged mitochondria through mitophagy. In the context of the provided pathway, SQSTM1 is upstream of LC3, a key component of autophagosome formation. Mutations in SQSTM1 disrupt this process, leading to the accumulation of dysfunctional mitochondria and cellular stress. This dysfunction is strongly associated with neurodegeneration. Specifically, SQSTM1 mutations contribute to Parkinson's disease by impairing the clearance of damaged mitochondria and aggregation of alpha-synuclein. The resulting neuronal loss underlies the clinical features of Parkinson's. Therefore, the biological effect of this SQSTM1 allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, functioning as a scaffold protein that recruits damaged mitochondria and ubiquitinated proteins into autophagosomes for degradation. In the context of the provided pathway, SQSTM1 interacts with PINK1 and PRKN, which are critical for mitophagy\u2014the selective autophagy of mitochondria. Mutations in SQSTM1 can impair this process, leading to the accumulation of damaged mitochondria and cellular stress. This dysfunction is strongly associated with neurodegenerative diseases. Specifically, SQSTM1 mutations contribute to Parkinson's disease by disrupting mitochondrial quality control and promoting neuronal toxicity. The disrupted PINK1-PRKN-SQSTM1 axis is a major pathway in Parkinson's pathogenesis. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene plays a critical role in the autophagy pathway, acting as a scaffold for the formation of autophagosomes and ubiquitin-binding platform. In the context of the provided pathway, SQSTM1 is positioned downstream of PINK1 and PRKN, which are key players in mitochondrial quality control. Mutations in SQSTM1 can impair autophagy and mitochondrial homeostasis, leading to the accumulation of damaged mitochondria and protein aggregates. This dysfunction is strongly associated with neurodegenerative processes. Specifically, SQSTM1 mutations contribute to Parkinson's disease by disrupting the ubiquitin-proteasome system and autophagy, leading to alpha-synuclein accumulation and neuronal loss. The involvement of SQSTM1 in this pathway underscores its role in maintaining cellular homeostasis and its importance in disease pathogenesis. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the apoptotic cascade initiated by the amyloid beta precursor protein (APP). The cleavage of APP produces amyloid beta, which accumulates and leads to neurodegeneration. This process is central to the pathogenesis of Alzheimer's disease. The cascade involves FAS-mediated death receptor signaling, leading to caspase activation and mitochondrial dysfunction through the release of cytochrome c and subsequent activation of caspase 9 and 3. This ultimately results in neuronal apoptosis. The accumulation of amyloid beta and the subsequent activation of these apoptotic pathways are strongly associated with the progressive neuronal loss observed in Alzheimer's disease. Therefore, mutations or dysregulation in the APP gene contribute to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the apoptotic cascade initiated by the amyloid beta precursor protein (APP). The cleavage of APP produces amyloid beta (Abeta), which can induce apoptosis through the Fas receptor pathway. This leads to the activation of caspases, including CASP8, which in turn activates BID, promoting mitochondrial dysfunction and the release of cytochrome c (CYCS). This triggers the intrinsic apoptotic pathway via APAF1 and CASP9, ultimately leading to the activation of CASP3, which executes apoptosis. This process is closely linked to neuronal cell death. The accumulation of abnormal amyloid beta and the activation of this apoptotic pathway are central to the pathogenesis of Alzheimer's disease. The dysregulation of this pathway contributes to neurodegeneration and cognitive decline. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this genomic pathway is the production of amyloid beta (Abeta), which initiates a cascade leading to apoptosis via the intrinsic and extrinsic pathways. This involves the activation of FAS, FADD, CASP8, and subsequent cleavage of BID, leading to mitochondrial outer membrane permeabilization by BAX and BAK1, releasing CYCS and APAF1 to activate CASP9, which in turn activates CASP3. This apoptotic process is central to neurodegeneration. Mutations in APP are associated with the accumulation of toxic Abeta plaques, a hallmark of Alzheimer's disease. The pathway directly contributes to neuronal cell death, a key feature of Alzheimer's. Therefore, this APP allele contributes to \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves KIT signaling leading to activation of PI3K, PIP3, and subsequent activation of AKT, which inhibits BAD, promoting cell survival. Mutations in KIT, such as gain-of-function mutations, lead to constitutive activation of this pathway, driving uncontrolled cell proliferation and survival. This is a hallmark of gastrointestinal stromal tumors (GISTs), where KIT mutations are prevalent. These mutations result in continuous signaling, contributing to tumor initiation and progression. Additionally, KIT mutations can be seen in other cancers, including some leukemias and lung tumors. However, the most characteristic and commonly associated disease with KIT mutations is gastrointestinal stromal tumor. \\boxed{Gastrointestinal Stromal Tumor}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is central to cell survival and proliferation. KIT activation leads to PI3K stimulation, increasing PIP3 levels, which activates AKT. Akt then inhibits BAD, preventing apoptosis. Mutations in KIT, such as activating mutations in KIT, result in constitutive pathway activation, promoting uncontrolled cell growth. This contributes to diseases characterized by cell proliferation and survival defects. The most notable disease associated with KIT mutations is **GIST (Gastrointestinal Stromal Tumor)**, a cancer of the gastrointestinal tract. These tumors often arise from mutations in KIT or PDGFRA, leading to autonomous signaling and tumor growth. Other diseases include certain leukemias and mast cell disorders. The hallmark of KIT-driven pathologies is the aberrant activation of the PI3K-AKT-BAD axis, which suppresses apoptosis and supports tumor cell survival. \\boxed{GIST}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is critical in cell survival and proliferation. Mutations in KIT, such as activating mutations in the KIT proto-oncogene, lead to constitutive activation of downstream effectors like PI3K and AKT. This results in the inhibition of BAD, promoting cell survival and resistance to apoptosis. Such dysregulation is commonly observed in cancers where cellular proliferation and survival are aberrantly enhanced. The most notable disease associated with KIT mutations is **Gastrointestinal Stromal Tumor (GIST)**, particularly due to activating mutations in KIT or PDGFRA. These mutations drive tumor growth by sustaining signaling through the PI3K/AKT pathway, leading to uncontrolled cell proliferation and survival. Therefore, the biological effect of this KIT allele is the promotion of tumor growth, contributing to **\\boxed{GIST}**."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that links oxidative stress to apoptosis. SOD1, a mitochondrial enzyme, catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. In the given pathway, SOD1 is upstream of BCL2, which regulates apoptosis via BAX and BAK1. These proteins promote the release of cytochrome c, activating APAF1 and initiating the caspase cascade (CASP9 \u2192 CASP3), leading to cell death. Mutant SOD1 contributes to neuronal death by enhancing oxidative stress and promoting apoptosis, which is central to the pathogenesis of ALS. Thus, the biological effect of the SOD1 allele in this context is the promotion of apoptosis, contributing to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1* allele is part of a pathway involving apoptosis regulation. SOD1, a superoxide dismutase, is implicated in oxidative stress. Mutations in SOD1 are a known cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. In this pathway, SOD1 likely interacts with BCL2, influencing the balance between cell survival and apoptosis. The pathway involves BAX and BAK1, which promote mitochondrial outer membrane permeabilization, releasing cytochrome c (CYCS) and activating APAF1, leading to caspase activation (CASP9 \u2192 CASP3), ultimately triggering apoptosis. Altered SOD1 function disrupts this balance, contributing to neuronal death. Thus, the biological effect of the SOD1 allele is linked to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with the production of superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. In the given pathway, SOD1 is upstream of BCL2, a key regulator of apoptosis. Mutations in SOD1, particularly in the context of familial amyotrophic lateral sclerosis (ALS), lead to the accumulation of toxic protein aggregates that disrupt mitochondrial function and trigger apoptosis via the intrinsic pathway. This results in the dysfunction and death of motor neurons, characteristic of ALS. The pathway described reflects the apoptotic cascade initiated by mitochondrial stress, linking SOD1 dysfunction to neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, when mutated, leads to the loss of function of the MEN1 gene, which encodes the menin protein. Menin is a tumor suppressor that plays a critical role in regulating cell cycle progression and apoptosis by interacting with various transcription factors, including KMT2A, a histone methyltransferase involved in chromatin remodeling. The disruption of this interaction, as indicated by the pathway definition (MEN1*+KMT2A // CDKN1B,CDKN2C), impairs the regulation of cyclin-dependent kinase inhibitors CDKN1B and CDKN2C, which control cell cycle checkpoint functions. This dysregulation contributes to uncontrolled cell proliferation. The biological effect of the MEN1 mutation is therefore the development of multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome characterized by tumors in hormone-producing glands. \n\n\\boxed{Multiple Endocrine Neoplasia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, when mutated, leads to loss of function of the MEN1 gene, which encodes the tumor suppressor protein menin. Menin plays a critical role in regulating cell growth and differentiation by interacting with various proteins, including KMT2A and CDKN1B/CDKN2C, which are involved in cell cycle control and chromatin remodeling. The disruption of this pathway contributes to uncontrolled cell proliferation and tumor formation. Specifically, mutations in MEN1 are the primary genetic cause of **multiple endocrine neoplasia type 1 (MEN1)**, a hereditary syndrome characterized by tumors in multiple endocrine glands, including parathyroid, pituitary, and pancreatic neuroendocrine tumors. The pathway described highlights the role of MEN1 in maintaining genomic stability and preventing tumorigenesis through its interactions with key regulators of cell cycle and chromatin structure.\n\n\\boxed{Multiple Endocrine Neoplasia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, when mutated, leads to loss of function of the menin protein, a tumor suppressor. Menin regulates gene expression through interactions with other proteins, including KMT2A, a histone methyltransferase, and CDKN1B and CDKN2C, which are cyclin-dependent kinase inhibitors. This pathway is critical for cell cycle regulation and suppression of tumor growth. Disruption of this pathway results in uncontrolled cell proliferation and increased risk of tumor formation. The most well-characterized disease associated with MEN1 mutations is **Multiple Endocrine Neoplasia Type 1 (MEN1)**, a hereditary disorder characterized by tumors in multiple endocrine glands, including the parathyroid, pituitary, and pancreas. \\boxed{Multiple Endocrine Neoplasia Type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a critical role in the WNT signaling pathway. The given pathway shows APC as a key regulatory node that interacts with GSK3B and AXIN proteins to modulate CTNNB1 stabilization. Mutations in APC, particularly loss-of-function mutations, disrupt this regulation, leading to aberrant CTNNB1 accumulation and activation of downstream genes like MYC, CCND1, and BIRC5. This dysregulation promotes uncontrolled cell proliferation and inhibition of apoptosis, contributing to neoplastic growth. The most well-known disease associated with APC mutations is **colorectal cancer**, where inherited or somatic mutations in APC are among the earliest events in tumor initiation. APC mutations also contribute to other cancers, including thyroid, breast, and endometrial cancers. The pathway described is central to colorectal carcinogenesis. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a critical role in the WNT signaling pathway. The pathway described involves the degradation of \u03b2-catenin (CTNNB1) through the action of GSK3B, AXIN1, AXIN2, and APC. When APC is mutated or inactivated, this degradation is impaired, leading to the stabilization and accumulation of \u03b2-catenin. This results in its nuclear translocation and activation of TCF/LEF transcription factors, driving the expression of genes such as MYC, BIRC5, and CCND1. This dysregulation promotes uncontrolled cell proliferation and inhibits apoptosis, contributing to the development of colorectal cancer. Loss-of-function mutations in APC are a hallmark of sporadic colorectal adenomas and carcinomas. These mutations disrupt the balance of cell growth and death, leading to the formation of polyps that can progress to malignancy. Thus, the biological effect of the APC allele is central to the development of colorectal cancer.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a critical role in the WNT signaling pathway. The pathway described involves the degradation of \u03b2-catenin (CTNNB1) by a complex including APC, GSK3B, AXIN1/AXIN2, and other components. When APC is mutated or inactivated, this degradation is impaired, leading to the stabilization and nuclear accumulation of \u03b2-catenin. This aberrant accumulation activates TCF/LEF transcription factors, promoting the expression of oncogenes such as MYC, CCND1, and BIRC5. These genes are involved in cell proliferation, survival, and resistance to apoptosis. The dysregulation of this pathway is a hallmark of colorectal cancer. Loss-of-function mutations in APC are among the earliest genetic events in colorectal tumorigenesis. Thus, the biological effect of the APC allele is the initiation and progression of colorectal cancer.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally neutralizes superoxide radicals. However, when mutated, it becomes toxic and contributes to motor neuron degeneration. The pathway described involves SOD1 interacting with DERL1, leading to ubiquitination and proteasomal degradation. Mutations in SOD1 disrupt this process, leading to protein misfolding, aggregation, and neurotoxicity. This results in the progressive loss of motor neurons, characteristic of ALS. The involvement of proteasome subunits (e.g., PSMA and PSMB genes) highlights the role of protein degradation in disease pathogenesis. Mutant SOD1 impairs the ubiquitin-proteasome system, exacerbating cellular stress and neuronal damage. This pathway is central to the development of ALS, making SOD1 a key contributor to the disease.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes ubiquitination and proteasomal degradation. SOD1, a copper/zinc superoxide dismutase, when pathologically mutated, leads to the accumulation of misfolded proteins, disrupting cellular proteostasis. This dysfunction is a key feature in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. Mutations in SOD1 are among the most common genetic causes of familial ALS, where the mutant protein gains toxic gain-of-function properties, including aggregation and disruption of mitochondrial function. These effects contribute to motor neuron death, leading to progressive muscle atrophy and paralysis. The pathway involving DERL1, ubiquitin ligases, and proteasome subunits is critical for the degradation of misfolded SOD1, and its disruption exacerbates the disease. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally breaks down superoxide radicals into less harmful molecules. Mutations in SOD1 can lead to the production of toxic protein aggregates, disrupting neuronal function and causing progressive motor neuron degeneration. The pathway described involves the ubiquitin-proteasome system, which is crucial for protein degradation. Mutant SOD1 can misfold and accumulate, leading to proteasomal stress and neurodegeneration. This contributes to the pathogenesis of ALS, a neurodegenerative disease characterized by the loss of motor neurons, resulting in muscle atrophy and paralysis. The involvement of proteasome subunits (PSMA, PSMB, PSMC) highlights the role of impaired protein clearance in disease progression. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide. Mutations in the SOD1 gene lead to the production of dysfunctional or toxic SOD1 proteins, which accumulate in motor neurons and trigger cellular stress, oxidative damage, and neuronal death. This pathway includes genes involved in microtubule transport and axonal transport, such as dynactin subunits (DCTN1-DCTN6) and dynein-related proteins (DNAH, DNAI, DNAL). These proteins are essential for intracellular transport, and their dysfunction contributes to neuronal degeneration. Mutations in SOD1 are one of the most well-characterized genetic causes of familial ALS. The accumulation of misfolded SOD1 proteins disrupts cellular homeostasis, leading to progressive motor neuron loss. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway involving SOD1 and its interactors, including dynactin subunits and dynein motor proteins, is critical for cellular processes such as axonal transport and protein homeostasis. Mutant SOD1 proteins misfold, aggregate, and disrupt these processes, leading to neuronal dysfunction and death. This contributes to the pathogenesis of ALS. The involvement of multiple dynein-related genes suggests a broader role in cytoskeletal dynamics and mitochondrial transport, all of which are impaired in SOD1-related ALS. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway includes genes related to dynein and dynactin complexes, which are essential for intracellular transport, particularly in neurons. Dysfunction in these complexes can exacerbate neuronal damage. The connection between SOD1 and ALS is further supported by the fact that mutations in SOD1 are among the most common genetic causes of familial ALS. These mutations lead to the accumulation of toxic protein aggregates and disruption of mitochondrial function, ultimately resulting in motor neuron death. Therefore, the biological effect of pathogenic SOD1 alleles is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in neurodegenerative processes. The pathway SNCA \u2192 VMAT2 suggests a regulatory relationship between alpha-synuclein and vesicular monoamine transporter 2, which is involved in neurotransmitter transport. Mutations or overexpression of SNCA are strongly associated with the accumulation of misfolded alpha-synuclein, leading to the formation of Lewy bodies. This pathological feature is a hallmark of Parkinson\u2019s disease. The interaction with VMAT2 may influence dopamine storage and release, contributing to neuronal dysfunction. Genetic variants in SNCA, such as multiplications or missense mutations, increase the risk of developing Parkinson\u2019s disease. Therefore, the SNCA allele contributes to the pathogenesis of \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. The pathway SNCA \u2192 VMAT2 indicates a regulatory relationship, where SNCA may influence vesicular monoamine transporter 2 (VMAT2), which is critical for neurotransmitter storage. Mutations or altered expression of SNCA are strongly associated with the aggregation of alpha-synuclein, a hallmark of neurodegenerative diseases. This contributes to the pathogenesis of Parkinson\u2019s disease, where misfolded alpha-synuclein forms Lewy bodies, leading to neuronal dysfunction and death. SNCA mutations increase the risk of early-onset Parkinson\u2019s and are linked to disease progression. The interaction with VMAT2 suggests a role in dopamine metabolism, as VMAT2 transports dopamine into synaptic vesicles. Dysregulation of this pathway impairs neuronal communication and contributes to the motor and non-motor symptoms of Parkinson\u2019s disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in Parkinson\u2019s disease. The pathway SNCA \u2192 VMAT2 suggests a regulatory relationship where SNCA may influence VMAT2, a vesicular monoamine transporter involved in dopamine storage. Overexpression or mutations in SNCA lead to the misfolding and aggregation of alpha-synuclein, forming Lewy bodies, a pathological hallmark of Parkinson\u2019s disease. This accumulation disrupts neuronal function, particularly in dopaminergic neurons of the substantia nigra, leading to motor deficits. The interaction with VMAT2 may further affect monoamine neurotransmitter homeostasis, exacerbating neurodegeneration. Thus, the SNCA allele contributes to the development and progression of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme activates CPS1 (carbamoyl-phosphate synthase 1) by converting N-acetylglutamate to N-acetylglutamate, a key regulator of CPS1 activity. Mutations in NAGS lead to reduced CPS1 activation, impairing carbamoyl phosphate synthesis, a crucial step in the urea cycle. This results in the accumulation of ammonia, a toxic substance, leading to neurological damage. The most common disease associated with NAGS mutations is **Hyperammonemia type 1**, a rare inherited disorder characterized by elevated blood ammonia levels, leading to seizures, developmental delays, and potentially life-threatening complications. The pathway involving NAGS and CPS1 is essential for nitrogen metabolism, and dysfunction in this pathway directly contributes to this severe metabolic disorder. \n\n\\boxed{Hyperammonemia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme activates carbamoyl phosphate synthetase I (CPS1) by converting N-acetylglutamate into N-acetylglutamate, which is essential for CPS1 activity. Mutations in NAGS lead to reduced CPS1 activation, impairing urea cycle function. This results in the accumulation of ammonia, a toxic substance, leading to neurological symptoms. This condition is known as **hyperammonemia**, which can cause seizures, coma, and in severe cases, death. The specific genetic disorder associated with NAGS mutations is **N-acetylglutamate synthase deficiency**, a rare autosomal recessive disorder. The impaired urea cycle leads to chronic neurological issues and requires strict management to prevent ammonia toxicity. \\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, which activates carbamoyl-phosphate synthase I (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing ammonia detoxification. This results in hyperammonemia, a condition characterized by elevated blood ammonia levels. The most common disorder associated with NAGS mutations is hyperammonemia due to N-acetylglutamate synthetase deficiency. This autosomal recessive disorder causes neurological symptoms such as seizures, coma, and developmental delay due to the toxic accumulation of ammonia. The pathway Glu -- NAGS* // NAG // CPS1 highlights the essential role of NAGS in urea cycle function. \\boxed{Hyperammonemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. In the given pathway, SOD1 is upstream of BIP and ERN1, which are involved in the unfolded protein response (UPR) and endoplasmic reticulum (ER) stress signaling. Mutant SOD1 can lead to ER stress and activation of the XBP1 pathway, contributing to neuronal dysfunction and death. This pathway disruption is implicated in the pathogenesis of ALS. Therefore, the biological effect of the SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. In the given pathway, SOD1 is upstream of BIP (HSPA5), which is involved in the unfolded protein response (UPR) in the endoplasmic reticulum. ERN1 activates XBP1, a transcription factor that promotes the expression of proteins involved in ER function and stress response. Dysregulation of this pathway due to SOD1 mutations leads to neurotoxicity, mitochondrial dysfunction, and protein misfolding, all of which contribute to ALS pathogenesis. Thus, the biological effect of pathogenic SOD1 alleles is the induction of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 pathway involves SOD1, which catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. Mutations in SOD1 are well-documented contributors to Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway includes HSPA5, ERN1, and XBP1, which are part of the unfolded protein response (UPR) in the endoplasmic reticulum (ER). Mutant SOD1 can disrupt ER homeostasis, leading to ER stress and activation of the UPR. This stress contributes to neuronal dysfunction and death, hallmark features of ALS. Thus, the biological effect of this SOD1 allele is the induction of ER stress and neuronal degeneration, primarily contributing to Amyotrophic Lateral Sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-PI3K-AKT-BAD pathway, contributes to the activation of downstream signaling that promotes cell survival and proliferation. Mutations in NRAS, a GTPase, lead to constitutive activation of the PI3K pathway, resulting in increased production of PIP3 and subsequent activation of AKT. This inhibits BAD, preventing apoptosis and driving uncontrolled cell growth. This mechanism is central to the development of various cancers. The most well-known disease associated with NRAS mutations is **colorectal cancer**, where NRAS mutations are frequently observed. Additionally, NRAS mutations are implicated in **non-small cell lung cancer**, **acute myeloid leukemia (AML)**, and **melanoma**. These mutations disrupt normal cell cycle regulation and apoptosis, leading to tumor progression. The activation of this pathway is a hallmark of several malignancies driven by RAS oncogene activation. \\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this pathway contributes to the activation of the PI3K-AKT signaling cascade. Mutated NRAS proteins are constitutively active, leading to increased production of PIP3 and subsequent activation of AKT. This results in the inhibition of BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. This mechanism is critical in the development and progression of cancers characterized by RAS pathway activation. The most common disease associated with NRAS mutations is **cancer**, specifically **pancreatic cancer**, **colorectal cancer**, and **melanoma**, among others. These mutations drive uncontrolled cell growth and resistance to apoptosis, making them important drivers of oncogenesis. The pathway described is central to tumor progression in various malignancies. \\boxed{Pancreatic Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in resistance to apoptosis and uncontrolled cell proliferation. Such alterations are commonly observed in cancers driven by oncogenic RAS signaling. Specifically, NRAS mutations are a well-known driver in **melanoma**, where they promote tumor growth and progression by disrupting normal cell cycle regulation and promoting survival signals. These mutations are also associated with other malignancies, including **non-small cell lung cancer (NSCLC)** and **colorectal cancer**, but their most characteristic and well-documented association is with **melanoma**. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to DNA repair, cell cycle regulation, and apoptosis. Mutations in TP53 disrupt its function, leading to impaired response to DNA damage and loss of cell cycle control. This contributes to genomic instability and uncontrolled cell proliferation. The listed genes\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014are downstream effectors of p53, involved in growth arrest, DNA repair, and apoptosis. Dysfunction in this pathway is a hallmark of various cancers. Specifically, TP53 mutations are strongly associated with Li-Fraumeni syndrome, a hereditary disorder with high risk of multiple cancers, including breast, ovarian, sarcomas, and brain tumors. Additionally, TP53 alterations are commonly found in lung, bladder, and colorectal cancers. Thus, the biological effect of a pathogenic TP53 allele is the promotion of tumorigenesis through loss of tumor suppression.\n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 allele, along with its downstream genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, plays a critical role in cell cycle regulation, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to loss of cell cycle control and increased genomic instability. This contributes to the development and progression of various cancers. Specifically, TP53 mutations are strongly associated with Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. Individuals with TP53 mutations have a significantly increased risk of developing multiple types of cancer, including sarcomas, breast cancer, brain tumors, and osteosarcomas. The impaired function of TP53 results in defective DNA repair and resistance to apoptosis, allowing the survival and proliferation of damaged cells. Thus, the biological effect of this TP53 allele is a high risk of developing \\boxed{Li-Fraumeni syndrome}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular responses to DNA damage and stress. Mutations in TP53 disrupt its role as a transcription factor, impairing the expression of downstream genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK. These genes are critical for cell cycle arrest, DNA repair, and apoptosis. Loss of TP53 function leads to unchecked cell proliferation and genomic instability. This contributes to the development and progression of various cancers. The most well-known disease associated with TP53 mutations is Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. TP53 mutations are also frequently observed in tumors such as breast, ovarian, lung, bone, and brain cancers. Overall, TP53 dysfunction is a key driver in tumorigenesis.\n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1*, plays a critical role in protecting cells from oxidative stress and maintaining mitochondrial function. Its pathway includes TP53, a key tumor suppressor gene, and DUSP1, which regulates MAPK signaling. Mutations in PARK7 are associated with impaired protein deglycation and mitochondrial dysfunction, leading to neuronal damage. This contributes to the pathogenesis of Parkinson's disease. The loss-of-function mutations in PARK7 disrupt cellular homeostasis, particularly in dopamine-producing neurons, resulting in neurodegeneration. This genetic pathway highlights the interplay between oxidative stress, mitochondrial health, and neurodegeneration. The biological effect of the PARK7 allele is thus a significant contributor to the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 (DJ1*) gene encodes a protein involved in protecting cells from oxidative stress and neurodegeneration. Its dysfunction, such as through mutations or altered expression, leads to impaired mitochondrial function and increased oxidative damage, which is critical in neuronal survival. The pathway involving PARK7, TP53, and DUSP1 highlights a regulatory network where TP53 activates DUSP1, which in turn modulates stress responses. Mutations in PARK7 are strongly associated with Parkinson's disease, as they contribute to the loss of dopaminergic neurons through mechanisms involving oxidative stress and mitochondrial dysfunction. This genetic disruption disrupts cellular homeostasis, leading to progressive neurodegeneration. Thus, the biological effect of the PARK7 allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1*, plays a critical role in protecting cells from oxidative stress and maintaining mitochondrial function. Mutations in PARK7 are associated with an increased risk of Parkinson's disease. The pathway involving PARK7, TP53, and DUSP1 suggests a role in stress response and cell survival. Loss-of-function mutations in PARK7 disrupt its protective effects, leading to neuronal dysfunction and death, particularly in dopamine-producing neurons in the substantia nigra. This contributes to the pathogenesis of Parkinson's disease. The interaction with TP53 and DUSP1 further supports its role in stress signaling and apoptosis regulation. Therefore, the biological effect of the PARK7 allele is a key contributor to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell growth and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in aberrant cell proliferation and survival. In the context of chromosome 4, FGFR3 mutations are most notably associated with **bladder urothelial carcinoma** (also known as transitional cell carcinoma). These mutations contribute to tumor progression by promoting uncontrolled cell growth and resistance to apoptosis. FGFR3 mutations are especially prevalent in low-grade, non-invasive bladder cancers, where they drive tumor initiation and progression. The activation of the pathway through FGFR3 leads to increased expression of downstream effectors like MYC, further promoting oncogenesis. Therefore, the biological effect of this FGFR3 allele is the development of **bladder urothelial carcinoma**.\n\n\\boxed{Bladder Urothelial Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cellular signaling, particularly in development and proliferation. Mutations in FGFR3 can lead to aberrant signaling, disrupting normal cellular processes. Specifically, gain-of-function mutations in FGFR3 are associated with **bladder cancer**, particularly **bladder urothelial carcinoma**. These mutations result in constitutive activation of the receptor, leading to uncontrolled cell proliferation and inhibition of apoptosis. The downstream activation of RAS and RAF pathways further promotes tumor progression by enhancing cell growth and survival. FGFR3 mutations are also implicated in other conditions, such as achondroplasia, but in the context of cancer, they are strongly linked to bladder cancer. The altered signaling cascade contributes to the transformation of normal cells into malignant ones, making FGFR3 a key player in the pathogenesis of bladder cancer. \\boxed{Bladder cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation, particularly in bone development. Mutations in FGFR3, especially gain-of-function mutations, lead to constitutive activation of the downstream signaling cascade, including RAS and RAF, ultimately resulting in aberrant cell growth. This dysregulation is most notably associated with **bladder urothelial carcinoma**. Specifically, activating mutations in FGFR3 are frequently observed in low-grade bladder tumors, where they drive tumorigenesis by promoting cell survival and proliferation. The pathway's role in maintaining cellular homeostasis means its disruption can lead to uncontrolled growth, making FGFR3 a key contributor to bladder cancer. \\boxed{Bladder Urothelial Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase, initiating the signaling cascade RET \u2192 PI3K \u2192 PIP3 \u2192 AKT \u2192 MTOR. This pathway is critical for cell survival, proliferation, and growth. Mutations in RET are strongly associated with **multiple endocrine neoplasia type 2 (MEN2)**. MEN2 is a hereditary syndrome characterized by the development of medullary thyroid carcinoma (MTC), often accompanied by pheochromocytoma and parathyroid adenoma. RET mutations, particularly in the codons 634, 635, 636, and 637, are the primary genetic cause of MEN2. These mutations result in uncontrolled cell growth and tumor formation, highlighting the oncogenic role of the RET pathway in this disease. \\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene encodes a receptor tyrosine kinase involved in cell growth and differentiation. When activated, RET initiates a signaling cascade: RET \u2192 PI3K \u2192 PIP3 \u2192 AKT \u2192 mTOR. This pathway promotes cell proliferation, survival, and metabolism. Mutations in RET, particularly activating mutations, lead to constitutive activation of this pathway, driving uncontrolled cell growth. This is associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome characterized by tumors in endocrine glands, including medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenomas. RET mutations also contribute to certain cancers, such as small cell lung cancer and Merkel cell carcinoma. The dysregulation of this pathway is a key driver in these diseases. \n\n\\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele in this pathway contributes to **Multiple Endocrine Neoplasia Type 2 (MEN2)**. RET is a receptor tyrosine kinase, and its activation through gain-of-function mutations leads to constitutive signaling via downstream effectors such as PI3K and AKT, ultimately activating MTOR. This persistent activation promotes uncontrolled cell proliferation and survival, contributing to tumor formation. In MEN2, RET mutations are commonly found in the RET proto-oncogene, leading to the development of medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid adenomas. These tumors arise from neural crest-derived cells, highlighting the critical role of the RET-PI3K-AKT-MTOR pathway in oncogenesis. The dysregulation of this pathway is a key driver in the pathophysiology of MEN2. \n\n\\boxed{Multiple Endocrine Neoplasia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a protein that binds to monomeric actin and facilitates its incorporation into filamentous actin structures. This process is critical for actin dynamics, essential for cellular functions such as muscle contraction, cell motility, and neurotransmitter release. Mutations in PFN1 disrupt actin filament formation, leading to impaired cellular function. This contributes to neurological disorders, particularly early-onset myoclonus epilepsy with ragged red fibers (MERRF). MERRF is a mitochondrial encephalomyopathy characterized by seizures, muscle weakness, and metabolic abnormalities. The PFN1 mutation impairs mitochondrial function by disrupting the actin cytoskeleton, which is vital for mitochondrial transport and stability. Therefore, the biological effect of the PFN1 allele is the development of \\boxed{MERRF}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) is a key regulator of actin dynamics, facilitating the nucleation and elongation of actin filaments. Mutations in PFN1 disrupt its ability to bind and regulate actin monomers, leading to impaired actin filament formation and stability. This dysfunction affects cellular processes such as cytoskeletal remodeling, cell motility, and neuronal development. Specifically, PFN1 mutations are associated with neurodevelopmental disorders, particularly **focal epilepsy** and **neurodevelopmental delays**. These mutations are linked to a syndrome characterized by early-onset seizures, intellectual disability, and abnormal brain development. The disruption of actin dynamics in neurons contributes to synaptic dysfunction and neuronal miswiring, which underlie the observed clinical features. Thus, the biological effect of the PFN1 allele is a disruption in neuronal actin dynamics, contributing to **focal epilepsy**.\n\n\\boxed{focal epilepsy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a protein that binds to monomeric actin and facilitates its polymerization into filamentous actin. This process is critical for cytoskeletal dynamics, cellular motility, and intracellular transport. Mutations in PFN1 can disrupt actin filament formation, leading to impaired cellular functions. Specifically, pathogenic variants in PFN1 are associated with autosomal dominant motor neuron disease known as **spinal muscular atrophy with lower extremity predominance (SMA-LED)**. This condition is characterized by progressive muscle weakness and atrophy, primarily affecting the lower limbs. The disrupted actin dynamics due to PFN1 dysfunction compromise neuronal survival and axonal transport, contributing to motor neuron degeneration. \\boxed{Spinal Muscular Atrophy with Lower Extremity Predominance}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-\u03b242 species, which aggregate into plaques in the brain. This pathological process is linked to neuronal dysfunction and death, contributing to cognitive decline and neurodegeneration. The pathway described involves calcium dysregulation through the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channel (VDAC), leading to mitochondrial dysfunction, cytochrome c release, and activation of the intrinsic apoptotic pathway via APAF1 and CASP9, ultimately resulting in cell death. These mechanisms align with the neurodegenerative processes in Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the sequential release of calcium from the endoplasmic reticulum (via RYR3) into mitochondria (via MCU and VDACs), leading to the mitochondrial permeability transition pore (MPTP) opening. This results in the release of cytochrome c (CYCS), which activates APAF1 and caspase-9, ultimately triggering apoptosis via CASP3 and CASP7. PSEN1 and PSEN2 are critical components of the \u03b3-secretase complex, which processes amyloid precursor protein (APP) into amyloid-\u03b2 peptides. Mutations in PSEN1 are well-established causes of early-onset familial Alzheimer's disease (FAD). These mutations disrupt \u03b3-secretase function, leading to increased amyloid-\u03b2 production and plaque formation, along with mitochondrial dysfunction and apoptosis. The pathway highlights the link between PSEN1 mutations, mitochondrial calcium dysregulation, and neuronal apoptosis, all contributing to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), producing amyloid-\u03b2 peptides. Mutations in PSEN1 are a major genetic cause of early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of toxic amyloid-\u03b242 species, which aggregate into plaques in the brain. The pathway described highlights the connection between PSEN1 and mitochondrial dysfunction through calcium homeostasis via RYR3, MCU, and VDACs, ultimately linking to apoptosis via the mitochondrial permeability transition pore (MPTP) and caspase activation. This underscores the role of PSEN1 in neurodegeneration. Therefore, the biological effect of the PSEN1 allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is a key component of the mitochondrial quality control pathway. Its product, parkin, functions as an E3 ubiquitin ligase, targeting damaged mitochondria for autophagic degradation. In the pathway PRKN \u2192 PLCG1 \u2192 IP3 \u2192 ITPR \u2192 Ca\u00b2\u207a, PRKN's role in mitochondrial degradation indirectly regulates calcium homeostasis via IP3 receptors. Mutations in PRKN lead to impaired mitophagy, resulting in mitochondrial dysfunction and aberrant calcium signaling. This contributes to neurodegeneration. The most well-known disease associated with PRKN mutations is Parkinson's disease, specifically early-onset Parkinson's, where PRKN mutations are a known genetic cause. These mutations disrupt the ubiquitin-proteasome system and mitochondrial quality control, leading to neuronal loss. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is a critical component of the pathway PRKN \u2192 PLCG1 \u2192 IP3 \u2192 ITPR \u2192 Ca\u00b2\u207a, which regulates intracellular calcium levels through the IP3 receptor. Mutations in PRKN lead to impaired ubiquitination and degradation of damaged mitochondria, disrupting mitochondrial quality control. This dysfunction contributes to mitochondrial dysfunction and oxidative stress, which are linked to neurodegeneration. PRKN mutations are a well-established cause of autosomal recessive Parkinson's disease (PD). Loss of PRKN function results in the accumulation of damaged mitochondria and neuronal death, particularly in dopamine-producing neurons. This pathway disruption is a key mechanism in the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through the ubiquitination and degradation of damaged mitochondria via mitophagy. Mutations in PRKN disrupt this process, leading to mitochondrial dysfunction and oxidative stress. This contributes to neurodegeneration. The most well-documented disease associated with PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are linked to autosomal recessive Parkinsonism, characterized by dopaminergic neuron loss and motor impairments. The disruption of the PRKN-PLCG1-IP3-ITPR-Ca2+ signaling cascade impairs calcium homeostasis and neuronal survival, further exacerbating neurodegeneration. Thus, PRKN mutations are a significant genetic contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein critical for neuronal function. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long huntingtin protein, causing toxic gain-of-function effects. This results in neurodegeneration and the clinical features of Huntington's disease. The pathway described involves components of the mitochondrial electron transport chain, particularly complex III, which is essential for ATP production and cellular energy homeostasis. Disruption of this pathway due to HTT dysfunction contributes to mitochondrial dysfunction and neuronal death. The biological effect of the mutant HTT allele is thus the progressive degeneration of neurons, leading to cognitive decline, motor dysfunction, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant form causes Huntington's disease. The pathway described involves components of the mitochondrial electron transport chain, particularly complex III, which includes genes like UQCRFS1, UQCRC1, UQCRC2, and others. The HTT protein interacts with complex III, and mutations in HTT lead to dysfunctional protein aggregation, impairing mitochondrial function and energy production. This contributes to neurodegeneration by causing oxidative stress, disrupting cellular metabolism, and triggering apoptosis in neurons. The accumulation of mutant huntingtin leads to the progressive breakdown of nerve cells, especially in the basal ganglia, resulting in cognitive decline, motor dysfunction, and psychiatric symptoms. This genetic mutation is the primary cause of Huntington's disease, an autosomal dominant neurodegenerative disorder. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in neuronal function. Mutations in HTT, particularly expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long huntingtin protein, which is toxic to neurons. This results in neurodegeneration. The pathway involving HTT, CxIII, and CytC is part of the mitochondrial respiratory chain, where complex III (CoxIII) and cytochrome c (CytC) are critical for electron transport and ATP production. Disruption of this pathway due to mutant HTT impairs mitochondrial function, contributing to neuronal death. This genetic abnormality is the primary cause of Huntington's disease, a hereditary neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase, disrupting normal signaling. This results in uncontrolled cell proliferation and survival, contributing to the development of **multiple endocrine neoplasia type 2 (MEN2)**. RET mutations are also implicated in **medullary thyroid carcinoma (MTC)**, a type of thyroid cancer. Additionally, RET activation can drive **pancreatic neuroendocrine tumors** and **non-small cell lung cancer (NSCLC)** in some cases. The pathway RET \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK is a key oncogenic cascade in these diseases, promoting cell growth, angiogenesis, and metastasis. Mutations in downstream components such as HRAS, KRAS, NRAS, BRAF, and RAF1 can also contribute to disease progression. Overall, RET mutations are a major driver in **medullary thyroid carcinoma** and associated syndromes.\n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase, initiating the signaling cascade RET \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This results in uncontrolled cell proliferation and survival, contributing to tumor formation. Mutations in RET are specifically associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome characterized by the development of medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid adenomas. These mutations typically involve gain-of-function alterations in RET, such as point mutations or fusions, which activate the receptor independently of ligand binding. This aberrant signaling drives oncogenesis by promoting cell survival, proliferation, and migration. Therefore, the biological effect of the RET allele mutation is the initiation and progression of medullary thyroid carcinoma, a hallmark of MEN2.\n\n\\boxed{Multiple Endocrine Neoplasia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, activates the RET receptor tyrosine kinase, initiating the RET-RAS-RAF-MEK-ERK signaling pathway. This pathway is critical for cell proliferation, differentiation, and survival. Mutations in RET can lead to constitutive activation of downstream effectors, promoting uncontrolled cell growth. This contributes to the development of medullary thyroid carcinoma (MTC). RET mutations are also associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome characterized by MTC and other endocrine tumors. The aberrant activation of this pathway disrupts normal cellular regulation, leading to tumor formation. Therefore, RET mutations are directly implicated in medullary thyroid carcinoma.\n\n\\boxed{Medullary Thyroid Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol-3 kinase (PI3K), a key enzyme in the PI3K-AKT-MTOR signaling pathway. Mutations in PIK3CA, such as gain-of-function mutations, lead to constitutive activation of this pathway, promoting cell growth, survival, and proliferation. This aberrant activation is commonly observed in various cancers. Specifically, PIK3CA mutations are strongly associated with **cancers such as breast, colorectal, endometrial, and ovarian cancers**. These mutations drive tumor progression by enhancing protein synthesis, cell cycle progression, and resistance to apoptosis. The resulting hyperactivation of the pathway contributes to oncogenesis and is a key driver in multiple malignancies. Therefore, the biological effect of this PIK3CA allele is **cancer development**, particularly **breast cancer**.\n\n\\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PI3K* \u2192 PIP3 \u2192 AKT \u2192 MTOR \u2192 S6K pathway is a key regulator of cell growth, survival, and protein translation. Mutations in PIK3CA, which encodes the catalytic subunit of phosphatidylinositol-3-kinase (PI3K), lead to constitutive activation of the pathway by increasing PIP3 levels. This results in hyperactivation of AKT and downstream MTOR signaling, promoting unchecked cell proliferation and resistance to apoptosis. This dysregulation is a hallmark of several cancers. The most common disease associated with PIK3CA mutations is **Breast Cancer**, where these mutations are frequently observed and contribute to tumor progression by enhancing cell survival and metabolic activity. Additionally, PIK3CA mutations are also implicated in **Colorectal Cancer**, **Endometrial Cancer**, and **Bladder Cancer**, among others. These mutations drive oncogenicity by sustaining the PI3K-AKT-MTOR pathway, making them important targets for therapeutic intervention.\n\n\\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PI3K* -> PIP3 -> AKT -> MTOR -> S6K pathway is central to cell growth, proliferation, and survival. PIK3CA encodes the catalytic subunit of PI3K, which phosphorylates PIP2 to generate PIP3, initiating the downstream activation of AKT and subsequently MTOR. This leads to the activation of S6K, promoting protein synthesis and cell growth. Mutations in PIK3CA, such as gain-of-function mutations, result in constitutive activation of this pathway, driving uncontrolled cell proliferation. This contributes to the development and progression of various cancers. Specifically, PIK3CA mutations are commonly found in cancers such as breast, endometrial, and colorectal cancer. These mutations drive tumor growth by enhancing cell survival and proliferation. Therefore, the biological effect of PIK3CA mutations is oncogenic activation of the PI3K/AKT/mTOR pathway, leading to cancer.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein quality control and mitochondrial function. Mutations in PRKN lead to impaired ubiquitin-mediated degradation of misfolded or damaged proteins, resulting in the accumulation of toxic protein aggregates. This dysfunction is central to neurodegenerative processes. PRKN mutations are a major genetic cause of Parkinson's disease, specifically dominant inheritance forms. The pathway includes UBE2L3 and UBE2L6, which are ubiquitin-conjugating enzymes that work with parkin to tag proteins for degradation. The presence of SNCA (alpha-synuclein) further links this pathway to Lewy body formation, a hallmark of Parkinson's. Thus, PRKN dysfunction contributes directly to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN allele, which encodes parkin, is a critical component of the ubiquitin-proteasome system. Mutations in PRKN lead to impaired ubiquitination and degradation of damaged proteins, disrupting cellular quality control. This dysfunction is strongly associated with neurodegeneration. Specifically, PRKN mutations are a major genetic cause of Parkinson's disease (PD), an alpha-synuclein (SNCA)-related disorder. The pathway involving UBCH7/8 (E2 enzymes) and PRKN (an E3 ligase) is essential for ubiquitin-dependent protein degradation. Loss-of-function PRKN alleles result in the accumulation of misfolded proteins, including alpha-synuclein, leading to Lewy body formation and dopaminergic neuron loss. This contributes to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein quality control and mitochondrial maintenance. Mutations in PRKN lead to loss of function, disrupting ubiquitin-mediated proteasomal degradation and contributing to the accumulation of damaged proteins. This is closely associated with neurodegeneration. PRKN mutations are a major cause of autosomal recessive Parkinson's disease, specifically a form characterized by early-onset and prominent dopaminergic neuronal loss. The pathway involving PRKN, along with UBCH7/8 and alphaSp22, highlights its role in ubiquitin conjugation and protein degradation. Dysfunction in this pathway leads to impaired clearance of misfolded proteins, including alpha-synuclein (SNCA), exacerbating neurotoxicity. The biological effect of PRKN allele dysfunction is therefore a critical contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in mitochondrial quality control. PINK1 and PRKN (parkin) function in a pathway that regulates mitochondrial integrity through ubiquitin-mediated degradation of damaged mitochondria. Mutations in PINK1 or PRKN lead to impaired mitophagy, the selective degradation of dysfunctional mitochondria. This disruption contributes to the accumulation of damaged mitochondria, leading to cellular dysfunction and neurodegeneration. The most well-documented disease associated with mutations in this pathway is Parkinson's disease. PINK1 mutations are among the genetic causes of inherited Parkinson's disease, characterized by the degeneration of dopaminergic neurons in the substantia nigra. The pathway's role in maintaining mitochondrial health makes it critical for neuronal survival, and its dysfunction directly contributes to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in mitochondrial quality control. PINK1 and PRKN (parkin) work together in the mitophagy pathway, where PINK1 stabilizes on damaged mitochondria and recruits PRKN to ubiquitinate mitochondrial proteins, marking them for degradation. MFN1 and MFN2 facilitate mitochondrial fusion, which is critical for maintaining mitochondrial function and preventing the accumulation of damaged mitochondria. Mutations in PINK1 or PRKN lead to dysfunctional mitophagy, resulting in the accumulation of impaired mitochondria, which contributes to neuronal loss. This pathway is particularly important in neurons, where mitochondrial dysfunction is a key factor in neurodegeneration. Mutations in this pathway are a major genetic cause of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele plays a critical role in mitochondrial quality control. PINK1 is essential for the stabilization of damaged mitochondria and the recruitment of parkin (PRKN) to depolarized mitochondria, where it mediates ubiquitination of mitofusins (MFN1/2), promoting mitophagy. Mutations in PINK1 disrupt this process, leading to impaired mitochondrial turnover and accumulation of dysfunctional mitochondria. This dysfunction is strongly associated with neurodegeneration. The most well-documented disease linked to PINK1 mutations is Parkinson's disease. Loss-of-function variants in PINK1 contribute to the pathogenesis of Parkinson's by disrupting mitochondrial homeostasis and increasing neuronal vulnerability. Thus, the biological effect of the PINK1 allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the processing of amyloid precursor protein (APP). Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (AD). The pathway described, involving PSEN1 \u2192 GSK3B and the kinesin light chain (KLC) family proteins, highlights the role of PSEN1 in regulating \u03b2-catenin signaling through GSK3B, which is disrupted in AD. This disruption leads to the accumulation of toxic amyloid-beta plaques and neurodegeneration. The involvement of kinesin proteins suggests impaired neuronal transport, contributing to synaptic dysfunction. Therefore, the biological effect of pathogenic PSEN1 alleles is the development of early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), producing amyloid-\u03b2 peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (AD). These mutations lead to altered \u03b3-secretase activity, resulting in increased production of toxic amyloid-\u03b242 peptides, which aggregate into plaques in the brain. This pathological process contributes to neuronal dysfunction and death, hallmark features of Alzheimer's disease. Additionally, PSEN1 interacts with GSK3B, KIF5 (kinesin family member 5), and KLC (kinesin light chains), suggesting roles in intracellular trafficking and neurodegeneration. Thus, the PSEN1 allele contributes to the development of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a primary cause of early-onset familial Alzheimer\u2019s disease (AD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in neurodegeneration through impaired protein trafficking and synaptic function. GSK3B, a downstream target, is involved in tau pathology and neuronal survival. Disruption of kinesin-mediated transport, including KIF5 and KLC, further contributes to axonal transport defects, exacerbating neuronal dysfunction. Collectively, these molecular changes underlie the pathogenesis of Alzheimer\u2019s disease. The PSEN1 allele therefore contributes to the development of \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex, which is essential for the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are a leading genetic cause of early-onset familial Alzheimer's disease (FAD). These mutations disrupt the normal function of gamma-secretase, leading to increased production of amyloid-beta peptides, particularly the toxic A\u03b242 form. This accumulation contributes to amyloid plaque formation in the brain, a hallmark of Alzheimer's disease. Additionally, the pathway involves GSK3B, KIF5, and KLC proteins, which are implicated in neurodegenerative processes, including tau pathology and microtubule transport. Together, these molecular interactions highlight the central role of PSEN1 in the pathogenesis of Alzheimer's disease. Therefore, the biological effect of this PSEN1 allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of amyloid-\u03b2 peptides, particularly the toxic A\u03b242 isoform, which aggregates into plaques in the brain. This accumulation disrupts synaptic function and neuronal communication, contributing to neurodegeneration. The pathway involving PSEN1 \u2192 GSK3B and the kinesin light chain (KLC) family suggests involvement in intracellular transport and tau pathology, both of which are critical in Alzheimer's disease. Thus, the biological effect of this PSEN1 allele is the increased risk and progression of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a well-documented cause of early-onset familial Alzheimer\u2019s disease (FAD). The pathway described involves PSEN1 influencing GSK3B, a kinase involved in neurodegenerative processes, and interacting with kinesin family members (KIF5A, KIF5B, KIF5C) and kinesin light chains (KLC1-4), which are involved in intracellular transport. These interactions suggest a role in neuronal transport and stability, both of which are disrupted in Alzheimer\u2019s disease. Impaired \u03b3-secretase activity due to PSEN1 mutations leads to increased amyloid-\u03b2 production and aggregation, contributing to plaque formation and neuronal toxicity. Therefore, the biological effect of this PSEN1 allele is the promotion of Alzheimer\u2019s disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for protein quality control and mitochondrial function. Mutations in PRKN lead to loss of function, impairing ubiquitin-mediated degradation of damaged proteins and mitochondria. This contributes to the accumulation of dysfunctional proteins and organelles, leading to neuronal toxicity. PRKN mutations are a major cause of autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and PAELR, highlights its role in ubiquitin-mediated proteolysis. Dysfunction in this pathway disrupts cellular homeostasis, particularly in neurons, resulting in neurodegeneration. The most significant disease associated with PRKN mutations is Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for mitochondrial quality control and protein degradation. Mutations in PRKN lead to impaired ubiquitin-mediated degradation, resulting in the accumulation of damaged proteins and dysfunctional mitochondria. This dysfunction is central to neurodegenerative processes. PRKN mutations are a well-established cause of Parkinson's disease, specifically in patients with early-onset, autosomal recessive Parkinsonism. The pathway involving PRKN, along with ubiquitin-conjugating enzymes UBE2L3 and UBE2L6, underscores its role in ubiquitin-mediated protein degradation. Dysfunction in this pathway disrupts proteostasis and mitochondrial health, contributing to neuronal loss. Therefore, PRKN mutations are strongly associated with Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN lead to impaired ubiquitination, resulting in the accumulation of damaged proteins and mitochondrial dysfunction. This contributes to neurodegeneration. PRKN is a key gene in the Parkin-PINK1 pathway, which is critical for mitochondrial quality control. Loss-of-function mutations in PRKN are a major cause of autosomal recessive Parkinson's disease. These mutations disrupt the clearance of dysfunctional mitochondria, leading to oxidative stress and neuronal death, particularly in dopamine-producing neurons. PRKN-related Parkinson's is characterized by late-onset, progressive motor symptoms. The presence of PRKN mutations in this pathway is strongly associated with increased risk and severity of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this pathway is the production of amyloid-beta (Abeta), which triggers a cascade leading to NMDA receptor activation, mitochondrial calcium overload via MCU, and subsequent mitochondrial permeability transition pore (MPTP) opening. This results in the release of cytochrome c (CYCS), promoting apoptosis. This pathway is central to neurodegeneration. The accumulation of Abeta and subsequent mitochondrial dysfunction are hallmarks of Alzheimer's disease. The involvement of NMDA receptors (GRIN1, GRIN2A-D) and mitochondrial calcium handling (MCU, VDACs, SLC25A4-6, SLC25A31) further supports neuronal damage and synaptic dysfunction. This pathway is strongly associated with the progression of Alzheimer's disease, making it a key contributor to the pathophysiology of the disorder. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of this APP allele involves the pathological cascade starting with the cleavage of amyloid beta precursor protein (APP) into \u03b2-amyloid (Abeta). This Abeta aggregates and activates NMDA receptors (GRIN1, GRIN2A-D), leading to excessive influx of Ca\u00b2+ through NMDAR. The calcium is transported into mitochondria via MCU and VDACs (VDAC1-3), along with SLC25A4-6 and SLC25A31. This mitochondrial Ca\u00b2+ overload triggers mitochondrial permeability transition pore (MPTP) opening, releasing cytochrome c (CYCS) and initiating apoptosis. This pathway is central to neurodegeneration. The accumulation of Abeta and subsequent mitochondrial dysfunction are hallmark features of Alzheimer's disease. Thus, this pathway contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes a cascade starting with the amyloid precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). This Abeta interacts with NMDA receptors (GRIN1, GRIN2A-D), leading to increased intracellular calcium via NMDAR and mitochondrial calcium uptake through MCU and VDACs. The resulting mitochondrial calcium overload triggers the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating apoptosis. This pathway is central to neurodegenerative processes. Mutations in APP and subsequent Abeta accumulation are strongly associated with Alzheimer's disease. The accumulation of toxic Abeta peptides disrupts synaptic function, causes oxidative stress, and leads to neuronal death. This pathway is a key contributor to the pathophysiology of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe thyroid peroxidase (TPO) enzyme plays a critical role in thyroid hormone synthesis by catalyzing the iodination of tyrosine residues on thyroglobulin (TG), forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). These intermediates are then coupled to form triiodothyronine (T3) and tetraiodothyronine (T4). Mutations in the TPO gene impair this process, leading to defective hormone production. This dysfunction results in hypothyroidism, as the thyroid gland cannot adequately produce thyroid hormones. TPO mutations are strongly associated with autoimmune thyroid diseases, particularly **Hashimoto's thyroiditis**, where the immune system attacks the thyroid gland, further exacerbating hormone deficiency. The TPO allele's biological effect is thus central to the pathogenesis of **Hashimoto's thyroiditis**, an autoimmune disorder characterized by chronic inflammation and hypothyroidism of the thyroid gland.\n\n\\boxed{Hashimoto's thyroiditis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe thyroid peroxidase (TPO) enzyme plays a critical role in thyroid hormone synthesis by catalyzing the organification of iodide onto tyrosine residues in thyroglobulin (TG), forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). These intermediates are then coupled to form triiodothyronine (T3) and thyroxine (T4). Mutations in the TPO gene impair this process, leading to reduced thyroid hormone production. This dysfunction results in hypothyroidism, characterized by elevated serum thyroid-stimulating hormone (TSH) and low free T4 levels. TPO mutations are a major cause of autoimmune thyroid disease, specifically **Hashimoto\u2019s thyroiditis**, an inflammatory condition where the immune system attacks the thyroid gland, leading to chronic lymphocytic thyroiditis and eventual hypofunction. The TPO allele is a key genetic contributor to this autoimmune disorder. \n\n\\boxed{Hashimoto's thyroiditis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe thyroid peroxidase (TPO) enzyme plays a critical role in thyroid hormone synthesis by catalyzing the organification of iodide onto tyrosine residues in thyroglobulin, forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). These intermediates are then coupled to form triiodothyronine (T3) and thyroxine (T4). Mutations in the TPO gene can impair this process, leading to defective hormone production. This impairment results in hypothyroidism, where the thyroid gland fails to produce sufficient thyroid hormones. TPO deficiency is a key factor in autoimmune thyroid diseases, particularly **Hashimoto's thyroiditis**, an inflammatory condition where the immune system attacks the thyroid gland, leading to chronic inflammation and reduced thyroid function. The TPO allele contributes to this disease by disrupting hormone synthesis and increasing susceptibility to autoimmune attack. \\boxed{Hashimoto's thyroiditis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme crucial for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, a key activator of carbamoyl-phosphate synthase I (CPS1), which initiates the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing ammonia detoxification. This results in hyperammonemia, characterized by elevated blood ammonia levels. The most common disease associated with NAGS mutations is **N-acetylglutamate synthase deficiency**, a rare autosomal recessive disorder. Affected individuals exhibit symptoms such as neurological dysfunction, developmental delay, and in severe cases, encephalopathy or coma. This condition is part of the urea cycle disorders, which are metabolic diseases affecting nitrogen metabolism. The NAGS allele contributes directly to the pathogenesis of this disorder by disrupting the urea cycle's initiation. \\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, which activates CPS1 (carbamoyl-phosphate synthase 1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced activation of CPS1, impairing urea synthesis and causing the accumulation of ammonia. This results in hyperammonemia, a condition characterized by elevated blood ammonia levels, which can lead to neurological damage. The most common disease associated with NAGS mutations is **N-Acetylglutamate Synthase Deficiency**, a rare autosomal recessive disorder. Affected individuals may present with seizures, developmental delays, and increased risk of liver dysfunction. The disorder underscores the essential role of the urea cycle in nitrogen homeostasis. \\boxed{N-Acetylglutamate Synthase Deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, which activates carbamoyl-phosphate synthetase I (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing the conversion of ammonia to urea. This results in hyperammonemia, a condition characterized by elevated ammonia levels in the blood. The most common disorder associated with NAGS mutations is **hyperammonemia due to N-acetylglutamate synthase deficiency**, a rare autosomal recessive disorder. This condition can cause severe neurological symptoms, including seizures, coma, and intellectual disability. The deficiency disrupts the urea cycle, leading to toxic accumulation of ammonia, which is particularly harmful to the brain. Therefore, the biological effect of the NAGS allele is the development of **hyperammonemia**.\n\n\\boxed{Hyperammonemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to neurodegeneration by disrupting cellular processes such as protein homeostasis and synaptic function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is linked to autophagy, a critical process for clearing misfolded proteins and damaged organelles. Impaired autophagy due to ATXN3 dysfunction exacerbates neuronal damage. This genetic alteration is a key driver of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor control. The biological effect of the ATXN3 allele is therefore the pathogenesis of \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. The pathway it is associated with includes genes critical for autophagy, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1. Mutations in ATXN3 are directly linked to **Spinocerebellar Ataxia Type 2 (SCA2)**, a neurodegenerative disorder characterized by progressive loss of coordination and motor function. SCA2 is caused by expansions of CAG repeats in the ATXN3 gene, leading to the production of an unstable, toxic ataxin-3 protein. This protein disrupts cellular processes, including protein degradation and autophagy, contributing to neuronal damage and degeneration, particularly in the cerebellum. The involvement of autophagy-related genes in this pathway underscores the importance of protein quality control in maintaining neuronal health. \\boxed{Spinocerebellar Ataxia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the accumulation of misfolded proteins, disrupting cellular homeostasis. This is most notably associated with spinocerebellar ataxia type 2 (SCA2), an autosomal dominant neurodegenerative disorder characterized by progressive cerebellar atrophy and motor dysfunction. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 suggests a role in autophagy, a process critical for clearing damaged proteins and organelles. Impaired autophagy due to ATXN3 dysfunction contributes to neuronal toxicity and disease progression. Thus, the ATXN3 allele is directly linked to the development of \\boxed{Spinocerebellar Ataxia Type 2}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele in the BRAF \u2192 MEK \u2192 ERK pathway contributes to the activation of the MAPK/ERK signaling cascade, which plays a critical role in cell proliferation, differentiation, and survival. Mutations in BRAF, particularly the V600E substitution, lead to constitutive activation of this pathway, driving uncontrolled cell growth. This dysregulation is a hallmark of several cancers. The most well-known disease associated with BRAF mutations is **melanoma**, where BRAF V600E mutations are found in approximately 50% of cases. These mutations promote tumor progression by enhancing cell cycle progression and inhibiting apoptosis. Additionally, BRAF mutations are implicated in other malignancies, including colorectal, lung, and thyroid cancers. The aberrant activation of the ERK pathway due to mutant BRAF contributes to oncogenesis and resistance to therapy, making it a significant target for therapeutic intervention. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a critical signaling cascade involved in cell proliferation, survival, and differentiation. The BRAF gene encodes a serine/threonine kinase that activates MEK, which in turn phosphorylates ERK, driving cellular responses. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway, promoting uncontrolled cell growth. This dysregulation is a hallmark of several cancers. The most well-known disease associated with BRAF mutations is **melanoma**, where BRAF mutations are found in approximately 40-50% of cases. Additionally, BRAF mutations contribute to other cancers such as colorectal, lung, and thyroid carcinomas. The continuous activation of this pathway leads to tumor progression, making it a key target for therapeutic intervention. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a critical signaling cascade in cell proliferation and survival. The BRAF gene encodes a serine/threonine kinase that activates MEK, which in turn phosphorylates ERK, promoting cell growth and division. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway, driving uncontrolled cell proliferation. This dysregulation is commonly associated with various cancers. The most well-known disease linked to BRAF mutations is **melanoma**, where BRAF mutations occur in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies such as colon cancer, non-small cell lung cancer, and thyroid cancer. The constitutive activation of the ERK pathway due to BRAF mutations promotes tumor growth, invasion, and resistance to apoptosis. Targeting BRAF with specific inhibitors has become a key therapeutic strategy in the treatment of BRAF-mutant cancers. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The pathway defined here shows SMO interacting with SUFU and KIF7, and GLI transcription factors downstream, which regulate genes such as BMP2/4, HHIP, GLI1, PTCH, and WNTs. Mutations in SMO, particularly gain-of-function mutations, lead to constitutive activation of the Hh pathway. This results in uncontrolled cell proliferation and tissue overgrowth. Such dysregulation is a hallmark of basal cell carcinoma (BCC), the most common malignant tumor of the skin. SMO mutations are frequently found in BCC, especially in cases with no known predisposing factors. They drive tumor growth by enhancing GLI-mediated transcription, promoting survival and proliferation of basal cells. Thus, the biological effect of the SMO allele in this context is the development of basal cell carcinoma.\n\n\\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. In the given pathway, SMO activates GLI transcription factors, which regulate downstream targets such as BMP2/4, HHIP, GLI1, PTCH, and WNT genes. Mutations in SMO, particularly gain-of-function mutations, lead to constitutive activation of the Hh pathway, resulting in uncontrolled cell proliferation and tissue dysregulation. This contributes to the development of basal cell carcinoma (BCC), a type of skin cancer. SMO mutations are frequently observed in BCC, and inhibitors targeting SMO, such as vismodegib and sonidegib, are used in its treatment. The aberrant activation of the pathway also plays a role in other cancers and developmental disorders. Thus, the biological effect of a pathogenic SMO allele is the activation of the Hh pathway, contributing to the development of basal cell carcinoma. \n\n\\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The pathway described involves SMO activating GLI transcription factors, which in turn regulate genes such as BMP2/4, HHIP, GLI1, PTCH, and WNTs. SMO mutations, particularly gain-of-function variants, lead to constitutive activation of the Hh pathway. This aberrant signaling contributes to uncontrolled cell proliferation and tissue patterning defects. Mutations in SMO are associated with basal cell carcinoma (BCC), a common skin cancer. Additionally, SMO overactivation has been linked to medulloblastoma and other cancers. Inherited mutations in SMO, such as those found in Gorlin syndrome, increase the risk of BCC and other developmental abnormalities. The dysregulation of SMO thus plays a critical role in the pathogenesis of these diseases. \n\n\\boxed{Basal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele, as described in the pathway APP \u2192 Abeta \u2192 CxIV \u2192 H2O, is the production of amyloid-beta (Abeta) peptides. These peptides aggregate to form plaques, a hallmark of neurodegenerative diseases. The pathway involves the cleavage of APP by enzymes such as beta-secretase and gamma-secretase, leading to the release of Abeta. The accumulation of Abeta disrupts cellular function and triggers inflammation, oxidative stress, and neuronal death. This process is central to the pathogenesis of Alzheimer's disease. The involvement of cytochrome c oxidase subunits suggests a potential link between mitochondrial dysfunction and Abeta toxicity, as these subunits are critical for cellular respiration. Therefore, the APP allele contributes to Alzheimer's disease through the dysregulation of Abeta production and downstream mitochondrial dysfunction. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele is the production of amyloid-beta peptides, which aggregate to form plaques in the brain. This pathway, APP \u2192 Abeta, is central to the pathological process in Alzheimer's disease. The accumulation of amyloid-beta plaques disrupts neuronal function and leads to neurodegeneration. The presence of these plaques is a hallmark of Alzheimer's disease and is strongly associated with cognitive decline and dementia. While the pathway also involves cytochrome c oxidase subunits (COX1-8A, COX4I1/2, etc.), these proteins are part of the mitochondrial electron transport chain and are not directly involved in amyloid-beta production. The primary disease associated with this pathway is Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele is the production of amyloid-beta (Abeta) peptides, which aggregate to form plaques in the brain. This process is a key pathogenic mechanism in Alzheimer's disease. The pathway described, APP \u2192 Abeta \u2192 CxIV \u2192 H2O, reflects the cleavage of APP to generate Abeta, which can disrupt cellular function and trigger neurodegeneration. The involvement of multiple cytochrome c oxidase subunits (COX1-8A, COX4I1/2, etc.) suggests a potential link between mitochondrial dysfunction and Abeta toxicity, as mitochondrial damage is a hallmark of Alzheimer's. This pathway contributes to the accumulation of Abeta, leading to synaptic dysfunction, neuronal death, and cognitive decline. Therefore, the disease associated with this APP allele is \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cellular signaling, particularly in neurite outgrowth, myelination, and cell survival. The NRG (Neuregulin) family of ligands bind to ERBB4, activating downstream signaling pathways such as PI3K/AKT and MAPK, which are essential for normal development and function of the nervous system. Mutations or dysregulation of ERBB4 or its ligands are associated with impaired neuronal development and connectivity. Specifically, aberrant ERBB4 signaling contributes to the pathogenesis of **schizophrenia**, a neurodevelopmental disorder characterized by disrupted brain connectivity and synaptic plasticity. Altered ERBB4 expression and signaling have been implicated in the etiology of schizophrenia, highlighting its role in this complex psychiatric disease.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell signaling, particularly in neurodevelopment, myelination, and tumor progression. Mutations or dysregulation of ERBB4 can lead to aberrant signaling in pathways involving neuregulins (NRG1-4), which are ligands for ERBB4. This disruption contributes to various diseases, including cancers such as non-small cell lung cancer (NSCLC) and metastatic breast cancer, where ERBB4 overexpression or amplification is associated with poor prognosis. Additionally, ERBB4 mutations have been linked to neurodevelopmental disorders, including schizophrenia and autism spectrum disorder, due to its role in brain development. Among these, the most commonly associated disease linked to ERBB4 alterations is \\boxed{non-small cell lung cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG (neuregulin) signaling pathway, which plays a critical role in neural development, myelination, and cell survival. ERBB4 is a receptor tyrosine kinase that binds neuregulins (NRG1-NRG4), mediating downstream signaling events essential for neuronal growth and differentiation. Mutations or dysregulation of ERBB4 can disrupt these processes, contributing to neurological disorders. Specifically, aberrant ERBB4 activity has been implicated in schizophrenia, where altered signaling in this pathway is associated with impaired synaptic plasticity and neurodevelopmental abnormalities. Additionally, ERBB4 has been linked to certain cancers, such as non-small cell lung cancer, through oncogenic activation. However, the most notable disease associated with ERBB4 dysfunction is \\boxed{Schizophrenia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene encodes ataxin-1, a protein involved in transcriptional regulation and RNA processing. The pathway described shows ATXN1 interacting with RORA and KAT5, influencing the expression of ITPR1, SLC1A6, and GRM1, which are involved in calcium signaling, neurotransmitter transport, and glutamatergic signaling. Mutations in ATXN1, particularly expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long ataxin-1 protein, resulting in neurodegeneration. This is a hallmark of spinocerebellar ataxia type 1 (SCA1), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor control. The dysregulated pathway contributes to neuronal dysfunction and cell death, particularly in the cerebellum. \\boxed{Spinocerebellar Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene is involved in a pathway that includes RORA and KAT5, leading to the regulation of ITPR1, SLC1A6, and GRM1. This pathway is crucial for neuronal function, particularly in the cerebellum, which is essential for motor coordination. Mutations in ATXN1 are associated with the expansion of the CAG repeat, leading to the production of an abnormally long polyglutamine tract in the ATXN1 protein. This results in protein misfolding, aggregation, and neuronal toxicity, particularly in Purkinje cells. These processes contribute to the progressive degeneration of the cerebellum, which is characteristic of a neurodegenerative disorder. The most well-documented disease linked to pathogenic ATXN1 alleles is \\boxed{Spinocerebellar ataxia type 1 (SCA1)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 pathway involves ATXN1, which encodes ataxin-1, a protein implicated in transcriptional regulation. Mutations in ATXN1 lead to the expansion of its polyglutamine tract, causing toxic gain-of-function. This results in neuronal dysfunction and degeneration, particularly in the cerebellum. The pathway includes RORA and KAT5, which are involved in gene regulation, and targets such as ITPR1, SLC1A6, and GRM1, which are associated with neuronal signaling and ion homeostasis. The accumulation of mutant ATXN1 disrupts these processes, leading to progressive neurodegeneration. This is the hallmark of Spinocerebellar Ataxia Type 1 (SCA1), an inherited neurodegenerative disorder characterized by impaired coordination and motor control. The biological effect of the ATXN1 allele is therefore the development of \\boxed{Spinocerebellar Ataxia Type 1}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of CDK4/6, which phosphorylates RB1. In the given pathway, CDKN2A negatively regulates MDM2, thereby stabilizing TP53. TP53 activates CDKN1A, which further inhibits CDK4/6, preventing RB1 phosphorylation and restricting E2F-driven cell cycle progression. Loss or mutation of CDKN2A disrupts this tumor suppressor network, leading to unchecked cell proliferation. This contributes to uncontrolled cell growth and genomic instability. CDKN2A mutations are strongly associated with **melanoma** and **pancreatic neuroendocrine tumors**, and are also implicated in **Li-Fraumeni syndrome**, a hereditary cancer syndrome. The loss of CDKN2A function enhances MDM2-mediated degradation of TP53, impairing DNA repair and apoptosis. Thus, CDKN2A dysfunction is a key driver in **melanoma**.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in the p53 tumor suppressor pathway. CDKN2A encodes for p14ARF, which inhibits MDM2, a negative regulator of TP53. This allows TP53 to remain active, promoting cell cycle arrest and apoptosis. CDKN2A also directly inhibits CDK4/6, preventing the phosphorylation of RB1, which in turn inhibits E2F-driven transcription of S-phase genes. Loss or mutation of CDKN2A disrupts this pathway, leading to unchecked cell proliferation. This contributes to the development of various cancers, including melanoma, pancreatic cancer, and sarcomas. The key disease associated with CDKN2A dysfunction is \\boxed{Melanoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of cyclin D-dependent kinases CDK4 and CDK6. In the given pathway, CDKN2A negatively regulates MDM2, which normally ubiquitinates and destabilizes TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its ability to induce cell cycle arrest and apoptosis. Mutations or loss of CDKN2A disrupt this regulation, leading to reduced TP53 activity, unchecked cell proliferation, and genomic instability. This contributes to uncontrolled cell growth, a hallmark of cancer. CDKN2A mutations are strongly associated with melanoma and pancreatic cancer, and are also implicated in other malignancies such as prostate and bladder cancer. The loss of CDKN2A function is a critical step in tumorigenesis, particularly in cancers where TP53 pathway dysfunction is prevalent. \\boxed{Melanoma}"]]